A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Phase: PHASE2
Conditions: Metastatic Prostate Cancer
Sponsor: National Cancer Institute (NCI)

Amendment
Protocol Number:
09C0195-X
Principal Investigator: Ravi Madan 
NCI 
GMB 
301.480.7168 
madanr@mail.nih.gov
(NIH Employee Name, Institute/Branch, Telephone and e-mail)
Reference Number:
365264
Protocol Title:
A Phase 2 trial of Bevacizumab, Lenalidomide, Docetaxel and Prednisone(ART-P) for Treatment of Metastatic Castrate-Resistant 
Prostate Cancer
SIGNATURES
Principal Investigator (*): 
William Dahut - applied signature on 12/23/2016 1:33 PM EST 
Ravi Madan - applied signature on 12/23/2016 1:25 PM EST
Accountable Investigator:
PI is the Accountable Investigator
Branch Chief/CC Department Head (**):
James L Gulley, MD PhD - applied signature on 12/25/2016 12:23 PM EST
Medical Advisory Investigator (if applicable):
N/A
Lead Associate Investigator signature:
N/A
Referral Contact signatures:
N/A
Associate Investigators signatures:
Ravi Madan - applied signature on 12/23/2016 1:24 PM EST
For Institute/Center Scientific Review Committee:
N/A
Other IC Clinical Director signatures:
N/A
APPROVALS
IRB Chair:
Michael Hamilton - applied signature on 01/12/2017 2:53 PM EST
Clinical Director:
N/A
CONCURRENCE
OPS Protocol Specialist:
Signature
Print Name
Date
* Signature signifies that investigators on this protocol have been informed that the collection and use of personally identifiable information at
the NIH are maintained in a system of record governed under provisions of the Privacy Act of 1974. The information provided is mandatory for
employees of the NIH to perform their assigned duties as related to the administration and reporting of intramural research protocols and
used solely for those purposes.  Questions may be addressed to the Protrak System Owner.
** I have reviewed this research project and considered the NIH Policy for Inclusion of Women and Minorities in Clinical Research. Taking into 
account the overall impact that the project could have on the research field involved, I feel the current plans adequately includes both sex/
gender, minorities, children, and special populations, as appropriate. The current enrollment is in line with the planned enrollment report for 
inclusion of individuals on the basis of their sex/gender, race, and ethnicity and is appropriate and of scientific and technical merit. 
IRB Meeting Date:
Expedited
DEC Clearance Date:
11/29/2016
Protocol Version Date:11/15/2016
Lemuel Clayborn                                                                             AM X                                                        01/24/2017

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
1 
 
CTEP Protocol #: 8217  
 CC Protocol #: 09C0195 Amendment X 
 
Title: A Phase 2 trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for 
Treatment of Metastatic Castrate-Resistant Prostate Cancer 
Abbreviated Title:   
 
ART-P for mCRPC  
 
NCI Principal Investigator:  
Ravi A. Madan, MDA- F 
Genitourinary Malignancies Branch (GMB), CCR, NCI 
Bldg 10, Room 13N240B 
10 Center Drive, Bethesda 20892 
Phone 301-480-7168, Email: madanr@mail.nih.gov 
 
Statistician:    
 
 
*Seth Steinberg, PhD, BDMS, NCI E, F 
 
NIH Associate Investigators: 
*William D. Figg, PharmD, GMB, CCR, NCI B, E, F 
James Gulley, MD, PhD, GMB, CCR, NCI A-F 
William L. Dahut , MD, GMB, CCR, NCI A-F 
Howard Parnes, MD, DCP, CCR, NCI A-F 
John Wright, MD, CTEP, NCI A-F 
 
Anna Couvillon, CRNP, GMB, CCR, NCI A-F 
*Jane Trepel, PhD, DTB, CCR, NCI E, F 
*Douglas Price, PhD, GMB, CCR, NCI E, F 
Andrea Apolo, MD GMB, CCR, NCI A-F 
Guinevere Chun, RN, OCD, CCR, NCI A, B, C, E, F 
Fatima Karzai, MD, NIMHD A-F  
 
Non-NIH Associate Investigator: *Michelle Ojemuyiwa, M.D. [V], OCD, CCR, NCI E, F  
 
    (Special Volunteer, Walter Reed National Military 
Medical Center) 
Philip Arlen, MD, OCD, CCR, NCI A-F 
    (Special Volunteer, Precision Biologics) 
 
Referral Contact/ 
 
 
Guinevere Chun, RN, OCD/CCR/NCI/NIHA,B,C,E,F 
Study Coordinator:  
 
10 Center Drive, Room 13N224 
Phone: 240-760-6065 
Email: gchun@mail.nih.gov 
 
 
  
Drug Monitor:  
 
 
Helen Chen, M.D., CTEP, NCI 
Howard Z. Streicher, M.D., CTEP, NCI 
 
Drug Sponsor: 
 
 
CTEP, NCI 
Drugs Supplied: 
 
 
Lenalidomide (CC-5013, IND 70116, NSC703813),  
Bevacizumab (IND 7921, NSC704865) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
2 
 
Commercial Agents:  
 
Docetaxel and Prednisone 
 
* These investigators will not be involved in direct patient care or clinical decision-making. 
Investigator Roles:  
A. Obtain information by intervening or interacting with living individuals for research 
purposes 
B. Obtaining identifiable private information about living individuals 
C. Obtaining the voluntary informed consent of individuals to be subjects 
D. Makes decisions about subject eligibility 
E. Studying, interpreting, or analyzing identifiable private information or data/specimens for 
research purposes 
F. Studying, interpreting, or analyzing de-identified data or specimens for research purposes 
G. Some/all research activities performed outside NIH 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
3 
 
PRECIS 
Background: 
 The dual antiangiogenic therapy with bevacizumab and thalidomide in combination with 
docetaxel and prednisone (ATTP) is highly active in patients with metastatic castration 
resistant prostate cancer (mCRPC), associated with unprecedented results (90% patients 
had PSA declines of >50% and 64% ORR in measurable disease) 
 Most patients in the ATTP trial required dose reduction due to thalidomide toxicities.  
 Lenalidomide, an analogue of thalidomide, is antiangiogenic and inhibits TNF-alpha, 
but has a favorable toxicity profile. Lenalidomide is well tolerated in patients with solid 
tumors when used alone or in combination with docetaxel. 
 To preserve the efficacy of ATTP and to potentially reduce toxicity, lenalidomide may 
be a good substitute for thalidomide. 
 
Objectives 
Primary:  
 To assess if lenalidomide at its approved dosing schedule can be safely combined with 
docetaxel, bevacizumab, and prednisone in patients with mCRPC (<25% Grade 4 
toxicity) 
 To evaluate the efficacy of the combination 
 
Eligibility:  
 Patients with progressive mCRPC who have not received any chemotherapy or 
antiangiogenic therapy for mCRPC 
 
Design: 
 A single-stage Phase 2 study, with an early stopping rule for excessive toxicity: the goal 
is to enroll 45 patients at the 25 mg dose level of lenalidomide. However, if 7 in the first 
18 or fewer patients receiving lenalidomide at 25 mg develop grade 4 non-hematologic 
toxicity at any time during study, no further patients will be enrolled. With respect to the 
stopping rule, a grade 4 hematologic toxicity will be considered if the episode has lasted 
for greater than or equal to 5 days.  Grade 4 lymphopenia of any duration will not be 
counted.  If less than 7 of the first 18 patients experience the above level of toxicity, 
accrual will continue until 45 patients have been enrolled at the 25 mg dose level of 
lenalidomide.  
 A run-in phase with lenalidomide at 15 mg will be conducted in the first three patients 
and at 20mg for the next three patients for assessing its tolerability within the 
combination prior to dosing at 25 mg thereafter.   
 An expansion cohort of a lower dose of lenalidomide (15 mg) in combination with 
docetaxel and bevacizumab will be conducted to assess if this lower dose of 
lenalidomide could have similar efficacy with less toxicity. 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
4 
 
Treatment Schema of ART-P  
Cycle Number: ________________ 
Day 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
1 
Dex 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Len 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
X 
Doc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Bev 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Pre 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
E 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Peg 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dex  
-Dexamethasone 8 mg po 12 hours pre, 3 hours pre, and 1 hour pre infusion of docetaxel 
(patients who were on prior regimen which included a lower dose of decadron and did not have 
a reaction do not have to increase their decadron to the 8 mg dose) 
Len 
- Lenalidomide 25 mg po, days 1-14. Lenalidomide 15 mg and 20mg for the proposed 
run-in phase.  Lenalidomide 15 mg for the expansion cohort. 
Doc 
- Docetaxel 75 mg/m2   IV  
Bev 
- Bevacizumab 15 mg/kg IV 
Pre 
- Prednisone 10 mg PO daily throughout cycle 
E  
- Enoxaparin given SQ daily based on weight (see dosing chart in section 5.2.5) 
Peg 
- Pegfilgrastim 6mg SQ given at least 24 hours after docetaxel administration 
Baseline screening evaluations are to be conducted within 15 days prior to protocol 
enrollment.  Baseline scans and x-rays must be performed 4 weeks prior to protocol 
enrollment.  Patients must be evaluated at the NCI clinic each cycle for treatment 
continuation. For patients who have been on study for at least 2 years and are being 
treated with prednisone only, follow-up evaluations may be performed every 6 weeks 
at the physician’s discretion.  Staging scans will be performed after the first 2 cycles 
of treatment and then every three cycles.  If the patient has been on study for at least 
two years, scans may be performed only if there is evidence of disease progression. 
All follow-up evaluations can be done on the last week of the prior cycle. 
 
 
 
 
 
 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
5 
 
 
TABLE OF CONTENTS 
SUMMARY OF CHANGES ..................................... ERROR! BOOKMARK NOT DEFINED. 
PRECIS ........................................................................................................................................... 3 
1 
BACKGROUND AND OBJECTIVES .............................................................................. 8 
1.1 
Objectives ....................................................................................................................... 8 
1.2 
Background ..................................................................................................................... 8 
2 
PATIENT SELECTION ................................................................................................... 20 
2.1 
Eligibility Criteria ......................................................................................................... 20 
2.2 
Inclusion of Women and Minorities ............................................................................. 23 
3 
ON-STUDY RESEARCH EVALUATION ..................................................................... 23 
3.1 
Exam ............................................................................................................................. 23 
3.2 
Imaging Studies (baseline) ............................................................................................ 23 
3.3 
Laboratory evaluation ................................................................................................... 23 
3.4 
EKG .............................................................................................................................. 24 
4 
PATIENT REGISTRATION ............................................................................................ 24 
5 
TREATMENT PLAN ....................................................................................................... 24 
5.1 
Study Design ................................................................................................................. 24 
5.2 
Agent Administration ................................................................................................... 25 
5.3 
Treatment Modifications ............................................................................................... 26 
5.4 
Protocol Evaluation ....................................................................................................... 32 
5.5 
Concurrent Therapies .................................................................................................... 34 
5.6 
Surgical Guidelines ....................................................................................................... 34 
5.7 
Radiation Therapy Guidelines ...................................................................................... 34 
5.8 
Off-Treatment Criteria .................................................................................................. 34 
5.9 
Post Treatment Evaluation ............................................................................................ 35 
5.10 
Off-Study Criteria ......................................................................................................... 35 
5.11 
Off-Study Procedures ................................................................................................... 35 
6 
SUPPORTIVE CARE ....................................................................................................... 35 
7 
SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN ................................................................................................................................ 35 
7.1 
Definitions .................................................................................................................... 36 
7.2 
Comprehensive Adverse Events and Potential Risks List ............................................ 38 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
6 
 
7.3 
Expedited Adverse Event Reporting ............................................................................. 50 
7.4 
Expedited Reporting Guidelines ................................................................................... 51 
7.5 
Routine Adverse Event Reporting ................................................................................ 52 
7.6 
NCI-IRB and NCI Clinical Director Reporting Requirements ..................................... 52 
8 
PHARMACEUTICAL INFORMATION ......................................................................... 53 
8.1 
DOCETAXEL (Taxotere-Aventis Pharmaceutical, Inc.; Bridgewater, NJ).............. 53 
8.2 
Lenalidomide ................................................................................................................ 55 
8.3 
Prednisone ..................................................................................................................... 58 
8.4 
Bevacizumab ................................................................................................................. 59 
8.5 
Pegfilgrastim ................................................................................................................. 61 
9 
CORRELATIVE STUDIES (MANDATORY FOR STUDY PARTICIPANTS) ........... 62 
9.1 
Genotyping of Patients .................................................................................................. 62 
9.2 
Cellular Analysis ........................................................................................................... 62 
9.3 
Angiogenesis Markers .................................................................................................. 64 
9.4 
Time Efficient Automatic Lesion Identification and Measurement on CT .................. 66 
10 
STUDY CALENDAR ...................................................................................................... 67 
11 
MEASUREMENT OF EFFECT....................................................................................... 70 
11.1 
Response Criteria for Radiographic Studies ................................................................. 70 
11.2 
Guidelines for Evaluation of Measurable Disease ........................................................ 74 
11.3 
Methods of Measurement ............................................................................................. 74 
12 
DATA REPORTING AND REGULATORY CONSIDERATIONS............................... 74 
12.1 
Record Keeping ............................................................................................................ 74 
12.2 
Drug Accountability ..................................................................................................... 75 
12.3 
Data Reporting .............................................................................................................. 75 
12.4 
Data and Safety Monitoring Plan .................................................................................. 75 
12.5 
CTEP multicenter Guidelines ....................................................................................... 76 
13 
COOPERATIVE 
RESEARCH 
AND 
DEVELOPMENT 
AGREEMENT 
(CRADA)/CLINICAL TRIALS AGREEMENT (CTA) .................................................. 76 
14 
STATISTICAL CONSIDERATIONS.............................................................................. 77 
15 
ACCRUAL TARGET TABLES....................................................................................... 80 
16 
HUMAN SUBJECTS PROTECTIONS ........................................................................... 80 
16.1 
Rationale for Subject Selection ..................................................................................... 80 
16.2 
Participation of Children ............................................................................................... 81 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
7 
 
16.3 
Participation of Subjects Unable to Give Consent ........................................................ 81 
16.4 
Evaluation of Benefits and Risks/Discomforts ............................................................. 81 
16.5 
Risks/Benefits Analysis ................................................................................................ 81 
16.6 
Consent and Assent Process and Documentation ......................................................... 81 
17 
REFERENCES ................................................................................................................. 83 
18 
APPENDICES .................................................................................................................. 86 
18.1 
Appendix A: Agents Metabolised through CYP450 .................................................... 86 
18.2 
Appendix B: Medication Checklist ............................................................................... 89 
18.3 
Appendix C: Medication Instruction Sheet .................................................................. 93 
18.4 
Appendix D: Celgene Pregnancy Prevention Counseling Program Site Counselor 
Identification Form ....................................................................................................... 94 
18.5 
Appendix E:  Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and 
Acceptable Birth Control Methods ............................................................................... 95 
18.6 
Appendix F:  Lenalidomide Education and Counseling Guidance Document ............. 97 
18.7 
Appendix G:  Lenalidomide Information Sheet ........................................................... 98 
18.8 
Appendix H: Guidelines for Prophylaxis and Treatment for Hypersensitivity Reactions 
(HSR) Associated with Docetaxel ................................................................................ 99 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
8 
 
1 
BACKGROUND AND OBJECTIVES 
1.1 
OBJECTIVES 
1.1.1 PRIMARY OBJECTIVES 
 To evaluate if lenalidomide is able to be safely incorporated with the combination of 
docetaxel, bevacizumab, and prednisone, to confirm that the drug does not have an 
excessively high rate of toxicity in a moderately large cohort of patients, and to evaluate 
the efficacy of the combination of the four agents. 
1.1.2 SECONDARY OBJECTIVES 
 To evaluate overall survival of patients studied  
 To evaluate the effects of the combination on the immune system before and 
after drug administration 
 To analyze the patients’ genotype with regard to genes involved in transport and 
metabolization of these agents to correlate that with efficacy 
 To evaluate changes in circulating apoptotic endothelial cells before and after 
drug administration 
 To determine whether there are changes in the molecular markers of 
angiogenesis (including, but not limited to serum and urine VEGF) before and 
after administration of docetaxel, prednisone, lenalidomide and bevacizumab 
 To evaluate the toxicity profile of the four-drug combination 
1.2 
BACKGROUND 
1.2.1 Prostate Cancer  
Metastatic prostate cancer is a leading cause of death from cancer in men. Though initially 
responsive to hormone therapy, metastatic prostate cancer eventually progresses in almost all 
patients. For this reason, there has been a search for novel agents to use in the treatment of 
castration resistant prostate cancer (CRPC).  
Historically, chemotherapy was not considered to have significant activity in metastatic CRPC.  
However, this view changed within the past 15 years due in part to the availability of prostate-
specific antigen (PSA) measurements to monitor tumor burden.  Estramustine, a tubulin-targeting 
drug, when combined with agents such as etoposide, vinblastine or paclitaxel, can induce 
responses in patients with CRPC 1-3. Docetaxel, both as a single agent and in combination with 
estramustine has activity as well. Two regimens containing docetaxel and either prednisone or 
estramustine improved overall survival when compared to mitoxantrone/prednisone, leading to the 
FDA approval of docetaxel and prednisone in CRPC. 4,5   
1.2.2 Docetaxel 
Docetaxel is a semi-synthetic taxane with potent antitumor activity in a variety of malignancies. 
Its mechanism in prostate cancer is thought to be two-fold. First it acts as a microtubule stabilizer 
by binding preferentially to Beta-tubulin, leading to assembly of microtubules without GTP and 
other various cofactors. This leads to static polymerization, which disrupts the normal mitotic 
process, causing cell arrest in G2/M phase, which ultimately leads to apoptosis 6. A second 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
9 
 
mechanism involves the bcl-2 gene. Bcl-2 is an oncogene that enhances tumor activity via 
inhibition of apoptosis. There have been several clinical and experimental studies that have shown 
that overexpression of bcl-2 in prostate cancer leads to chemotherapy and androgen resistance as 
well as protection from apoptosis 7,8. During the G2/M cell cycle interface, bcl-2 is normally 
temporarily phosphorylated to facilitate mitosis. Docetaxel has been shown to induce continuous 
bcl-2 phosphorylation, which leads to the loss of its normal antiapoptotic properties9. 
Based on this preclinical data, there has been much investigation in the use of docetaxel both as a 
single agent and as part of combination therapy in patients with CRPC. Several phase II studies 
used single agent docetaxel every three weeks at 75 mg/m2 and demonstrated a PSA decrease of 
at least 50% in 38-46% of patients with CRPC 10,11.  
Tannock et al. conducted a phase III trial of docetaxel in combination with prednisone in 1006 
patients with CRPC. Patients were randomized to prednisone (5 mg bid) plus either a) docetaxel 
(75 mg/m2 q 3 wk x 10 cycles) b) docetaxel (30 mg/m2 q wk for 5/6 weeks x 5 cycles) or c) 
mitoxantrone (12 mg/m2 q 3 wk x 10 cycles). Results showed that the combination of daily 
prednisone plus docetaxel given every 3 weeks had a statistically significant improvement in 
survival (18.9 vs. 16.5 mos.) and PSA response (45% vs. 32 %) over prednisone plus mitoxantrone. 
While the prednisone plus weekly docetaxel had comparable PSA benefit, the survival benefit was 
less and not statistically significant. 
Petrylak et al. conducted SWOG 99-16, a phase III study of 770 men with CRPC randomized to 
either docetaxel (60-70 mg/m2 q 3 weeks) plus estramustine (280 mg d 1-5 q 3 wk) versus 
mitoxantrone (12-14 mg/m2 q 3 wk) plus daily prednisone (5 mg po bid). Results showed that the 
docetaxel and estramustine arm was superior to the mitoxantrone and prednisone arm in median 
survival (18 vs. 15 mos) as well as several other meaningful endpoints.  
These larger randomized studies were the first to demonstrate survival benefit in men with CRPC 
and strongly encourage further trials using these and other docetaxel combinations in this disease. 
1.2.3  Prednisone 
Prednisone, a glucocorticoid has been shown to have some activity in patients with CRPC.  
Twenty-nine patients received prednisone at a dose of 10 mg orally twice a day.  Of the 29 patients, 
48% of patients had a > 25% PSA decline, 34% had a PSA decline > 50% and 14% experienced a 
PSA decline of > 75%.  The average PSA declined in this study population was 33%. However,  
the median progression free survival was only 2.8 months12. 
1.2.4 Lenalidomide 
Lenalidomide (Revlimid) is an immunomodulator that is an analogue of thalidomide. Thalidomide 
is most well known for being a potent teratogen that causes dysmelia (stunted limb growth) in 
humans 13. But since that time several pre-clinical models have shown the potential for anti-tumor 
activity based on anti-angiogenesis 14-16. Since angiogenesis may have a significant role in prostate 
cancer 17,18, several clinical trials have been conducted with thalidomide. 
Clinical Trials with Thalidomide 
Seventy-five chemotherapy naïve CRPC patients received 30-mg/m2 weekly docetaxel for 3 
consecutive weeks followed by a 1-week rest period; or docetaxel at the same dosing schedule, 
plus thalidomide 200 mg orally each day. After a follow-up period of 26.4 months, the percentage 
of patients with a greater than 50% decline of PSA was higher in the combination group (51% vs. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
10 
 
37% in the single agent docetaxel group). Median progression-free survival was 5.9 months in the 
combination arm and 3.7 months in the docetaxel arm. The median survival in the docetaxel group 
was 14.7 months and 28.9 months in the combined group. It should be noted that though the study 
was not powered to detect a survival difference, the addition of thalidomide nearly doubled the 
median survival in patients with metastatic CRPC and eventually became statistically significant 
19,20. 
Currently ongoing is a study combining bevacizumab, docetaxel, thalidomide and prednisone 
(ATTP trial) in the MOB, CCR, NCI. The most recent analyses of the trial after the targeted 
enrollment of 60 pts has competed were reported in the 2008 ASCO annual meeting.  Most patients 
in the trial had multiple poor prognostic factors, with a median predicted survival of 14.7 months 
based on the Halabi’s model.  As of the report, the median treatment cycles were 15 (2-51).  The 
toxicities that have been noted are:  febrile neutropenia (6/60), syncope (7/60), colon perforation 
or fistula (4/60), grade 3 bleeding (3/60), thrombosis (3/60). In addition, most patients experienced 
lower grade toxicities related to thalidomide, including neuropathy, fatigue, somnolence and 
constipation. Although none of the toxicities were more than grade 2 in intensity, almost all of the 
patients required initial intervention. In efficacy evaluation, fifty-two of 58 patients with PSA 
positive disease (90%) had PSA declines of >50%, with a median >50% PSA-duration of 14 cycles 
[0~50]. Forty-four of the 58 patients (76%) had >75% PSA declines. Thirty-three patients with 
measurable disease were evaluable: 2 CR and 19 PR, with an ORR of 64%. 
The toxicities related to thalidomide in the ATTP trial appear consistent with the known side 
effects of thalidomide.  These include but are not limited to sedation, peripheral neuropathy, rash, 
dizziness, constipation, tremors, mood changes and headaches 21. The exploration of other anti-
angiogenic compounds associated with thalidomide lead to further development of lenalidomide 
due to its increased potency and less side effects. 
Lenalidomide [3-(4-amino-1-oxo 1, 3-dihydro-2H-isoindol-2-yl) piperidine-2, 6-dione] has 
already been through multiple clinical trials. The immunomodulation properties include of 
inhibition of TNF-α, up-regulation of IL-10 and induction of T-cell proliferation after T-cell 
receptor activation 22. It is an FDA approved agent (with dexamethasone) in patients with multiple 
myeloma and for patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) 
associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic 
abnormalities. The drug has gained interest in solid tumors not only because of the 
immunomodulation properties but also because of its anti-angiogenic properties, anti-neoplastic 
properties and favorable toxicity profile. Like thalidomide, the precise mechanism of action of 
lenalidomide remains to be identified.  
Lenalidomide has been investigated in solid tumors, including a phase I study conducted in the 
MOB.  In this phase 1 trial (n=45) accrued to 9 dose levels using two dosing schedules consisting 
of 21 days on and 7 days off (15-40 mg/day) and continuous 28 day dosing (5-20 mg/day). The 
patients were heavily pretreated with a median of 5 prior chemotherapeutic regimens. The majority 
of tumors in this study were prostate cancer (n=35). Using a modified Fibonacci design of 
escalation, the study demonstrated that in the continuous dosing scale at the 20 mg dose two 
patients had grade 3 DVT and hypotension. The toxicities observed during the 21 day dosing 
consisted of grade 3 (3) and 4 (3) neutropenia, grade 3 diarrhea (1) and grade 4 arrhythmia (1) and 
hemolysis (1). There were no responses per RECIST criteria. The study demonstrated that doses 
of up to 40 mg/ day were well tolerated with minimal toxicity. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
11 
 
Miller et al. also conducted a Phase 1 trial (n=20) at doses of 5, 10, and 25 mg/day for 28 days 23. 
There were several tumor types (lung, colorectal, breast) that were evaluated. Toxicities consisted 
of grade 3 neuropathy (1) and thrombocytopenia (1) at the 25 mg/ day dose. One patient had a 
partial response and three had stable disease. The study showed that 25mg/ day continuous dosing 
was well tolerated with minimal toxicity.  
Trials have shown the applicability of lenalidomide with cytotoxic chemotherapeutic agents. A 
Phase 1 trial (n= 19) assessed the tolerability of lenalidomide (10-25 mg/day for days 1-14) in 
combination with docetaxel (60 or 75 mg/m2 on day 1 of 21) in metastatic CRPC (less than two 
prior regimens). 24. The toxicities consisted of grade 3 neutropenia (3) and grade 2 neuropathy (1) 
and fatigue (1).  Nine pts (47.4%) had a >50% decline in serum PSA.  A total of 13 patients had 
measurable disease.  5 (38.5%) achieved a partial response (PR) and 7 pts (53.9%) had stable 
disease. The MTD had not been reached at the time of the publication. Although the results of the 
study have been not updated recently, the safety profile and tolerability of the combination at the 
25 mg dose level of lenalidomide were acceptable and the responses were encouraging (per Dr. 
Dahut’s personal communication with the investigator of the study). 
It should also be noted that currently several combination trials are ongoing in multiple myeloma. 
This includes combinations of bevacizumab and lenalidomide with dexamethasone that is 
currently ongoing at the Mayo Clinic.  
Toxicities 
The most common grade 3 and 4 toxicities as seen in the above solid tumor trials have been 
thrombocytopenia and neutropenia. It appears from the initial trials that the occurrence of 
thrombosis is lower than in thalidomide trials. 
Lenalidomide Dosing 
Studies have evaluated combined angiogenesis inhibition with docetaxel in the treatment of 
metastatic castration resistant prostate cancer.  A previous study of docetaxel, thalidomide and 
bevacizumab demonstrated higher response rates and longer survival than either docetaxel with 
thalidomide or docetaxel with bevacizumab.25 The combination of lenalidomide, bevacizumab, 
docetaxel and prednisone (ART-P) is highly effective in metastatic castration-resistant prostate 
cancer.  A PSA decline of ≥ 50% was seen in 86.4% of patients and 87.5% of the patients with 
measurable disease achieved either complete remission or partial response. In this trial, 
lenalidomide was administered at 25 mg daily for 14 days of a 21-day cycle, with the exception of 
the initial 6 patients enrolled during the dose-escalation phase of the study.  Three patients in two 
cohorts were dosed at 15 mg and 20 mg to ensure tolerability. All 3 of the patients, who were 
treated with 15 mg, have demonstrated both PSA decline of ≥ 75% and partial responses of their 
measurable diseases. 26 
Among patients treated at the 25 mg, 20/47 patients (44.7%) required dose reductions of 
lenalidomide due to grade 3/4 adverse events, including cytopenia, febrile neutropenia, fatigue, 
and diarrhea. Of these 20 patients, 7 (14.9%) experienced ≥ 2 dose reductions along the course of 
their treatments. One patient developed repeated thrombocytopenia which necessitated the 
discontinuation of lenalidomide. The toxicities associated with 25 mg lenalidomide appeared 
higher than those of lower doses (15 and 20 mg) of lenalidomide. 26 These findings are consistent 
with a previous phase I/II randomized trial where patients received either 25 mg or 5 mg 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
12 
 
lenalidomide for biochemical recurrent prostate cancer. The majority of toxicities were 
experienced in the 25 mg cohort.  Most of the toxicity was experienced in the 25 mg cohort 27.  
Several investigations demonstrate no significant alterations in immunological and clinical 
parameters when higher dose lenalidomide (25 mg) is compared to low dose (5 mg). Plasma 
concentrations of lenalidomide have not correlated with the changes in PSA slope (3). The 
progression rates are similar in patients with biochemically recurrent prostate cancer receiving 
either 5 mg or 25 mg lenalidomide 27. Furthermore, from the experience of CLL and multiple 
myeloma studies, lenalidomide at 5 mg dosing may be sufficient for potentiating an immune 
response in vivo, by reducing regulatory T cells and production of IL-17 as well as improved 
clinical activity 28,29.    
Although initial PSA decline is not a validated predictive or prognostic biomarker, data from TAX 
327 and SWOG 99-16 showed that PSA decline of ≥ 30% within 3 months of chemotherapy has 
the highest degree of surrogacy for OS 30,31. Despite a small cohort with only 3 patients treated at 
15 mg daily, there is a suggestion that the clinical activity of a lower dose lenalidomide with less 
accompanying side effects may be comparable to those of the higher dose when used in 
combination with docetaxel, bevacizumab, and prednisone. 26 
In summary, the lack of significant variation in clinical parameters between lenalodimide 25 mg 
and lower dose levels, and the toxicity profile favoring lower doses make it reasonable to pursue 
further investigation of lower dose lenalidomide in metastatic castration-resistant prostate cancer. 
This approach could potentially allow for improved quality of life for patients on trial and sustained 
therapy, which could lead to improved clinical outcomes. 
 
1.2.5 Bevacizumab (rhuMab) 
Background:  Bevacizumab (rhuMAb) is a recombinant humanized anti-VEGF monoclonal 
antibody composed of human IgG1 framework regions and antigen-binding complementarily-
determining regions from a murine monoclonal antibody (muMAb VEGF A.4.6.1) which blocks 
the binding of human VEGF to its receptors. Approximately 93% of the amino acid sequence, 
including most of the antibody framework, is derived from human IgG1, and ~7% of the sequence 
is derived from the murine antibody.  
Bevacizumab has been approved by the FDA as first line therapy in combination with 
chemotherapy for treatment of patients with metastatic colorectal cancer or unresectable, locally 
advanced, recurrent or metastatic, non-squamous non-small cell lung cancer because of improved 
overall survival in the patients receiving combination therapy as compared to receiving 
chemotherapy alone.  In addition, bevacizumab has also received accelerated approval for use in 
patients with HER-2 negative, untreated metastatic breast cancer in combination with weekly 
paclitaxel because of a marked improvement in progression free survival. These lines of evidence 
demonstrate that bevacizumab is clinically effective when combined with chemotherapy. The 
important information about this agent and its use in studying prostate cancer is discussed as 
follows.      
Preclinical data: In cynomolgus monkeys, twice weekly IV treatments with bevacizumab (doses 
of 2, 10 and 50 mg/kg) for 4, 13 or 26 weeks were well tolerated, with no overt signs of acute 
toxicity 32,33. Animals with open growth plates showed physeal dysplasia as well as focal to diffuse 
chondroid necrosis and linear fissuring of the cartilaginous growth plate. Females treated with 10-

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
13 
 
50mg/kg twice weekly had decreased ovarian and uterine weights, which were associated with 
absence of corpora lutea. These findings were expected, considering the known role of VEGF in 
formation of the corpora lutea and of the growing bone 34.  A further study using a similar treatment 
regimen, in the recovery period the physeal dysplasia and ovarian and uterine changes induced by 
rhuMAb VEGF were partially reversible. No antibodies against bevacizumab were detected. 
Phase 1 Clinical studies: 
Two phase-1 studies have been performed. Study AVF0737g was a 
dose escalation trial of single and multiple intravenous (IV) administration of rhuMAb in patients 
with advanced malignancies. Five dose levels were evaluated (0.1, 0.3, 1.0, 3.0, and 10mg/kg). 
rhuMAb VEGF was administered as a 90 minute infusion on days 0, 28, 35 and 42 35. Study 
AVF0761g evaluated multiple doses of rhuMAb VEGF 3 mg/kg weekly for up to 8 weeks in 
combination with one of three cytotoxic chemotherapy regimens (5-fluorouracil/leucovorin, 
carboplatin/paclitaxel, or doxorubicin) in subjects with advanced solid malignancies 35. rhuMAb 
VEGF was administered as eight weekly doses of 3mg/kg. 
In both studies, rhuMAb VEGF appeared to be well tolerated. In study AVF0737g, 3 of 25 patients 
treated experienced tumor-related hemorrhagic events, possibly related to the administration of 
rhuMAb VEGF. In two cases the event was considered serious: an intracranial hemorrhage (at an 
occult cerebral metastasis) in a patient with hepatocellular carcinoma and bleeding at the tumor 
site in a 38-year-old woman with a slowly progressing sarcoma of the thigh. No patient in 
AVF0761g reported serious bleeding. No dose limiting toxicity was reached in either study. No 
antibodies to rhuMAb VEGF were detected after therapy in either study. Three subjects from each 
study subsequently enrolled in the extension study. 
Pharmacokinetics: In study AVF0737g, the pharmacokinetics of rhuMAb VEGF appeared to be 
linear for doses  1mg/kg with a half-life of approximately 15 days. Comparable pharmacokinetic 
data was seen in study AVF0761g. Co-administration of rhuMAb and cytotoxic chemotherapy did 
not appear to result in a change in the systemic concentration of the cytotoxic agents. 
Phase 2 Clinical Studies:   
Study 
Population 
Study Treatment 
rhuMAb VEGF 
Dosing Regimen 
AVF0757g 
Stage IIIB or IV non-
small cell lung cancer 
Carboplatin/paclitaxel  
rhuMAb VEGF 
7.5mg or 15mg/kg every 
3 weeks until disease 
progression 
AVF0780g 
Metastatic 
colorectal 
cancer 
5-FU/leucovorin 
 rhuMAb VEGF 
5mg or 10mg/kg every 
other week until disease 
progression 
AVF0776g 
Relapsed 
metastatic 
breast cancer 
Single-agent rhuMAb 
VEGF 
3,10 or 20 mg/kg every 
other week over a 168-
day treatment period or 
until disease progression 
AVF0775g 
Hormone-refractory 
prostate cancer 
Single-agent rhuMAb 
VEGF 
10mg/kg every other 
week over a 168-day 
treatment period or until 
disease progression 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
14 
 
In Study AVF0780g, patients with metastatic colon cancer were treated with either 5-
FU/leucovorin (500mg/m2 5-FU and 500mg/m2 leucovorin administered weekly for six weeks, 
with courses repeated every eight weeks) alone or in combination with rhuMAb VEGF 5mg/kg or 
10mg/kg every two weeks. Response rates were 17%, 40% (p=. 03) and 24% (p=. 23), respectively. 
A prolonged time to disease progression was seen in patients treated with rhuMAb VEGF 5mg/kg 
in combination with chemotherapy (9.0 months p=. 005) compared with those who received 
rhuMAb VEGF 10mg/kg (7.2 months p= .217) or chemotherapy alone (5.2 months) 36.  
The anti-VEGF antibody Bevacizumab (rhuMAb) was evaluated as a single agent in several 
malignancies including CRPC 35,37. In a Phase II trial 15 patients with CRPC were treated with 10 
mg/kg every 14 days. Results of the study showed that though the drug was tolerated well, there 
were no significant objective responses. Picus et al. is conducted a CALGB trial looking at the use 
of bevacizumab, estramustine and docetaxel in 79 patients with CRPC using a dose of 15 mg/kg 
of bevacizumab every 3 weeks.  Early results show that 60% of patients had a PR and 78% of 
patients had a >50% decrease in PSA in those patients with sufficient data to analyze. The 
estimated median survival was 24 months. This regimen was well tolerated, though there was some 
increase in thrombosis, which might be associated with estramustine or the combination of 
estramustine with bevacizumab 38.   
1.2.5.1 Toxicities  
 
The following are the important toxicities. The detailed information can be seen in Section 7.2.  
Hemorrhage:  Life threatening hemorrhage was seen in a Phase I trial (AVF0737g) in the form of 
an intracranial hemorrhage (at an occult cerebral metastasis) in a patient with hepatocellular 
carcinoma and in the Phase II study (AVF0757g) in the form of massive hemoptysis or 
hematemesis. There were 6 life-threatening hemorrhages among 66 patients receiving rhuMAb 
VEGF-treated patients of which four of these events were fatal. An analysis of possible risk factors 
for life-threatening bleeding identified squamous cell histology as a risk factor (4 of 6 bleeds 
occurred in patients with squamous cell histology whereas only 13 of 66 rhuMAb VEGF-treated 
patients had squamous histology). A number of investigations were performed on two of the 
patients with pulmonary hemorrhage and in eight patients in AVF0780g receiving rhuMAb VEGF 
including platelet count, prothrombin time, activated prothrombin time, fibrinogen, bleeding time, 
euglobulin clot lysis, d-dimer, alpha2-antiplasmin, PFA-100 (a platelet function assay) and these 
were all within normal range (Novotny,W. Genentech Inc personal communication).  
Overall, grade 3 and 4 bleeding events were observed in 4.0% of 1132 patients treated with 
bevacizumab in a pooled database from eight phase I, II, and III clinical trials in multiple tumor 
types (bevacizumab Investigator Brochure, October 2005). The hemorrhagic events that have been 
observed in bevacizumab clinical studies were predominantly tumor-associated hemorrhage (see 
below) and minor mucocutaneous hemorrhage. 
Mucocutaneus Hemorrage:  Across all bevacizumab clinical trials, mucocutaneous hemorrhage 
has been seen in 20%-40% of patients treated with bevacizumab. These were most commonly 
NCI-CTC Grade 1 epistaxis that lasted less than 5 minutes, resolved without medical intervention 
and did not require any changes in bevacizumab treatment regimen. There have also been less 
common events of minor mucocutaneous hemorrhage in other locations, such as gingival bleeding 
and vaginal bleeding. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
15 
 
Thrombosis:  Both venous and arterial thromboembolic (TE) events, ranging in severity from 
catheter-associated phlebitis to fatal, have been reported in patients treated with bevacizumab in 
the colorectal cancer trials and, to a lesser extent, in patients treated with bevacizumab in NSCLC 
and breast cancer trials.  
In Study AVF0780g in metastatic colorectal cancer, venous and arterial thrombosis were seen 
more frequently than in patients treated with rhuMAb VEGF plus 5-FU/leucovorin than in patients 
treated with 5-FU/leucovorin alone: 3 of 35 patients in the control arm, 9 of 35 patients in the 
5mg/kg rhuMAb VEGF arm and 4 of 32 patients in the 10mg/kg rhuMAb VEGF arm. One event 
was fatal (a pulmonary embolism in the 10mg/kg arm) and three events required study 
discontinuation (a pulmonary embolism and a superior mesenteric vein occlusion in the 5mg/kg 
arm and a cerebrovascular event in the 10mg/kg arm). Cancer patients are known to be at high risk 
for thromboembolism owing to a number of factors including intrinsic tumor pro-coagulant 
activity, immobilization, indwelling catheters and the pro-thrombotic effects of chemotherapy. 
The incidence of thrombosis among patients with breast cancer receiving chemotherapy is 
approximately 5-10% being higher in patients on tamoxifen and in patients with metastatic disease 
39. In the first 59 patients with metastatic breast cancer treated with rhuMAb VEGF monotherapy, 
two patients have developed a subclavian/axillary deep venous thrombosis on the side of the 
indwelling central line. 
Aspirin is a standard therapy for primary and secondary prophylaxis of arterial thromboembolic 
events in patients at high risk of such events, and the use of aspirin ≤ 325 mg daily was allowed in 
the five randomized studies discussed above. Use of aspirin was assessed routinely as a baseline 
or concomitant medication in these trials, though safety analyses specifically regarding aspirin use 
were not preplanned. Due to the relatively small numbers of aspirin users and arterial 
thromboembolic events, retrospective analyses of the ability of aspirin to affect the risk of such 
events were inconclusive. However, similarly retrospective analyses suggested that the use of up 
to 325 mg of aspirin daily does not increase the risk of grade 1-2 or grade 3-4 bleeding events. 
Further analyses of the effects of concomitant use of bevacizumab and aspirin in colorectal and 
other tumor types are ongoing. 
Hypertension: An increased incidence of hypertension has been observed in patients treated with 
bevacizumab.  Grade 4 and 5 hypertensive events are rare. Clinical sequelae of hypertension are 
rare but have included hypertensive crisis, hypertensive encephalopathy, and reversible posterior 
leukoencephalopathy syndrome (RPLS) (product insert). 
VEGF has been shown to induce nitric oxide-mediated vasodilatation and hypotension 40. In a 
recent study, VEGF has been shown to govern endothelial nitric oxide synthase expression via a 
KDR/flk-1 receptor and protein kinase C signaling pathway, which suggests a possible mechanism 
for rhuMAb VEGF 18. 
There is no information on the effect of bevacizumab in patients with uncontrolled hypertension 
at the time of initiating bevacizumab therapy.  Therefore, caution should be exercised before 
initiating bevacizumab therapy in these patients.  Monitoring of blood pressure is recommended 
during bevacizumab therapy.  Optimal control of blood pressure according to standard public 
health guidelines is recommended for patients on treatment with or without bevacizumab.   
Temporary interruption of bevacizumab therapy is recommended in patients with hypertension 
requiring medical therapy until adequate control is achieved.  If hypertension cannot be controlled 
with medical therapy, bevacizumab therapy should be permanently discontinued.  Bevacizumab 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
16 
 
should be permanently discontinued in patients who develop hypertensive crisis or hypertensive 
encephalopathy. 
Proteinuria:   
The severity of proteinuria has ranged from asymptomatic and transient events detected on routine 
dipstick urinalysis to nephrotic syndrome; the majority of proteinuria events have been Grade 1.   
NCI-CTC Grade 3 proteinuria was reported in up to 3% of bevacizumab-treated patients, and 
Grade 4 in up to 1.4% of bevacizumab-treated patients.  The proteinuria seen in bevacizumab 
clinical trials was not associated with renal impairment and rarely required permanent 
discontinuation of bevacizumab therapy.  Bevacizumab should be discontinued in patients who 
develop Grade 4 proteinuria (nephrotic syndrome) 
Patients with a history of hypertension may be at increased risk for the development of proteinuria 
when treated with bevacizumab.  There is evidence from the dose-finding, Phase II trials 
(AVF0780g, AVF0809s, and AVF0757g) suggesting that Grade 1 proteinuria may be related to 
bevacizumab dose. 
A recent study has shown that VEGF mediates glomerular repair, which suggested a possible 
mechanism for rhuMAb VEGF-associated proteinuria 18. 
Congestive Heart Failure (CHF):   
In clinical trials CHF was observed in all cancer indications studied to date, but predominantly in 
patients with metastatic breast cancer.  In the Phase III clinical trial of metastatic breast cancer 
(AVF2119g), 7 (3%) bevacizumab-treated patients experienced CHF, compared with two (1%) 
control arm patients.  These events varied in severity from asymptomatic declines in left 
ventricular ejection fraction (LVEF) to symptomatic CHF requiring hospitalization and treatment.  
All the patients treated with bevacizumab were previously treated with anthracyclines 
(doxorubicin cumulative dose of 240360 mg/m2).  Many of these patients also had prior 
radiotherapy to the left chest wall.  Most of these patients showed improved symptoms and/or left 
ventricular function following appropriate medical therapy. 
In a randomized, Phase III trial of patients with previously untreated metastatic breast cancer 
(E2100), the incidence of LVEF decrease (defined as NCI-CTC Grade 3 or 4) in the 
paclitaxel  bevacizumab arm was 0.3% versus 0% for the paclitaxel alone arm  
No information is available on patients with preexisting CHF of New York Heart Association 
(NYHA) Class IIIV at the time of initiating bevacizumab therapy, as these patients were excluded 
from clinical trials 
Dyspnea: In study AVF2107g, an ongoing trial with bevacizumab with 5FU/leucovorin in 
metastatic colon cancer, one patient on this study developed dyspnea and pneumonitis requiring 
intubation eleven days after receiving her fifth infusion of bevacizumab with irinotecan and 5-FU.  
Two other patients on this study also developed grade IV respiratory failure felt to be related to 
end-of-life events and not directly related to the drug.  In study AVF0757g, for stage IIIb and IV 
non-small cell lung cancer, 3 patients had grade IV dyspnea events, the etiology of which is unclear 
but at least partially attributable to their underlying disease.  No other grade IV dyspnea events 
were reported in other trials.  
Other rare but severe toxicities, which include gastrointestinal perforation, fistula, reversible 
posterior leukoencephalopathy syndrome, and neutropenia. Reference should be made to the 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
17 
 
product labeling of bevacizumab. Specific caution and clinical alertness should be exercised for 
patients receiving the agent.  
1.2.6 Rationale for combinatorial therapy 
The rationale in replacing thalidomide is based not only on the toxicity of lenalidomide but also 
on its molecular properties. Although lenalidomide does have less VEGF inhibition, it has more 
TNF inhibition.  In microarray experiments using thalidomide and thalidomide analogs (the 
analogs are similar to the active metabolite of thalidomide) multiple angiogenesis factors are down 
regulated (KIF5A, TTK, etc), but not VEGF. (Dr. Figg’s unpublished data).   VEGF expression 
was not altered in xenograft experiments using these analogs, however PDGF was significant 
reduced.   
During the development of thalidomide analogs such as lenalidomide (RevlimidTM), chemical 
modifications of the thalidomide template were made in an effort to specifically optimize the anti-
TNFα activity.  Two discrete sub-structures of the thalidomide molecule were altered, namely the 
phthaloyl and glutarimide portions of the molecule.  Both families of compounds were tested for 
TNF-α inhibition and further structural modifications were made to optimize this activity.  The 
primary hydrolysis products of thalidomide were also used as subsidiary templates even though 
they showed poor potency as TNF-α modulators in their unmodified form.  This strategy led to the 
development of two primary families of compounds showing enhanced TNF-α-inhibition 
properties: substituted phthaloyl analogs with intact glutarimide functionality and molecules which 
retain the basic phthaloyl moiety, but have substituted α-amino acid functionality in place of the 
glutarimide ring of thalidomide, such as lenalidomide (RevlimidTM).  The finding that these varied 
structural modifications could yield the same enhanced potency in TNF-α inhibition suggests the 
presence of two different pharmacophores that most likely have different pharmacological targets, 
but are both capable of TNF-α downregulation. 
1.2.7 TNF Inhibition 
Lenalidomide (RevlimidTM) is a member of the Immunomodulatory (ImiD) class of thalidomide 
analogs.  In vitro studies have shown that lenalidomide is more potent than thalidomide in 
inhibiting TNF-α production.  Furthermore, in preliminary non-clinical and clinical studies 
conducted to date, lenalidomide (RevlimidTM) appears to lack the sedative and teratogenic activity 
of thalidomide. 
The pertinent pharmacologic activity of lenalidomide (RevlimidTM) has been investigated in two 
in vitro studies.  These studies suggest a pharmacological activity profile for lenalidomide 
(RevlimidTM) that is similar to, but with a higher potency than that of thalidomide.  Lenalidomide 
(RevlimidTM) is approximately 50 to 2000 times more potent than thalidomide in these assays.  In 
addition, these studies have demonstrated that lenalidomide (RevlimidTM) has pharmacological 
activities that could be beneficial in the treatment of patients with MDS, i.e., inhibition of secretion 
of pro-inflammatory cytokines.  Corral et al. examined the modulation of production of various 
cytokines by lenalidomide (RevlimidTM) and other thalidomide analogs.  Lenalidomide was 
approximately 50 to 100 times more potent than thalidomide in stimulation the proliferation of T-
cells following primary induction provided by T-cell receptor (TCR) activation.  Lenalidomide 
(RevlimidTM) was also approximately 50 to 100 times more potent than thalidomide in augmenting 
the production of IL-2 and IFNα following TCR activation of PBMC (IL-2) or T-cells (IFN-α).  In 
addition, lenalidomide (RevlimidTM) exhibited dose-dependent inhibition of LPS-stimulated 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
18 
 
production of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 by PBMC. Finally, 
lenalidomide increased production of the anti-inflammatory cytokine IL-10 by LPS-stimulated 
PBMC. 
In vitro models of anti-TNF activity have shown that lenalidomide, an analogue of thalidomide, 
has IC50s of ~100 nM (25.9 ng/ml) and ~480 nM (103.6 ng/ml) against TNF produced by LPS-
stimulated human peripheral blood mononuclear cells and LPS-LPS-stimulated human whole 
blood respectively (Investigator’s brochure). Thalidomide, by comparison, has TNF IC50 in human 
peripheral blood mononuclear cells of ~194 µM (50.2 µM) (Investigator’s brochure) (see Table 
1). These data suggest an overlap of biologic function between thalidomide and lenalidomide.  
1.2.8 Antiangiogenic Activity 
Recent data suggest this overlap also includes antiangiogenic effects. In the rat aortic ring 
angiogenesis assay, lenalidomide demonstrated a 45% inhibitory effect on microvessel outgrowth 
over a range of 0.1 - 100 µM compared to the controls by Figg’s laboratory, while Celgene reported 
over 66% inhibition.   
Table 1 compares the activity of lenalidomide to thalidomide in several preclinical models.  
Treatments 
Mean MVD 
Control 
29 
Thalidomide 
19 
lenalidomide 
10 
 
The combination of the four drugs is based on principles similar to that from our current ongoing 
trial. The CALGB has published data to suggest that an elevation in VEGF is a poor prognosis 
factor in prostate cancer and the reduction of VEGF results in a survival advantage. We believe 
that by combining the anti-VEGF activity of bevacizumab with the anti-angiogenic activity of 
lenalidomide (against multiple targets but not VEGF) we will have effectively suppressed all of 
the important angiogenic factors (preliminary data from Dr. Figg’s lab). This approach will begin 
to test the hypothesis that the blockade of multiple factors in angiogenic is the most effective anti-
tumor strategy. 
Picus et al combined docetaxel and estramustine with the anti-VEGF antibody bevacizumab in a 
phase II study of 79 patients with CRPC. [11] The rationale for this study was in part based on the 
evidence that patients with CRPC treated with suramin who had lower baseline VEGF levels 
showed an increase in overall survival compared to those with higher baseline VEGF levels (17 
vs. 10 mos. p= .024). In the same study, patients who had at least a 15% reduction of VEGF levels 
form their baseline also had increased survival advantage (28). 
In the study by Picus, patients received docetaxel (70 mg/m2 every 21 days), estramustine (280 
mg on day 1-5) and bevacizumab (15 mg/kg) over a 21- day cycle. Preliminary analysis showed 
that 78% of patients had a PSA decline of  50% and that 60% of patients had a partial response 
in their measurable disease. While the regimen was fairly well tolerated, there was an increase in 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
19 
 
thrombotic events. Based on these promising results, a phase 3 trial (CALBG 90401) is currently 
ongoing, though estramustine is substituted for by prednisone to improve on the toxicity profile.   
As discussed earlier the combinations of docetaxel and lenalidomide and docetaxel with 
bevacizumab appear to be generally tolerated in CRPC with encouraging anti-tumor activity. The 
unprecedented antitumor activity observed with the combination of docetaxel, bevacizumab, 
thalidomide and prednisone, presumably through targeting different angiogenic factors, suggests 
that the new combination with lenalidomide’s replacing thalidomide is highly worthy of being 
studied for development of a more effective regimen for metastatic CRPC but with less toxicity.  
1.2.9 Correlative Studies 
Plasma concentrations of docetaxel will be determined to assess interactions between docetaxel 
and the concomitant therapy. Plasma concentrations of lenalidomide will be determined to assess 
a possible interaction between lenalidomide and the concomitant therapy. Single nucleotide 
polymorphisms (SNPs) in genes that play an important role in elimination pathways for docetaxel 
(in the CYP3A4 and CYP3A5 genes) and lenalidomide (CYP2C19) will be evaluated.  
Further analysis will be performed for the following genes on blood samples: ABCB1, ABCG2, 
CYP1B1, NQO1, COMT, CYP17 and CYP19, OATP1B3, HIF-1alpha, VEGF, TSP1, Il-6, TNF-
alpha, CYP2B6, ABCC1, ABCC6, UGT1A1, UGT1A9, CYP2A7, PPARD, SULT1C2, and 
CHST3.  
For evaluating angiogenic markers, we will collect both serum and urine samples at baseline and 
monthly to measure vascular endothelial growth factor (VEGF) levels. 
Circulating apoptotic endothelial cells may serve as a surrogate marker in monitoring anti-
angiogenesis.  The combination of thalidomide with docetaxel led to an increase in apoptotic 
endothelial cells in prostate cancer xenograft models, which was correlated with the observed 
enhanced anti-tumor activity of the combination.   With those preclinical findings, circulating 
apoptotic endothelial cells were evaluated at baseline and again at 6 weeks in the patients enrolled 
in the ATTP trial. (Preliminary data from Dr. Trepel’s lab) Patients with >75% PSA declines had 
a significant increase in the apoptotic endothelial cells as compared to those with PSA declines 
less than 75%, suggesting that this triple combination may be hitting tumor angiogenesis target. 
We will continue to evaluate circulating apoptotic endothelial cells pre- and post-treatment in this 
trial with lenalidomide.  
1.2.10 Conclusion 
Though this would be the first trial to combine docetaxel with bevacizumab, lenalidomide, and 
prednisone in patients with metastatic CRPC, the combination of lenalidomide with bevacizumab 
or with docetaxel has been found to be acceptable in safety from other studies. Most importantly, 
we have found from our phase 2 study that the combination of docetaxel, bevacizumab, 
thalidomide and prednisone, although highly active, requires dose reductions in thalidomide in the 
majority of patients. We believe that the new combination with docetaxel, bevacizumab, 
lenalidomide and prednisone has the potential to make a significant impact in the treatment of the 
disease. If this trial is successful, a larger randomized trial through the cooperative groups with 
survival as an endpoint would be warranted.  

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
20 
 
2 
PATIENT SELECTION 
2.1 
ELIGIBILITY CRITERIA 
2.1.1 Inclusion Criteria 
 
Castrate-resistant metastatic adenocarcinoma of the prostate defined as progressive 
metastatic disease (see below) while on GnRH agonists or post surgical castration.  All 
patients enrolled will be required to have   evaluable disease on imaging studies. 
 
Histopathological documentation of prostate cancer confirmed in the NCI Laboratory 
of Pathology at the National Institutes of Health, the Pathology Department at Walter 
Reed Medical Center, or the Pathology Department at National Naval Medical Center, 
prior to starting this study.  In addition, patients whose slides are lost or unavailable 
will be eligible for the study if they provide documentation of prostate cancer and if 
they meet criteria of clinically progressive prostate cancer as outline (see below). 
 
Clinically progressive prostate cancer documented prior to entry.  Progression must be 
evidenced and documented by any of the following parameters: 
i) Two consecutively rising PSA levels apart of 2 weeks 
ii) At least one new lesion on bone scans. 
iii) Progressive measurable disease. 
 
Patients must have undergone bilateral surgical castration or must continue on 
GnRH agonist. 
 
Those patients receiving an anti-androgen agent for at least 6 months and are 
entering the trial due to a rise in PSA must demonstrate a continued rise in PSA 
4 weeks after stopping flutamide and 6 weeks after stopping bicalutamide or 
nilutamide. 
 
May not have received any chemotherapy or antiangiogenic therapy (including 
thalidomide, lenalidomide, bevacizumab and its target’s receptor inhibitors) for 
metastatic prostate cancer.  (Prior immunotherapy/vaccine, experimental 
hormonal therapy, radiation and (neo)adjuvant chemotherapy is permitted) 
 
Age > 18 years 
 
ECOG performance status < 2 
 
Must have adequate organ and marrow function as defined below: 
 
 
 
Laboratory 
Test 
 
Required value 
Leukocytes 
>3,000/μl 
Absolute neutrophil count 
>1,500/μl 
Platelets 
>100,000/μl 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
21 
 
Total bilirubin 
 
≤1.5 X institutional upper limits of 
normal, or < 3 mg/dl in a subject with 
Gilbert Syndrome 
AST (SGOT) and ALT (SGPT) 
<2.5 X institutional upper limit of 
normal 
Creatinine clearance 
> 50 mL/min/1.73 m2 for patients with 
creatinine levels above institutional 
normal. 
 
 
Recovered from any acute toxicity from surgery or radiotherapy, with 
minimum 4 weeks from major surgical procedures and 2 weeks from 
radiotherapy 
 
Must be willing to travel from their home to the NIH for follow-up visits 
 
Able and willing to follow instructions and conform to protocol. 
 
Patients may have had no other active malignancy within the past 2 years with 
the exception of non-melanoma skin cancer and superficial bladder carcinoma. 
 
No history of myocardial infarction within the past 6 months, uncontrolled 
CHF or uncontrolled angina pectoris 
 
Patients must agree to use adequate contraception (abstinence; hormonal or 
barrier method of birth control) prior to the study, during the study, and at least 
six months after completion.  Males must agree to use a latex condom during 
sexual contact with females of childbearing potential while participating in the 
study and for at least six months following, even if a man has undergone a 
successful vasectomy. All patients must be counseled at a minimum of every 
28 days about pregnancy precautions and risks of fetal exposure as indicated 
in the consent.  
 
Subjects must agree not to share study drug and not donate blood, sperm, or semen. 
A female of childbearing potential is a sexually mature woman who: 1) has not 
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally 
postmenopausal for at least 24 consecutive months (i.e., has had menses at any time 
in the preceding 24 consecutive months).  
 
Ability to understand and the willingness to sign a written informed consent 
document. 
2.1.2 Exclusion Criteria 
 
Present clinical signs or symptoms of current active brain and/or leptomeningeal 
metastases confirmed by CT or MRI brain scan. Patients with previously treated 
brain metastases are allowed to participate in the study.  
 
Treated brain metastases are defined as having no ongoing requirement for steroids 
and no evidence of progression or hemorrhage after treatment for at least 3 months, 
as ascertained by clinical examination and brain imaging (MRI or CT).  (Stable dose 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
22 
 
of anticonvulsants are allowed).  Treatment for brain metastases may include whole 
brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or 
equivalent) or a combination as deemed appropriate by the treating physician.  
Patients with CNS metastases treated by neurosurgical resection or brain biopsy 
performed within 3 months prior to Day 1 will be excluded.       
 
Uncontrolled, intercurrent illness including, but not limited to, symptomatic 
congestive heart failure (AHA Class II or worse), unstable angina pectoris  
 
Psychiatric illness/social situations that would limit compliance with study 
requirements. 
 
Prior history of hypertensive crisis or hypertensive encephalopathy 
 
Proteinuria, as demonstrated by a 24 hour protein of  2000 mg.  Urine protein should 
be screened by urine analysis. If urine dipstick is >1.0+, then a 24 hour urine 
collection for total protein will need to be obtained and the level should be < 2000mg 
for patient enrollment. 
 
Serious, non-healing wound, active ulcer, or untreated bone fracture, including tumor-
related pathological fracture 
 
Evidence of bleeding diathesis or significant coagulopathy (in the absence of 
therapeutic anticoagulation) 
 
HIV-positive patients receiving combination anti-retroviral therapy are excluded from 
the study because of possible pharmacokinetic interactions with docetaxel, 
bevacizumab, and/or the combination. 
 
Greater than Grade 2 peripheral neuropathy at baseline  
 
History of allergic reaction to docetaxel, prednisone, lenalidomide and/or 
bevacizumab or related products. 
 
Patients who are unable to ingest oral medication. 
 
Patients on treatment for VTE. 
 
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess      
within 6 months prior to day 1  
 
Major surgical procedure, open biopsy or significant traumatic injury within 28 days      
prior to Day 1 therapy 
 
Anticipation of need for major surgical procedures during the course of the study 
 Core biopsy or other minor surgical procedure, excluding placement of a vascular 
access device, within 7 days prior to Day 1 
 Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair, aortic 
dissection or recent peripheral arterial thrombosis) within 6 months prior to Day 1  
 Patients with clinically significant cardiovascular disease are excluded 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
23 
 
o Inadequately controlled HTN (SBP > 160 mmHg and/or DBP > 90 mmHg despite    
antihypertensive medication)  
o History of CVA within 6 months (see additional requirement for adjuvant 
protocols), myocardial infarction or unstable angina within 6 months (see 
additional requirement for adjuvant protocols) 
o New York heart association grade II or greater congestive heart failure 
o Serious and inadequately controlled cardiac arrhythmia 
o Clinically significant vascular disease as stated above  
 
Patients with known hypersensitivity of Chinese hamster ovary cell products or           
other recombinant human antibodies 
2.2 
INCLUSION OF WOMEN AND MINORITIES 
Men of all races and ethnic groups are eligible for this trial.  Every effort will be made to recruit 
minorities in this study.  Women are ineligible for this study due to the nature of the disease. 
3 
ON-STUDY RESEARCH EVALUATION 
3.1 
EXAM 
Complete history and physical examination (including height, weight, and ECOG performance 
score) with documentation of 1) measurable disease, 2) narcotic use and pain assessment and 3) 
prior therapies (hormonal, surgical, radiotherapeutic, and cytotoxic) will be conducted prior to 
starting therapy.  A complete medication history will be obtained prior to starting, including over 
the counter medications, homeopathic remedies, vitamins, and alternative therapies.  Dental 
evaluation will be obtained for selected patients as time allows prior to initiating protocol therapy. 
3.2 
IMAGING STUDIES (BASELINE)   
Within 4 weeks prior to enrollment 
3.2.1 Chest X-ray, CT scan of chest, abdomen and pelvis, and Technetium-99 Bone 
Scintigraphy.  For selected patients as time allows, CT of the mandible will be obtained. 
3.3 
LABORATORY EVALUATION 
Baseline is to be obtained within 16 days prior to enrollment 
o Hematological Profile: CBC with differential and platelet count, prothrombin 
time, activated partial thromboplastin time 
o Biochemical Profile: electrolytes, BUN, creatinine, glucose, AST, ALT, 
bilirubin, calcium, phosphorous, albumin, magnesium, alkaline phosphatase, 
TSH  
o Urine analysis 
o Tumor Marker Profile, PSA (within 7 days prior to enrollment) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
24 
 
o Testosterone level (baseline only, should be obtained within 8 weeks prior to 
day 1); not required for patients with prior bilateral orchiectomy.  
o Thyroid stimulating hormone (TSH) 
3.4 
EKG  
EKG within 16 days prior to enrollment. 
4 
PATIENT REGISTRATION 
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) 
within 24 hours of signing consent. A registration Eligibility Checklist from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm) must be completed and sent via 
encrypted email to:  NCI Central Registration Office (HOIS) ncicentralregistration-
l@mail.nih.gov. After confirmation of eligibility at Central Registration Office, CRO staff will 
call pharmacy to advise them of the acceptance of the patient on the protocol prior to the release 
of any investigational agents. Verification of Registration will be forwarded electronically via e-
mail. Please note, it is very important for all registrars to acquire encrypted e-mail from NIH Help 
Desk, since the verification of registration includes patient’s information. A recorder is available 
during non-working hours. 
Each site must have two trained counselors available for counseling all patients receiving 
lenalidomide supplied by the Division of Cancer Treatment and Diagnosis.  Trained counselors 
must complete training using the online program provided free by Celgene, the Celgene Pregnancy 
Prevention Counseling Program (CPPCP). Registration for CPPCP is done by completing the form 
found in Appendix D and following the directions provided in the email notification. After the 
training is complete, the counselors must generate a training certificate and provide it to the PMB 
(fax# 301-402-0429 attn. CPPCP) for documentation. Sites may not order lenalidomide until 
documentation for two trained counselors is provided to the appropriate office. 
5 
TREATMENT PLAN 
5.1 
STUDY DESIGN  
This is an open label, phase 2 study of up to 45 patients who will receive docetaxel 75 mg/m2 IV 
over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle), plus bevacizumab 15 
mg/kg cycle 1 day 1, repeated every 21 days, lenalidomide once daily days 1-14 of every 21, and 
prednisone 10 mg orally every day.  All patients will receive 8 mg of oral dexamethasone 12 hours 
before, 3 hours before, and 1 hour before docetaxel treatment.  If a patient misses a pretreatment 
dose of dexamethasone, he may receive dexamethasone 8 mg intravenously prior to docetaxel. 
Patients who were on prior regimen which included a lower dose of decadron and did not have a 
reaction do not have to increase their decadron to the 8 mg dose.  All patients will be given 
pegfilgrastim on day 2 of each cycle at least 24 hours after the administration of docetaxel to 
reduce the risk of febrile neutropenia. 
Radiographic studies (CT scans of the chest, abdomen, and pelvis, Technetium-99m bone 
scintigraphy) will be performed at baseline, after second cycle and then every 3 cycles.  In order 
to minimize radiation exposure, if there is no evaluable soft tissue disease on baseline CT, future 
CT scans will not be obtained unless clinically indicated.  Patients remaining on-study after two 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
25 
 
years will have CT and bone scans performed only if there are signs of clinical progression at 
physician’s discretion. If there is no significant toxicity or evidence of disease progression (as 
defined below), therapy will continue.  In addition, patients who had not undergone bilateral 
orchiectomy will continue to receive medical castration with a LHRH agonist (such as leuprolide 
or goserelin acetate). 
5.2 
AGENT ADMINISTRATION 
Study agents may be administered within 3 days of timepoints given below in order to 
accommodate patient travel, hospitalizations, variations in clinical availability due to holidays, or 
other unpredictable personal or family situations.  
5.2.1 Docetaxel Administration 
Docetaxel 75 mg/m2 will be administered intravenously over 60 minutes on cycle 1 day 1 and 
repeated every 21 days (i.e. a 3-week cycle).  All patients will receive 8 mg of dexamethasone 
orally 12 hours, 3 hours prior and 1 hour prior to docetaxel.  Patients who were on prior regimen 
which included a lower dose of decadron and did not have a reaction do not have to increase their 
decadron to the 8 mg dose.  If a patient misses a pretreatment dose of dexamethasone, he may 
receive dexamethasone 8 mg intravenously prior to docetaxel.  Patients who have excessive 
dexamethasone-induced toxicity (defined as Grade 3 toxicity in the CTCAE v3.0 until December 
31, 2010 and in CTCAE v4.0 beginning January 1, 2011 felt to be caused by dexamethasone) may 
have their doses altered to a single 8 mg intravenously dose of dexamethasone prior to docetaxel 
administration. 
In the event of a hypersensitivity reaction, infusion times may be longer.  Hypersensitivity 
reactions may be managed clinically according to PI discretion.  Please see Appendix H for 
suggested management guidelines (optional). 
 
5.2.2 Bevacizumab Administration 
Bevacizumab 15 mg/kg diluted in 0.9% Sodium Chloride Injection, USP, to a total volume of 100 
ml. Administration will be as an intravenous infusion over 30-90 minutes every 21 days (see 
below). The initial bevacizumab dose will be delivered as an IV infusion over 90  10 minutes. If 
the first infusion is tolerated without infusion-associated adverse events (fevers and/or chills), the 
second infusion maybe delivered over 60  10 minutes. If the 60 minute infusion is well tolerated, 
all subsequent infusions maybe delivered over 30  10 minutes. If a patient experiences an 
infusion-associated adverse event, subsequent infusions will be given over the shortest period that 
was well tolerated. The patient may be pre-medicated for the next bevacizumab infusion. 
5.2.3 Lenalidomide Administration 
A two dose level escalation of lenalidomide, from 15 mg to 20mg to 25 mg once daily administered 
for 14 days every 21 days, will be evaluated at the beginning of the study. The first 3 patients will 
receive lenalidomide 15 mg orally. If none of the 3 patients develops an unacceptable toxicity in 
the first cycle that is felt to be probably or definitely related to lenalidomide and not the other 
agents (>Grade 3 non-hematologic toxicity), next three patients will receive lenalidomide at 20 
mg once daily. If none of the 3 patients develops an unacceptable toxicity in the first cycle that is 
felt to be probably or definitely related to lenalidomide and not the other agents (>Grade 3 non-

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
26 
 
hematologic toxicity), next three patients will receive lenalidomide at 25 mg once daily.  However, 
if 1 of the 3 patients at 15 mg or 20mg level of lenalidomide has an unacceptable toxicity, then 3 
more patients will be treated at 15 mg or 20mg.  Dose escalation to 25 mg of lenalidomide would 
occur only if 1 of the 6 patients has an unacceptable lenalidomide-related toxicity. Dose escalation 
would be halted if >2 of the 6 patients develop unacceptable toxicity related to lenalidomide, and 
the lenalidomide’s dosing for continuation of the study will be evaluated at 10 mg once daily for 
its suitability for combination. In general, the dose selected for combination will be the maximum 
dose at which no more than 1/6 has unacceptable toxicity. 
Patients treated with lenalidomide at 25 mg once daily will follow the same rules as discussed 
above. Three to six patients will be evaluated at 25 mg of lenalidomide, depending on the incidence 
of unacceptable toxicity in the first three patients treated. Once the 25 mg dosing of lenalidomide 
or other doses safe for the combination is determined, future patients will all start at that dose level 
and continue it while being on study. Patients will continue their initial starting dose throughout 
the study.  
Patients in the expansion cohort will receive a lower dose of lenalidomide (15 mg) and will follow 
the same rules as discussed above.  Up to eleven patients may be evaluated at the 15 mg dose of 
lenalidomide.   
5.2.4 Prednisone Administration 
Patients will receive their first dose of prednisone orally on day 1 (10 mg/day), administered at 5 
mg twice daily, and will continue this dosing throughout the cycle. 
5.2.5 Other treatments required  
Enoxaparin will be administered subcutaneously once daily while on lenalidomide. If lenalidomide 
is discontinued, enoxaparin will be continued for 7 days after its cessation, then enoxaparin will 
be discontinued. Dosing of enoxaparin will be guided by the table below: 
Weight (kg) 
Enoxaparin Dose  
<55 
40mg subcut once daily 
55 – 75 
60mg subcut once daily 
>75  
80mg subcut once daily 
 
Patients will receive pegfilgrastim at a dose of 6mg subcutaneously on day 2 of each cycle at least 
24 hours after the administration of docetaxel. 
5.2.6 Self-administered medications 
Patients will be provided with a medication checklist (see Appendix B) as well as a medication 
instruction sheet (see Appendix C) to assist in keeping track of self –administered medications. 
5.3 
TREATMENT MODIFICATIONS 
The following adjustments will only apply if the toxicities reported are attributed by the 
investigators to be at least possibly related to docetaxel, bevacizumab, or lenalidomide.    Dose 
delay and dose reduction will be according to the following rules: 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
27 
 
5.3.1 Dose modifications for docetaxel 
Administration of docetaxel will be withheld on a treatment day for the occurrence of dose-limiting 
toxicity (DLT) defined as grade 3 or 4 hematologic toxicity or non-hematologic toxicity ≥ grade 3.  
Patients should have an ANC 1500 cells/mm3, a platelet count  75,000 cells/mm3 (grade 1 
hematologic toxicity) and resolution of any grade 3 or higher non-hematologic toxicity to < grade 
1 or baseline in order to initiate another treatment cycle of docetaxel. It should be noted that no 
platelet transfusions would be allowed within 7 days prior to docetaxel administration.  
For febrile neutropenia developed within a prior cycle and resolved before next cycle, docetaxel 
can be continued at a dosage decreased by 25% during future cycles.  Additionally, for grade 4 
neutropenia lasting greater than or equal to 5 days, docetaxel can be continued at a dosage 
decreased by 25% during future cycles. 
5.3.2 Docetaxel Dose Modifications for Neutropenia without Fever: 
When Neutrophils fall to 
for a Duration of 
Recommended Course 
<1000 but ≥ 500/mcL (Grade 3) 
Any length of time 
No dose reduction for future cycles. 
<500/mcL (Grade 4) 
< 5 days 
No dose reduction for future cycles. 
<500/mcL (Grade 4) 
≥ 5 days 
Dose reduce DOCETAXEL 25% for future 
cycles.  
 
For grade 3 constipation or fatigue, treatment can resume with a 25% dose reduction after 
resolution of toxicity to < grade 2.   For other grade 3 toxicities felt to be related to both 
lenalidomide and docetaxel consideration will be given to possibly reducing or holding both 
agents.  The occurrence of DLT or a delay of > 2 weeks in initiating a new treatment cycle for the 
recovery of docetaxel-induced toxicities would result in a docetaxel dose reduction of 25%. In 
patients whose Grade III fatigue and/or constipation are felt to be caused by lenalidomide; then 
docetaxel need not be held or reduced. Patients will be allowed to continue docetaxel treatment at 
successively reduced doses as long as they do not have progressive disease, regardless of the time 
required for recovery from ADEs.  For dose-limiting toxicities related to docetaxel that lead to 
withholding docetaxel temporarily, lenalidomide and bevacizumab may be withheld along with 
docetaxel at the discretion of the investigators for the best interest and safety of patients. However, 
prednisone and Lovenox should not be interrupted. 
Patients should potentially discontinue Docetaxel if a grade 3 or 4 toxicity considered probably or 
likely related to docetaxel persists for  21 days.  The other agents may continue 
5.3.3 Dose modifications for bevacizumab 
5.3.3.1 Dose Modifications/Delays guidelines 
 
Note:  There will be no dose reduction for bevacizumab.  Treatment should be interrupted or 
discontinued for certain adverse events, as described below. 
Note 2:  If bevacizumab is interrupted for ANY reasons for > 8 weeks, the patient should 
discontinue bevacizumab therapy on protocol. 
5.3.3.2 Treatment Modification for Bevacizumab-Related Adverse Events 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
28 
 
Event 
CTCAE.v3.0 Grade 
Action to be Taken 
Allergic reactions,  
or  
Acute 
infusion 
reactions/ 
cytokine release syndrome  
Grade 1-3 
 
 
Infusion of bevacizumab should be interrupted for subjects who 
develop dyspnea or clinically significant hypotension.  
Subjects who experience Grade 3 or 4 allergic reaction / 
hypersensitivity, adult respiratory distress syndrome, or 
bronchospasm (regardless of grade) should discontinue 
bevacizumab. 
For infusion-associated symptoms not specified above, infusion 
should be slowed to 50% or less or interrupted. Upon complete 
resolution of the symptoms, infusion may be continued at no more 
than 50% of the rate prior to the reaction and increased in 50% 
increments every 30 minutes if well tolerated. Infusions may be 
restarted at the full rate during the next cycle.  
 
Grade 4 
Discontinue bevacizumab 
Arterial Thrombosis 
- Cardiac 
ischemia/ 
infraction 
- CNS 
ischemia 
(TIA, 
CVA) 
- any peripheral or visceral 
arterial 
ischemia/thrombosis 
Grade 2 ( if new or 
worsened since 
bevacizumab therapy) 
Discontinue bevacizumab. 
Grade 3-4 
Discontinue bevacizumab 
Venous Thrombosis  
 
 
 
Grade 3 
OR 
asymptomatic Grade 4 
 
 Hold bevacizumab treatment.  If the planned duration of full-
dose anticoagulation is <2weeks, bevacizumab should be held 
until the full-dose anticoagulation period is over. 
 If the planned duration of full-dose anticoagulation is >2 
weeks, bevacizumab may be resumed during full-dose 
anticoagulation IF all of the criteria below are met: 
- The subject must not have pathological conditions that carry 
high risk of bleeding (e.g. tumor involving major vessels or 
other conditions) 
- The subject must not have had hemorrhagic events while on 
study 
- The subject must on stable dose of heparin or have an in-
range INR (usually   2-3) on a stable dose of warfarin prior to 
restarting bevacizumab. 
 
 If thromboemboli worsen/recur upon resumption of study 
therapy, discontinue bevacizumab 
Grade 4 (symptomatic) 
Discontinue bevacizumab 
Hypertension* 
 
[Treat with anti-hypertensive medication as needed.  The goal of BP control should be 
consistent with general medical practice] 
Grade 1  
Consider increased BP monitoring 
Controlled BP 
Continue bevacizumab 
Persistent or 
symptomatic HTN 
Hold bevacizumab.  If treatment is delayed for >4 weeks due to 
uncontrolled hypertension, discontinue bevacizumab. 
Grade 4 
Discontinue bevacizumab. 
Congestive Heart Failure 
Grade 3 (symptomatic) 
Discontinue bevacizumab 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
29 
 
Event 
CTCAE.v3.0 Grade 
Action to be Taken 
Grade 4 
Discontinue bevacizumab 
Proteinuria 
 
Proteinuria should be monitored by urinalysis  
≥2+ on UA 
Obtain 24 hour urine for total protein 
24 hour total protein is > 
2 grams 
Hold bevacizumab for one cycle.   
nephrotic syndrome 
Discontinue bevacizumab. 
Hemorrhage 
(CNS 
or 
pulmonary) 
Grade 2-4 
 Discontinue bevacizumab 
Hemorrhage (other) 
Grade 3 (non-CNS or 
non-pulmonary) 
G1 (CNS or pulmonary) 
 
 Patients 
receiving 
full-dose 
anticoagulation 
should 
discontinue bevacizumab. 
 For patients not on full-dose anticoagulation, hold 
bevacizumab until ALL of the following criteria are met: 
- 
the bleeding has resolved and Hb is stable 
- 
there is no bleeding diathesis that would increase the risk 
of therapy 
- 
there is no anatomic or pathologic condition that could 
increase the risk of hemorrhage recurrence. 
 Patients who experience recurrence of grade 3 hemorrhage 
should discontinue study therapy. 
Grade 4 
Discontinue bevacizumab 
RPLS 
(Reversible 
Posterior 
Leukoencephalopathy 
syndrome or PRES (Posterior Reversible Encephalopathy 
Syndrome) 
 Discontinue bevacizumab upon diagnosis of RPLS.   
Wound dehiscence requiring medical or surgical 
intervention 
 Discontinue bevacizumab 
Perforation (GI, or any other organ) 
Discontinue bevacizumab 
Fistula (GI, pulmonary or any other organ) 
Discontinue bevacizumab 
Bowel obstruction 
G2 requiring medical 
intervention 
 Hold bevacizumab until complete resolution  
 
G3-4 
 Hold bevacizumab until complete resolution 
 If surgery is required, patient may restart bevacizumab after 
full recovery from surgery, and at investigator’s discretion 
Other 
Unspecified 
bevacizumab-related 
AEs 
(except 
controlled 
nausea/vomiting). 
Grade 3 
 Hold bevacizumab until symptoms resolve to 
 
< grade 1 
Grade 4 
 Discontinue bevacizumab 
 Upon consultation with the study chair, resumption of 
bevacizumab may be considered if a patient is benefiting from 
therapy, and the G4 toxicity is transient, has recovered to < 
grade 1 and unlikely to recur with retreatment. 
 
In addition to the toxicities listed above, bevacizumab will be discontinued if it is likely related to 
a persistent (3 weeks) NCI-CTCAE Grade 3 or 4 adverse event or any other significant adverse 
event that compromises the subjects’ ability to participate in the study.  
Any toxicity associated or possibly associated with bevacizumab treatment should be managed 
according to standard medical practice.   

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
30 
 
Discontinuation of bevacizumab will have no immediate therapeutic effect. Bevacizumab has a 
terminal half-life of 21 days; therefore, its discontinuation results in slow elimination over several 
months. There is no available antidote for bevacizumab.  
If bevacizumab is held or discontinued due to toxicity, patients should continue the rest of the 
regimen provided that patients have no toxicities that require dose interruption or dose 
modification of other agents of the regimen.  For potentially overlapping toxicities between 
bevacizumab and lenalidomide, both agents should be discontinued or dose modified. 
Patients should be assessed clinically for toxicity prior to, during, and after each infusion. If severe 
bevacizumab-related toxicity, such as visceral perforation, aortic dissection, or nephritic 
syndrome, occurs at any time during the study, treatment with bevacizumab should be 
discontinued.  
In general, bevacizumab will be withheld or discontinued for its related toxicities, but not dose-
reduced.  
5.3.4 Dose modification for lenalidomide 
Doses may be reduced by 5 mg at a time, to alleviate adverse reactions quickly, with slow 
escalation back to upper limit of tolerability. Patients with CrCl <50ml/min will be dose reduced 
by 5mg daily.  If not rapidly corrected, or lasts longer than 1 week, dose reduce by 50%.  Patients 
with CrCl < 30ml/min, not corrected within 1 week, will be taken off treatment, and dialysis 
initiated.  Patients with a grade 3 or 4 non-hematological toxicity felt to be caused by lenalidomide 
will have lenalidomide withheld. Lenalidomide can be resumed with a dose reduction of 5 mg 
when the toxicity returns to the patients’ baseline or becomes < grade 1. Lenalidomide should be 
discontinued if patients continue to experience the toxicity after two times of reduction. If Grade 
2 or 3 rash occurs, patients should undergo appropriate clinical evaluation before resuming 
lenalidomide.   
Dose modifications for lenalidomide that occur as a result of venous thrombosis are as follows:  
CTCAE Grade  
Action to be Taken  
Grade 3 or asymptomatic/minimally 
symptomatic Grade 4 
 Hold lenalidomide treatment. If the 
planned 
duration 
of 
full-dose 
anticoagulation 
is 
< 
2 
weeks, 
lenalidomide should be held until the 
full-dose anticoagulation period is 
over.  
 If the planned duration of full-dose 
anticoagulation 
is 
> 
2 
weeks, 
lenalidomide may be resumed during 
full-dose anticoagulation IF all of the 
criteria below are met:  
o The 
subject 
must 
not 
have 
pathological conditions that carry 
high risk of bleeding (e.g. tumor 
involving major vessels or other 
conditions)  

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
31 
 
CTCAE Grade  
Action to be Taken  
o The subject must not have had 
hemorrhagic events while on study  
o The subject must be on stable doses 
of heparin or have an in-range INR 
(usually 2-3) on a stable dose of 
warfarin 
prior 
to 
restarting 
lenalidomide  
o If thromboemboli worsen/recur 
upon resumption of study therapy, 
discontinue lenalidomide 
 Placeholder  
Grade 4 Symptomatic 
Discontinue lenalidomide 
 
For dose-limiting toxicities related to lenalidomide, it should be noted that docetaxel and 
bevacizumab should not be interrupted. 
For patients who experience grade 4 neutropenia lasting <3 days, lenalidomide will be held until 
ANC ≥1000 then may be re-started without any dose reduction. For grade 4 neutropenia lasting 
greater than or equal to 3 days, once ANC ≥1000 lenalidomide may be re-started with a 5mg dose 
reduction. 
For febrile neutropenia developed within a prior cycle and resolved before next cycle, 
lenalidomide can be continued at a dosage decreased by 5 mg during future cycles 
For grade 3 toxicities felt to be related to both lenalidomide and docetaxel consideration will be 
given to possibly reducing or holding both agents.   
Dose modification guidelines, as summarized below are recommended to manage Grade 3 or 4 
neutropenia or thrombocytopenia judged to be related to lenalidomide. 
Lenalidomide Dose Modifications for Thrombocytopenia: 
When Platelets 
Recommended Course 
Fall to <50,000/mcL 
 
Return to ≥50,000/mcL 
Interrupt 
LENALIDOMIDE 
treatment, 
follow CBC weekly 
Restart LENALIDOMIDE at 15 mg daily 
For each subsequent drop <50,000/mcL 
 
Return to ≥50,000/mcL 
Interrupt LENALIDOMIDE treatment 
 
Resume LENALIDOMIDE at 5 mg less 
than the previous dose. Do not dose 
below 5 mg daily 
 
Lenalidomide Dose Modifications for Neutropenia without Fever: 
When Neutrophils fall to 
for a Duration of 
Recommended Course 
<500/mcL (Grade 4) 
< 3 days 
Hold LENALIDOMIDE until ANC≥1000 then 
restart without dose reduction. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
32 
 
When Neutrophils fall to 
for a Duration of 
Recommended Course 
<500/mcL (Grade 4) 
≥ 3 days 
Hold LENALIDOMIDE until ANC≥1000 then 
restart with a 5mg dose reduction. 
<1000/mcL but ≥ 500 (Grade 3) 
Any length of time 
Hold LENALIDOMIDE until ANC≥1000 then 
restart without dose reduction. 
 
The dose of lenalidomide will not be reduced below 5mg daily. 
 
5.3.5 Other modifications 
 As this trial allows patients to receive treatment indefinitely, patients may have the doses 
of any or all drugs (docetaxel, bevacizumab, lenalidomide and prednisone) withheld 
temporarily for resolution of toxicities or taking drug holidays, and potentially resume 
treatment as long as they do not fulfill the off-study criteria outlined in section 5.10. 
 Although the treatment is planned every 21 days (42 days if on prednisone only after 2 
years) as a cycle, patients may have their treatments administered and their 
clinical/radiographic evaluation about or after the end of each cycle in order to 
accommodate their travel, hospitalization, variations in clinical availability due to holidays, 
or other unpredictable personal or family situations. Every effort will be made to minimize 
delay from their planned cycles and/or staging evaluations. Continuation of the treatment 
will be decided at the investigational physicians’ discretion for the best benefits of patients 
with no violations of the protocol.  Each patient’s treatment plan will be reviewed annually 
in order to determine continuing clinical benefit.  
 Patients who develop >Grade 3 thrombosis will receive appropriate medical care and will 
continue on docetaxel and prednisone.   Dose modifications for bevacizumab and 
lenalidomide are outlined elsewhere in this protocol.  This reflects from the prior 
mentioned trials with docetaxel/ lenalidomide versus docetaxel alone in a similar patient 
population, where those patients in the docetaxel alone arm had no episodes of thrombosis 
 There will be no dose modification of study medications for lymphopenia of any grade.  
5.4 
PROTOCOL EVALUATION  
All Patients will be evaluated for toxicities and efficacy after enrollment 
5.4.1 History and physical examination  
(including weight and ECOG performance status) each clinic visit, as well as height at the first 
visit.  History and PE do not need to be included in the electronic database.  However, weight will 
be included in the electronic database.  Patients will be seen and examined on or about day 21, and 
then about every 3 weeks by a physician in the NCI outpatient clinic (weight and ECOG 
performance status should be included in the database).  Patients remaining on-study for at least 2 
years and who are being treated with prednisone only, may have follow-up evaluations performed 
on Day 42 (every 6 weeks) at the physician’s discretion.  

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
33 
 
5.4.2 Dental Evaluations 
Follow-up dental evaluations will be performed following cycle five of protocol therapy and then 
following every other re-staging visit. Specifically, follow-up dental evaluations will occur post 
cycle 5, then post cycle 11 and then post cycle 17. Additional dental examinations will be 
performed once per year as long as patient is on study.  Tests during these evaluations might 
include:   
5.4.2.1 Oral fluid collection 
In order to study the local changes associated with the potential development of bisphosphonate 
related osteonecrosis of the jaws (BRONJ), saliva and other oral fluids, such as gingival crevicular 
fluid (GCF) and plaque samples, may be taken at an initial dental visit and at follow-up dental 
visits.  Collection procedures are non-invasive and non-painful, without the potential for harm 
beyond that of a standard dental examination.   
5.4.2.2 Oral Microbiome 
Bacterial samples may be collected from multiple sites in the oral cavity, by scraping the gingival 
tissue around teeth using a dental instrument. Initial microbial profiling will be performed with the 
Human Oral Microbe Identification Microarray (HOMIM), which allows for the simultaneous 
detection of about 300 of the most prevalent oral bacterial species, including those that are 
uncultivable. The oral microbiome could be compared both longitudinally and across groups (those 
developing BRONJ and those not). Future studies may involve culturing of select species and deep 
sequencing of oral bacteria. 
5.4.2.3 Protein Assays 
Evaluation of host defense molecules and collagen and bone metabolism proteins could be 
performed with whole saliva or targeted salivary gland saliva or GCF. Levels of such biomarkers 
will be measured in the oral fluids of patients, and could be compared both longitudinally and 
across groups (those developing BRONJ and those not). In parallel in vitro assays may interrogate 
the changes involved in BRONJ pathology.     
5.4.3 Laboratory Evaluation  
hematological profile (weekly) – if lenalidomide and docetaxel are held during a cycle or for 
continuous cycles for reasons unrelated to treatment toxicity, weekly blood work is not necessary; 
PSA (every cycle); acute care panel (every cycle), including hepatic panel and LDH; mineral panel 
(calcium, phosphorus, albumin, magnesium) every cycle; urinalysis (every cycle).  For a patient 
found to have verified 2+ or greater proteinuria on urinalysis, a 24-hour urine collection will be 
collected to assess the total protein. Patients remaining on-study for at least 2 years and who are 
being treated with prednisone only, may have follow-up evaluations performed on Day 42 (every 
6 weeks) at the physician’s discretion. 
5.4.4 Radiographic Evaluation 
CT scan and bone scan will be performed 2 cycles after start of the study and then every 3 cycles 
thereafter. For patients whose initial CT scan shows no soft tissue disease, subsequent CT scans 
will not be required unless clinically indicated.  Patients remaining on-study after two years will 
have CT and bone scans performed only if there are signs of clinical progression at physician’s 
discretion.    

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
34 
 
5.5 
CONCURRENT THERAPIES 
A medication history including complementary and alternative medications, herbal and nutritional 
products, and dietary supplements should be reviewed at the initial screening visit and at each 
clinic visit to assure that no agents have been introduced that may interact with experimental 
treatment. No concurrent medications will be recorded in the database captured except those 
designated in the protocol (lovenox, prednisone, decadron, pegfilgrastim). 
All patients will be instructed to consult a member of the study team prior to commencing any 
other medications (including over the counter agents) or herbal supplements.   
Patients who have not undergone surgical castration should be maintained on an LHRH agonist. 
Patients who need or continue treatment with zoledronic acid should have a dental evaluation to 
ensure it is appropriate to initiate the treatment. Patients should avoid dental procedures or notify 
the research team as early as possible for planning.   
5.6 
SURGICAL GUIDELINES 
There are no specific guidelines for this protocol; however, additional precautions should be 
exercised regarding elective surgery during treatment with bevacizumab.   Warning of possible 
wound healing delays, and increased bleeding risk may occur in patients that must undergo surgery 
during the study. Bevacizumab should be held at least 4 weeks prior to surgery. 
5.7 
RADIATION THERAPY GUIDELINES 
There are no radiation therapy guidelines in this protocol. However, patients whose disease needs 
radiation therapy will be taken off the study. 
5.8 
OFF-TREATMENT CRITERIA 
 
Disease progression as evidenced by radiographic (defined in section 11) or 
clinical progression.  Clinical disease progression is defined as  
 1)  Worsening disease requiring intervention with radiation therapy or 
additional chemotherapy 
 2)  Worsening performance status preventing patients from tolerating 
the treatment. 
 Bone lesions progression as defined in Section 11 
 Soft tissue and visceral lesions will be measured for progression based 
on RECIST criteria. 
 
Patient request 
 
Best medical judgment of the Principal Investigator or a physician in the list 
of Associate Investigators 
 
Inter-current illness that prevents further administration of the treatment 
regimen 
 
Unacceptable toxicities will be used as off-study criteria defined as a grade 
3 or 4 toxicity that is probably or likely related to protocol therapy that 
persists for  21 days. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
35 
 
5.9 
POST TREATMENT EVALUATION 
Once the patient is no longer receiving treatment (as per section 5.8) he may receive follow-up 
calls as well as medical evaluations to monitor his well-being and progress. For patients who are 
taken off treatment due to treatment toxicities, a follow up evaluation will be conducted within a 
month and if appropriate, the subject will be taken off study. The phone calls and medical 
evaluations will likely be annual though no specific guidelines shall be set.  
5.10 OFF-STUDY CRITERIA 
The patient will be considered off study upon either patient’s death or patient’s decision to no 
longer participate in the study or post treatment follow-up. 
5.11 OFF-STUDY PROCEDURES 
Off-Study Procedure: Authorized staff must notify Central Registration Office (CRO) when a 
patient 
is 
taken 
off-study. 
An 
off-study 
form 
from 
the 
web 
site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm) main page must be completed and sent 
via encrypted email to:  NCI Central Registration Office (HOIS) <ncicentralregistration-
l@mail.nih.gov>. 
Unacceptable toxicities that have not resolved at time of “off treatment” or “off study” must be 
followed until stabilization or resolution. 
6 
SUPPORTIVE CARE 
Anti-emetic treatment and secondary prophylaxis may be given as needed. Agent-specific 
expected adverse events are listed in Section 7.2.  The supportive treatment plan for the important 
adverse events is discussed in detail in Section 5. Pegfilgrastim 6 mg will be administrated 
subcutaneously 24 hours post-docetaxel infusion as described in section 5.2.5. Other supportive 
care will be provided in accordance with good medical care and consistent with standard care for 
the individual’s type of cancer.  Supportive care will continue until patient care can resume with 
primary medical doctors. 
Transfusions of red blood cells (RBCs) or platelets will be allowed as clinically required. 
7 
SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN 
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for 
AE reporting until December 31, 2010.  CTCAE version 4.0 will be utilized beginning January 1, 
2011.  All appropriate treatment areas should have access to a copy of the CTCAE version 3.0 and 
CTCAE version 4.0.  A copy of the CTCAE version 3.0 and CTCAE version 4.0 can be 
downloaded from the CTEP web site (http://ctep.cancer.gov).  Dose limiting toxicity is defined in 
section 5.2. 
All new malignant tumors must be reported through CTEP-AERS whether or not they are thought 
to be related to either previous or current treatment and should be referred to as second/secondary 
malignancies.  All new malignancies should be reported including solid tumors (including non-
melanoma 
skin 
malignancies), hematologic 
malignancies, 
Myelodysplastic 
Syndrome 
(MDS)/Acute Myelogenous Leukemia (AML), and in situ tumors. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
36 
 
Using CTCAE v4.0, the event(s) may be reported as one of the following: (1) Leukemia secondary 
to oncology chemotherapy; (2) Myelodysplastic syndrome; (3) Treatment-related secondary 
malignancy; or (4) Neoplasm other, malignant (grade 3 or 4).   
These events should be reported for the duration of the study treatment and during any protocol-
specified follow-up periods.   
As specified above, CTEP-AERS reports for these events should be submitted regardless of 
attribution.  The distinction between secondary and second or new primary malignancies is 
difficult to make based on a single event.  Whenever possible, the CTEP-AERS report should 
include the following:  tumor pathology; history of prior tumors; prior treatment/current treatment 
including duration; any associated risk factors or evidence regarding how long the tumor may have 
been present; when and how the tumor was detected; molecular characterization or cytogenetics 
of the original tumor (if available) and of any new tumor; and tumor treatment and outcome, if 
available. 
7.1 
DEFINITIONS 
7.1.1 Adverse Event 
An adverse event is defined as any reaction, side effect, or untoward event that occurs during the 
course of the clinical trial associated with the use of a drug in humans, whether or not the event is 
considered related to the treatment or clinically significant. For this study, AEs will include events 
reported by the patient, as well as clinically significant abnormal findings on physical examination 
or laboratory evaluation. A new illness, symptom, sign or clinically significant laboratory 
abnormality or worsening of a pre-existing condition or abnormality is considered an AE.  Only 
Grade 2 AE’s and higher will be recorded on the AE case report form with the exception of Grade 
1 Osteonecrosis of the jaw.  [Exception: Grade 1 and Grade 2 laboratory abnormalities will not be 
recorded as adverse events unless considered clinically significant by the investigators, e.g., Grade 
2 increase in creatinine should be clinically important, whereas Grade 2 hepatic transaminase may 
not be.] 
All AEs, including clinically significant abnormal findings on laboratory evaluations, regardless 
of severity, will be followed until return to baseline or stabilization of event. Serious adverse events 
that occur more than 30 days after the last administration of investigational agent/intervention and 
have an attribution of at least possibly related to the agent/intervention should be recorded and 
reported as per sections 7.4, 7.6. 
An abnormal laboratory value will be considered an AE if the laboratory abnormality is 
characterized by any of the following: 
 
Results in discontinuation from the study 
 
Is associated with clinical signs or symptoms  
 
Requires treatment or any other therapeutic intervention 
 
Is associated with death or another serious adverse event, including hospitalization.  
 
Is judged by the Investigator to be of significant clinical impact 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
37 
 
 
If any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test drug and about the patient’s 
outcome. 
7.1.2 Suspected adverse reaction 
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of IND safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the 
adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality 
than adverse reaction, which means any adverse event caused by a drug. 
7.1.3 Unexpected adverse reaction 
An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed; or, if an 
investigator brochure is not required or available, is not consistent with the risk information 
described in the general investigational plan or elsewhere in the current application. "Unexpected”, 
also refers to adverse events or suspected adverse reactions that are mentioned in the investigator 
brochure as occurring with a class of drugs or as anticipated from the pharmacological properties 
of the drug, but are not specifically mentioned as occurring with the particular drug under 
investigation. 
7.1.4 Serious  
An Unanticipated Problem or Protocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety, welfare or rights of subjects or others. 
7.1.5 Serious Adverse Event 
An adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following: 
 
Death, 
 
A life-threatening adverse drug experience 
 
Inpatient hospitalization or prolongation of existing hospitalization 
 
Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions 
 
A congenital anomaly/birth defect. 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
7.1.6 Disability 
 A substantial disruption of a person’s ability to conduct normal life functions. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
38 
 
7.1.7 Life-threatening adverse drug experience 
Any adverse event or suspected adverse reaction that places the patient or subject, in the view of 
the investigator or sponsor, at immediate risk of death from the reaction as it occurred, i.e., it does 
not include a reaction that had it occurred in a more severe form, might have caused death. 
7.1.8 Protocol Deviation (NIH Definition) 
Any change, divergence, or departure from the IRB-approved research protocol. 
7.1.9 Non-compliance (NIH Definition) 
The failure to comply with applicable NIH Human Research Protections Program (HRPP) policies, 
IRB requirements, or regulatory requirements for the protection of human research subjects. 
7.1.10 Unanticipated Problem 
Any incident, experience, or outcome that: 
  Is unexpected in terms of nature, severity, or frequency in relation to  
(a) the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigator’s Brochure or other study documents, and 
(b) the characteristics of the subject population being studied; AND 
 Is related or possibly related to participation in the research; AND 
 Suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. 
7.2 
COMPREHENSIVE ADVERSE EVENTS AND POTENTIAL RISKS LIST 
The Comprehensive Adverse Events and Potential Risks (CAEPR) list provides a single, 
complete list of reported and/or potential adverse events associated with an agent, using a 
uniform presentation of events by body system. 
Below is the CTEP-provided CAEPR about lenalidomide. 
7.2.1 Comprehensive Adverse Events and Potential Risks list (CAEPR) for Lenalidomide 
(CC-5013, NSC 703813) 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform presentation 
of events by body system. In addition to the comprehensive list, a subset, the Specific Protocol 
Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold 
and italicized text. This subset of AEs (SPEER) is a list of events that are protocol specific exceptions 
to expedited reporting to NCI (except as noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse 
Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for further 
clarification. Frequency is provided based on 4081 patients. Below is the CAEPR for lenalidomide 
(CC-5013). 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
39 
 
NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses 
next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using 
multiple investigational agents and has an AE listed on different SPEERs, use the lower of 
the grades to determine if expedited reporting is required. 
 
Version 2.6, December 24, 20151 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 4.0 Term) 
[n= 4081] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious 
(<3%) 
 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
  
 Anemia 
 
 
 Anemia (Gr 3) 
CARDIAC DISORDERS 
  
 
 
Myocardial infarction2   
ENDOCRINE DISORDERS 
  
 
 Hypothyroidism 
 
 Hypothyroidism (Gr 3) 
GASTROINTESTINAL DISORDERS 
  
Constipation 
 
 
 Constipation (Gr 3) 
Diarrhea 
 
 
 Diarrhea (Gr 3) 
 
Nausea 
 
 Nausea (Gr 3) 
 
 
Pancreatitis 
  
 
Vomiting 
 
 Vomiting (Gr 3) 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 
  
 
Chills 
 
 Chills (Gr 2) 
 
Edema limbs 
 
 Edema limbs (Gr 2) 
Fatigue 
 
 
 Fatigue (Gr 3) 
 
Fever 
 
 Fever (Gr 2) 
HEPATOBILIARY DISORDERS 
  
 
 
Hepatic failure 
  
IMMUNE SYSTEM DISORDERS 
  
 
 
Anaphylaxis 
  
 
 
Immune system 
disorders - Other (graft 
vs. host disease)3  
  
INFECTIONS AND INFESTATIONS 
  
 
Infection4 
 
 Infection (Gr 3)4  
INVESTIGATIONS 
  
 
 
Lipase increased 
  
 
Lymphocyte count 
decreased 
 
 Lymphocyte count decreased (Gr 
3) 
Neutrophil count 
decreased 
 
 
 Neutrophil count decreased (Gr 3) 
Platelet count decreased  
 
 Platelet count decreased (Gr 3) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
40 
 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 4.0 Term) 
[n= 4081] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious 
(<3%) 
 
 
 
Weight loss 
 
 Weight loss (Gr 2) 
 
White blood cell 
decreased 
 
 White blood cell decreased (Gr 3) 
METABOLISM AND NUTRITION DISORDERS 
  
 
Anorexia 
 
 Anorexia (Gr 3) 
 
 
Tumor lysis syndrome   
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
  
 
Arthralgia 
 
  
 
Back pain 
 
 
 
Musculoskeletal and 
connective tissue 
disorders - Other (muscle 
cramp/muscle spasm) 
 
 Musculoskeletal and connective 
tissue disorders - Other (Muscle 
cramp/muscle spasm) (Gr 2) 
 
Myalgia 
 
 Myalgia (Gr 2) 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS 
AND POLYPS) 
  
 
 
Leukemia secondary to 
oncology 
chemotherapy5 
  
 
 
Myelodysplastic 
syndrome5 
  
 
 
Neoplasms benign, 
malignant and 
unspecified (incl cysts 
and polyps) - Other 
(tumor flare)6  
  
 
 
Treatment related 
secondary malignancy5   
NERVOUS SYSTEM DISORDERS 
  
 
Dizziness 
 
  
 
Headache 
 
  
 
 
Stroke2 
  
 
 
Leukoencephalopathy 
  
PSYCHIATRIC DISORDERS 
  
 
Insomnia 
 
 Insomnia (Gr 2) 
RENAL AND URINARY DISORDERS 
  
 
 
Acute kidney injury 
  
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 
  
 
Cough 
 
 Cough (Gr 2) 
 
Dyspnea 
 
 Dyspnea (Gr 2) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
41 
 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 4.0 Term) 
[n= 4081] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious 
(<3%) 
 
 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 
  
 
 
Erythema multiforme 
  
 
Hyperhidrosis 
 
 Hyperhidrosis (Gr 2) 
 
Pruritus 
 
 Pruritus (Gr 2) 
 
Rash maculo-papular 
 
 Rash maculo-papular (Gr 2) 
 
Skin and subcutaneous 
tissue disorders - Other 
(pyoderma gangrenosum) 
 
  
 
 
Stevens-Johnson 
syndrome 
  
 
 
Toxic epidermal 
necrolysis 
  
SURGICAL AND MEDICAL PROCEDURES 
  
 
 
Surgical and medical 
procedures - Other 
(impaired stem cell 
mobilization)7 
  
VASCULAR DISORDERS 
  
 
Thromboembolic event8 
 
 Thromboembolic event8 (Gr 2) 
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision. The current version can be obtained by contacting 
PIO@CTEP.NCI.NIH.GOV. Your name, the name of the investigator, the protocol and the agent should 
be included in the e-mail. 
 
2Myocardial infarction and cerebrovascular accident (stroke) have been observed in multiple myeloma 
patients treated with lenalidomde and dexamethasone. 
 
3Graft vs. host disease has been observed in subjects who have received lenalidomide in the setting of 
allo-transplantation. 
 
4Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC. 
 
5There has been an increased frequency of secondary malignancies (including AML/MDS) in multiple 
myeloma patients being treated with melphalan, prednisone, and lenalidomide post bone marrow 
transplant. 
 
6Serious tumor flare reactions have been observed in patients with chronic lymphocytic leukemia (CLL) 
and lymphoma. 
 
7A decrease in the number of stem cells (CD34+ cells) collected from patients treated with >4 cycles of 
lenalidomide has been reported. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
42 
 
 
8Significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial 
thrombosis has been observed in patients with multiple myeloma receiving lenalidomide with 
dexamethasone. 
 
9Gastrointestinal hemorrhage includes:  Anal hemorrhage, Cecal hemorrhage, Colonic hemorrhage, 
Duodenal hemorrhage, Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, 
Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra-abdominal hemorrhage, Jejunal hemorrhage, Lower 
gastrointestinal hemorrhage, Oral hemorrhage, Pancreatic hemorrhage, Rectal hemorrhage, 
Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrhage under the GASTROINTESTINAL 
DISORDERS SOC. 
 
10Gastrointestinal obstruction includes:  Colonic obstruction, Duodenal obstruction, Esophageal 
obstruction, Ileal obstruction, Jejunal obstruction, Obstruction gastric, Rectal obstruction, and Small 
intestinal obstruction under the GASTROINTESTINAL DISORDERS SOC. 
 
11Osteonecrosis of the jaw has been seen with increased frequency when lenalidomide is used in 
combination with bevacizumab, docetaxel (Taxotere®), prednisone, and zolendronic acid (Zometa®). 
 
 
NOTE:  While not observed in human subjects, lenalidomide, a thalidomide analogue, caused limb 
abnormalities in a developmental monkey study similar to birth defects caused by thalidomide in humans. 
If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. Pregnancy 
must be excluded before start of treatment. Prevent pregnancy during treatment by the use of two reliable 
methods of contraception. 
 
Adverse events reported on Lenalidomide (CC-5013) trials, but for which there is insufficient 
evidence to suggest that there was a reasonable possibility that Lenalidomide (CC-5013) caused the 
adverse event: 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS - Blood and lymphatic system disorders - Other 
(eosinophilia); Blood and lymphatic system disorders - Other (monocytosis); Blood and lymphatic system 
disorders - Other (pancytopenia); Disseminated intravascular coagulation; Febrile neutropenia; 
Hemolysis; Spleen disorder 
CARDIAC DISORDERS - Acute coronary syndrome; Atrial fibrillation; Atrial flutter; Atrioventricular 
block first degree; Cardiac arrest; Cardiac disorders - Other (cardiovascular edema); Cardiac disorders - 
Other (ECG abnormalities); Chest pain - cardiac; Heart failure; Left ventricular systolic dysfunction; 
Palpitations; Pericarditis; Sinus bradycardia; Sinus tachycardia; Supraventricular tachycardia; Ventricular 
tachycardia 
EAR AND LABYRINTH DISORDERS - Tinnitus 
ENDOCRINE DISORDERS - Cushingoid; Hyperthyroidism 
EYE DISORDERS - Blurred vision; Conjunctivitis; Dry eye; Flashing lights; Retinopathy 
GASTROINTESTINAL DISORDERS - Abdominal distension; Abdominal pain; Anal mucositis; 
Ascites; Colonic perforation; Dry mouth; Dyspepsia; Dysphagia; Flatulence; Gastritis; Gastroesophageal 
reflux disease; Gastrointestinal disorders - Other (Crohn's disease aggravated); Gastrointestinal disorders - 
Other (diverticulitis); Gastrointestinal disorders - Other (pale feces); Gastrointestinal hemorrhage9; 
Gastrointestinal obstruction10; Ileus; Mucositis oral; Rectal mucositis; Small intestinal mucositis 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - General disorders and 
administration site conditions - Other (edema NOS); Malaise; Multi-organ failure; Non-cardiac chest 
pain; Pain 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
43 
 
HEPATOBILIARY DISORDERS - Cholecystitis 
IMMUNE SYSTEM DISORDERS - Allergic reaction; Immune system disorders - Other (angioedema) 
INFECTIONS AND INFESTATIONS - Infections and infestations - Other (Opportunistic infection 
associated with >=grade 2 lymphopenia) 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Bruising; Fall; Fracture; Hip 
fracture; Vascular access complication 
INVESTIGATIONS - Activated partial thromboplastin time prolonged; Alanine aminotransferase 
increased; Alkaline phosphatase increased; Aspartate aminotransferase increased; Blood bilirubin 
increased; Cholesterol high; Creatinine increased; Electrocardiogram QT corrected interval prolonged; 
INR increased; Investigations - Other (hemochromatosis) 
METABOLISM AND NUTRITION DISORDERS - Acidosis; Dehydration; Hypercalcemia; 
Hyperglycemia; Hyperkalemia; Hyperuricemia; Hypocalcemia; Hypoglycemia; Hypokalemia; 
Hypomagnesemia; Hyponatremia; Hypophosphatemia 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthritis; Bone pain; Chest 
wall pain; Generalized muscle weakness; Joint effusion; Muscle weakness lower limb; Musculoskeletal 
and connective tissue disorders - Other (rhabdomyolysis); Neck pain; Osteonecrosis of jaw11; Pain in 
extremity 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) - 
Tumor pain 
NERVOUS SYSTEM DISORDERS - Ataxia; Cognitive disturbance; Depressed level of consciousness; 
Dysgeusia; Dysphasia; Edema cerebral; Encephalopathy; Intracranial hemorrhage; Ischemia 
cerebrovascular; Memory impairment; Myelitis; Nervous system disorders - Other (hyporeflexia); 
Nervous system disorders - Other (spinal cord compression); Peripheral motor neuropathy; Peripheral 
sensory neuropathy; Seizure; Somnolence; Syncope; Transient ischemic attacks; Tremor 
PSYCHIATRIC DISORDERS - Agitation; Anxiety; Confusion; Depression; Psychosis 
RENAL AND URINARY DISORDERS - Urinary frequency; Urinary incontinence; Urinary tract pain 
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Reproductive system and breast 
disorders - Other (hypogonadism); Vaginal hemorrhage 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Adult respiratory distress 
syndrome; Allergic rhinitis; Atelectasis; Bronchopulmonary hemorrhage; Epistaxis; Hypoxia; Laryngeal 
mucositis; Pharyngeal mucositis; Pleural effusion; Pneumonitis; Pulmonary hypertension; Respiratory 
failure; Tracheal mucositis; Voice alteration 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Alopecia; Dry skin; Nail loss; 
Photosensitivity; Rash acneiform; Skin and subcutaneous tissue disorders - Other (Sweet’s syndrome); 
Urticaria 
VASCULAR DISORDERS - Hot flashes; Hypertension; Hypotension; Phlebitis; Vascular disorders - 
Other (hemorrhage NOS) 
 
Note: Lenalidomide (CC-5013) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by the other agent, or the combination may result in events 
never previously associated with either agent. 
 
7.2.2 Comprehensive Adverse Events and Potential Risks list (CAEPR) for Bevacizumab 
(rhuMAb VEGF, NSC 704865) 
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by body system. In addition to the comprehensive list, a subset, the 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
44 
 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and 
is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are 
protocol specific exceptions to expedited reporting to NCI (except as noted below).  Refer to the 
'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for 
further clarification. Frequency is provided based on 3540 patients. Below is the CAEPR for 
bevacizumab (rhuMAb VEGF). 
NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses 
next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the grades 
to determine if expedited reporting is required. 
 Version 2.4, May 23, 20161 
 
 Adverse Events with Possible  
 Relationship to Bevacizumab (rhuMAb VEGF) 
 (CTCAE 4.0 Term) 
[n= 3540] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
  
 
Anemia 
 
 Anemia (Gr 3) 
 
 
Blood and lymphatic 
system disorders - Other 
(renal thrombotic 
microangiopathy) 
  
 
Febrile neutropenia 
 
 Febrile neutropenia (Gr 3) 
CARDIAC DISORDERS 
  
 
 
Acute coronary 
syndrome2 
  
 
Cardiac disorders - Other 
(supraventricular 
arrhythmias)3 
 
 Cardiac disorders - Other 
(supraventricular arrhythmias)3 
(Gr 3) 
 
 
Heart failure 
  
 
 
Left ventricular systolic 
dysfunction 
  
 
 
Myocardial infarction2 
  
 
 
Ventricular arrhythmia 
  
 
 
Ventricular fibrillation 
  
GASTROINTESTINAL DISORDERS 
  
 
Abdominal pain 
 
 Abdominal pain (Gr 3) 
 
Colitis 
 
 Colitis (Gr 3) 
 
Constipation 
 
 Constipation (Gr 3) 
 
Diarrhea 
 
 Diarrhea (Gr 3) 
 
Dyspepsia 
 
 Dyspepsia (Gr 2) 
 
 
Gastrointestinal fistula4 
  
 
Gastrointestinal 
hemorrhage5 
 
 Gastrointestinal hemorrhage5 (Gr 
2) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
45 
 
 
 Adverse Events with Possible  
 Relationship to Bevacizumab (rhuMAb VEGF) 
 (CTCAE 4.0 Term) 
[n= 3540] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
 
Gastrointestinal 
obstruction6 
 
  
 
 
Gastrointestinal 
perforation7 
  
 
 
Gastrointestinal ulcer8 
  
 
Ileus 
 
  
 
Mucositis oral 
 
 Mucositis oral (Gr 3) 
 
Nausea 
 
 Nausea (Gr 3) 
 
Vomiting 
 
 Vomiting (Gr 3) 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 
  
 
Fatigue 
 
 Fatigue (Gr 3) 
 
Infusion related reaction  
 Infusion related reaction (Gr 2) 
 
Non-cardiac chest pain 
 
 Non-cardiac chest pain (Gr 3) 
 
Pain 
 
 Pain (Gr 3) 
HEPATOBILIARY DISORDERS 
  
 
 
Gallbladder perforation 
  
IMMUNE SYSTEM DISORDERS 
 
 
 
Allergic reaction 
 
 Allergic reaction (Gr 2) 
 
 
Anaphylaxis 
  
INFECTIONS AND INFESTATIONS 
  
 
Infection9 
 
 Infection9 (Gr 3) 
 
 
Infections and 
infestations - Other 
(necrotizing fasciitis) 
  
 
Infections and infestations 
- Other (peri-rectal 
abscess) 
 
  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS 
  
 
 
Injury, poisoning and 
procedural complications 
- Other (anastomotic 
leak)10 
  
 
Wound complication 
 
 Wound complication (Gr 2) 
 
Wound dehiscence 
 
 Wound dehiscence (Gr 2) 
INVESTIGATIONS 
  
 
Alanine aminotransferase 
increased 
 
 Alanine aminotransferase 
increased (Gr 3) 
 
Alkaline phosphatase 
increased 
 
 Alkaline phosphatase increased 
(Gr 3) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
46 
 
 
 Adverse Events with Possible  
 Relationship to Bevacizumab (rhuMAb VEGF) 
 (CTCAE 4.0 Term) 
[n= 3540] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
 
Aspartate 
aminotransferase 
increased 
 
 Aspartate aminotransferase 
increased (Gr 3) 
 
Blood bilirubin increased  
 Blood bilirubin increased (Gr 2) 
 
 Creatinine increased 
 
  
Neutrophil count 
decreased 
 
 
 Neutrophil count decreased (Gr 3) 
 
Platelet count decreased 
 
 Platelet count decreased (Gr 4) 
 
Weight loss 
 
 Weight loss (Gr 3) 
 
White blood cell 
decreased 
 
 White blood cell decreased (Gr 3) 
METABOLISM AND NUTRITION DISORDERS 
  
 
Anorexia 
 
 Anorexia (Gr 3) 
 
Dehydration 
 
 Dehydration (Gr 3) 
 
Hyperglycemia 
 
  
 
Hypokalemia 
 
  
 
Hyponatremia 
 
  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
  
 
Arthralgia 
 
 Arthralgia (Gr 3) 
 
 
Avascular necrosis11 
  
 
Generalized muscle 
weakness 
 
  
 
Musculoskeletal and 
connective tissue disorder 
- Other (bone metaphyseal 
dysplasia)12 
 
  
 
Myalgia 
 
 Myalgia (Gr 3) 
 
Osteonecrosis of jaw13 
 
  
NERVOUS SYSTEM DISORDERS 
  
 
Dizziness 
 
 Dizziness (Gr 2) 
 
Headache 
 
 Headache (Gr 3) 
 
 
Intracranial hemorrhage   
 
 
Ischemia cerebrovascular2   
 
Peripheral sensory 
neuropathy14 
 
  
 
 
Reversible posterior 
leukoencephalopathy 
syndrome 
  
 
Syncope 
 
  
RENAL AND URINARY DISORDERS 
  
 
 
Acute kidney injury 
  

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
47 
 
 
 Adverse Events with Possible  
 Relationship to Bevacizumab (rhuMAb VEGF) 
 (CTCAE 4.0 Term) 
[n= 3540] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
 
Hematuria 
 
 Hematuria (Gr 3) 
 
Proteinuria 
 
 Proteinuria (Gr 2) 
 
 
Renal and urinary 
disorders - Other 
(nephrotic syndrome) 
  
 
 
Urinary fistula 
  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS 
  
Reproductive system and 
breast disorders - Other 
(ovarian failure)15 
 
 
  
 
 
Vaginal fistula 
  
 
Vaginal hemorrhage 
 
 Vaginal hemorrhage (Gr 3) 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 
  
 
Allergic rhinitis 
 
 Allergic rhinitis (Gr 3) 
 
 
Bronchopleural fistula 
  
 
 
Bronchopulmonary 
hemorrhage 
  
 
Cough 
 
 Cough (Gr 3) 
 
Dyspnea 
 
 Dyspnea (Gr 2) 
 
Epistaxis 
 
 Epistaxis (Gr 3) 
 
Hoarseness 
 
 Hoarseness (Gr 3) 
 
 
Respiratory, thoracic and 
mediastinal disorders - 
Other (nasal-septal 
perforation) 
  
 
 
Respiratory, thoracic and 
mediastinal disorders - 
Other (tracheo-
esophageal fistula) 
  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 
  
 
Dry skin 
 
  
 
Erythroderma 
 
  
 
 
Palmar-plantar 
erythrodysesthesia 
syndrome 
  
 
Pruritus 
 
 Pruritus (Gr 2) 
 
Rash maculo-papular 
 
 Rash maculo-papular (Gr 2) 
 
Urticaria 
 
 Urticaria (Gr 2) 
VASCULAR DISORDERS 
  
Hypertension 
 
 
 Hypertension (Gr 3) 
 
Thromboembolic event 
 
 Thromboembolic event (Gr 3) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
48 
 
 
 Adverse Events with Possible  
 Relationship to Bevacizumab (rhuMAb VEGF) 
 (CTCAE 4.0 Term) 
[n= 3540] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
 
 
Vascular disorders - 
Other (arterial 
thromboembolic event)2,16 
  
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by contacting 
PIO@CTEP.NCI.NIH.GOV.  Your name, the name of the investigator, the protocol and the agent should 
be included in the e-mail. 
 
2The risks of arterial thrombosis such as cardiac or CNS ischemia are increased in elderly patients and in 
patients with a history of diabetes. 
 
3Supraventricular arrhythmias may include supraventricular tachycardia, atrial fibrillation, and atrial 
flutter. 
 
4Gastrointestinal fistula may include: Anal fistula, Colonic fistula, Duodenal fistula, Esophageal fistula, 
Gastric fistula, Gastrointestinal fistula, Rectal fistula, and other sites under the GASTROINTESTINAL 
DISORDERS SOC. 
 
5Gastrointestinal hemorrhage may include: Colonic hemorrhage, Duodenal hemorrhage, Esophageal 
hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, Hemorrhoidal hemorrhage, Intra-
abdominal hemorrhage, Oral hemorrhage, Rectal hemorrhage, and other sites under the 
GASTROINTESTINAL DISORDERS SOC. 
 
6Gastrointestinal obstruction may include: Colonic obstruction, Duodenal obstruction, Esophageal 
obstruction, Ileal obstruction, Jejunal obstruction, Rectal obstruction, Small intestinal obstruction, and 
other sites under the GASTROINTESTINAL DISORDERS SOC. 
 
7Gastrointestinal perforation may include: Colonic perforation, Duodenal perforation, Esophageal 
perforation, Gastric perforation, Jejunal perforation, Rectal perforation, and Small intestinal perforation. 
 
8Gastrointestinal ulcer may include: Duodenal ulcer, Esophageal ulcer, Gastric ulcer, and other sites under 
the GASTROINTESTINAL DISORDERS SOC. 
 
9Infection may include any of the 75 infection sites under the INFECTIONS AND INFESTATIONS 
SOC. 
 
10Anastomotic leak may include Gastric anastomotic leak; Gastrointestinal anastomotic leak; Large 
intestinal anastomotic leak; Rectal anastomotic leak; Small intestinal anastomotic leak; Urostomy leak; 
Vaginal anastomotic leak. 
 
11There have been reports of non-mandibular osteonecrosis (avascular necrosis) in patients under the age 
of 18 treated with bevacizumab. 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
49 
 
12Metaphyseal dysplasia was observed in young patients who still have active epiphyseal growth plates. 
 
13Cases of osteonecrosis of the jaw (ONJ) have been reported in cancer patients in association with 
bevacizumab treatment, the majority of whom had received prior or concomitant treatment with i.v. 
bisphosphonates. 
 
14Increased rate of peripheral sensory neuropathy has been observed in trials combining bevacizumab and 
chemotherapy compared to chemotherapy alone.  
 
15Ovarian failure, defined as amenorrhea lasting 3 or more months with follicle-stimulating hormone 
(FSH) elevation (≥30 mIU/mL), was increased in patients receiving adjuvant bevacizumab plus 
mFOLFOX compared to mFOLFOX alone (34% vs. 2%).  After discontinuation of bevacizumab, 
resumption of menses and an FSH level <30 mIU/mL was demonstrated in 22% (7/32) of these women.  
Long term effects of bevacizumab exposure on fertility are unknown. 
 
16Arterial thromboembolic event includes visceral arterial ischemia, peripheral arterial ischemia, heart 
attack, and stroke. 
 
 
Adverse events reported on bevacizumab (rhuMAb VEGF) trials, but for which there is insufficient 
evidence to suggest that there was a reasonable possibility that bevacizumab (rhuMAb VEGF) 
caused the adverse event: 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS - Blood and lymphatic system disorders - Other 
(idiopathic thrombocytopenia purpura); Bone marrow hypocellular; Disseminated intravascular 
coagulation; Hemolysis 
CARDIAC DISORDERS - Atrioventricular block complete; Atrioventricular block first degree; Cardiac 
arrest; Myocarditis; Pericardial effusion; Restrictive cardiomyopathy; Right ventricular dysfunction 
EAR AND LABYRINTH DISORDERS - Ear and labyrinth disorders - Other (tympanic membrane 
perforation); Hearing impaired; Tinnitus; Vertigo 
ENDOCRINE DISORDERS - Hyperthyroidism; Hypothyroidism 
EYE DISORDERS - Blurred vision; Cataract; Dry eye; Extraocular muscle paresis; Eye disorders - 
Other (blindness); Eye disorders - Other (conjunctival hemorrhage); Eye disorders - Other (corneal 
epithelial defect); Eye disorders - Other (floaters); Eye disorders - Other (ischemic CRVO); Eye disorders 
- Other (macular pucker); Eye disorders - Other (transient increased IOP > or =30 mm Hg); Eye disorders 
- Other (vitreous hemorrhage); Eye pain; Keratitis; Optic nerve disorder; Photophobia; Retinal 
detachment; Retinal tear; Retinopathy; Watering eyes 
GASTROINTESTINAL DISORDERS - Ascites; Chelitis; Colonic stenosis; Dry mouth; Dysphagia; 
Enterocolitis; Esophageal pain; Esophageal stenosis; Flatulence; Gastrointestinal disorders - Other 
(peritonitis); Oral pain; Pancreatitis; Proctitis; Rectal mucositis; Rectal stenosis; Typhlitis 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Death NOS; Edema 
face; Edema limbs; Edema trunk; Facial pain; Fever; Flu like symptoms; Gait disturbance; Injection site 
reaction; Localized edema; Multi-organ failure; Sudden death NOS 
HEPATOBILIARY DISORDERS - Cholecystitis; Gallbladder necrosis; Gallbladder obstruction; 
Hepatic failure; Hepatic necrosis 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Arterial injury; Bruising; Burn; 
Dermatitis radiation; Fracture 
INVESTIGATIONS - Activated partial thromboplastin time prolonged; Blood antidiuretic hormone 
abnormal; CD4 lymphocytes decreased; CPK increased; Carbon monoxide diffusing capacity decreased; 
Electrocardiogram QT corrected interval prolonged; Forced expiratory volume decreased; GGT 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
50 
 
increased; INR increased; Lipase increased; Lymphocyte count decreased; Serum amylase increased; 
Weight gain 
METABOLISM AND NUTRITION DISORDERS - Acidosis; Hypercalcemia; Hyperkalemia; 
Hypermagnesemia; Hypernatremia; Hypertriglyceridemia; Hyperuricemia; Hypoalbuminemia; 
Hypocalcemia; Hypomagnesemia; Hypophosphatemia 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthritis; Back pain; Bone 
pain; Chest wall pain; Fibrosis deep connective tissue; Head soft tissue necrosis; Joint effusion; Muscle 
weakness lower limb; Muscle weakness upper limb; Musculoskeletal and connective tissue disorder - 
Other (aseptic necrotic bone); Musculoskeletal and connective tissue disorder - Other (myasthenia 
gravis); Musculoskeletal and connective tissue disorder - Other (polymyalgia rheumatica); Neck pain; 
Pain in extremity; Pelvic soft tissue necrosis; Soft tissue necrosis lower limb 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) - 
Tumor pain 
NERVOUS SYSTEM DISORDERS - Arachnoiditis; Ataxia; Central nervous system necrosis; 
Cerebrospinal fluid leakage; Cognitive disturbance; Depressed level of consciousness; Dysesthesia; 
Dysgeusia; Dysphasia; Encephalopathy; Extrapyramidal disorder; Facial nerve disorder; Hydrocephalus; 
Leukoencephalopathy; Memory impairment; Nervous system disorders - Other (increased intracranial 
pressure); Paresthesia; Peripheral motor neuropathy; Pyramidal tract syndrome; Seizure; Somnolence; 
Tremor; Vasovagal reaction 
PSYCHIATRIC DISORDERS - Agitation; Anxiety; Confusion; Depression; Insomnia; Libido 
decreased; Psychosis 
RENAL AND URINARY DISORDERS - Bladder spasm; Chronic kidney disease; Cystitis 
noninfective; Renal and urinary disorders - Other (dysuria); Renal and urinary disorders - Other 
(ureterolithiasis); Renal hemorrhage; Urinary frequency; Urinary incontinence; Urinary retention; Urinary 
tract obstruction; Urinary tract pain 
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Breast pain; Erectile dysfunction; 
Irregular menstruation; Pelvic pain; Vaginal discharge 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Adult respiratory distress 
syndrome; Atelectasis; Hypoxia; Nasal congestion; Pulmonary fibrosis; Pulmonary hypertension; 
Respiratory failure; Respiratory, thoracic and mediastinal disorders - Other (dry nares); Respiratory, 
thoracic and mediastinal disorders - Other (pulmonary infarction) 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Alopecia; Hyperhidrosis; Nail loss; Pain of 
skin; Photosensitivity; Purpura; Rash acneiform; Skin and subcutaneous tissue disorders - Other (diabetic 
foot ulcer); Skin and subcutaneous tissue disorders - Other (skin breakdown/ decubitus ulcer); Skin 
hyperpigmentation; Skin induration; Skin ulceration; Stevens-Johnson syndrome 
VASCULAR DISORDERS - Flushing; Hot flashes; Hypotension; Lymphocele; Phlebitis; Vasculitis  
 
Note: Bevacizumab (rhuMAb VEGF) in combination with other agents could cause an exacerbation of 
any adverse event currently known to be caused by the other agent, or the combination may result in 
events never previously associated with either agent. 
 
 
7.3 
EXPEDITED ADVERSE EVENT REPORTING 
Expedited AE reporting for this study must use CTEP-AERS (CTEP Adverse Event Reporting 
System), accessed via the CTEP home page (http://ctep.cancer.gov).  The reporting procedures to 
be followed are presented in the “CTEP, NCI Guidelines: Adverse Event Reporting Requirements” 
which can be downloaded from the CTEP home page (http://ctep.cancer.gov).  These requirements 
are briefly outlined in the table below. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
51 
 
 
7.4 
EXPEDITED REPORTING GUIDELINES   
CTEP-AERS Reporting Requirements for Adverse Events That Occur Within 30 Days of the Last 
Dose of the Investigational Agent on Phase 2 Trials 
 
Note:  All deaths on study require both routine and expedited reporting 
regardless of causality.  Attribution to treatment or other cause must be 
provided. 
 Expedited AE reporting timelines defined: 
 “24 hours; 5 calendar days” – The investigator must initially report the AE via 
CTEP-AERS within 24 hours of learning of the event followed by a complete 
CTEP-AERS report within 5 calendar days of the initial 24-hour report. 
 “10 calendar days” - A complete CTEP-AERS report on the AE must be 
submitted within 10 calendar days of the investigator learning of the event.  
 Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates 
hospitalization (or prolongation of existing hospitalization) must be reported 
regardless of attribution and designation as expected or unexpected with the 
exception of any events identified as protocol-specific expedited adverse event 
reporting exclusions.   
 Any event that results in persistent or significant disabilities/incapacities, 
congenital anomalies, or birth defects must be reported via CTEP-AERS if the 
event occurs following treatment with an agent under a CTEP IND. 
 Use the NCI protocol number and the protocol-specific patient ID assigned 
during trial registration on all reports. 
 Pregnancy  
o If a female partner of a male subject taking investigational product 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
52 
 
becomes pregnant, the male subject taking lenalidomide should 
notify the Investigator, and the pregnant female partner should be 
advised to call her healthcare provider immediately. 
7.5 
ROUTINE ADVERSE EVENT REPORTING 
 Adverse Events that do not require expedited reporting must be reported in routine study 
data submissions.  AEs reported through CTEP-AERS must also be reported in routine 
study data submissions. 
7.6 
NCI-IRB AND NCI CLINICAL DIRECTOR REPORTING REQUIREMENTS 
7.6.1 NCI-IRB and NCI Clinical Director Expedited Reporting of Unanticipated Problems 
and Deaths 
The Protocol PI will report in the NIH Problem Form to the NCI-IRB and NCI Clinical 
Director: 
 All deaths, except deaths due to progressive disease  
 All Protocol Violations or Deviations 
 All Unanticipated Problems 
 All non-compliance 
Reports must be received within 7 days of PI awareness via iRIS. 
7.6.2 NCI-IRB Requirements for PI Reporting at Continuing Review 
The protocol PI will report to the NCI-IRB:  
1. A summary of all protocol deviations in a tabular format to include the date the 
deviation occurred, a brief description of the deviation and any corrective action. 
2. A summary of any instances of non-compliance 
3. A tabular summary of the following adverse events: 
 All Grade 2 unexpected events that are possibly, probably or definitely related 
to the research;  
 All Grade 3 and 4 events that are possibly, probably or definitely related to the 
research;  
 All Grade 5 events regardless of attribution;  
 All Serious Events regardless of attribution.  
NOTE: Grade 1 events are not required to be reported.  
7.6.3 NCI-IRB Reporting of IND Safety Reports 
Only IND Safety Reports that meet the definition of an unanticipated problem will need to be 
reported to the NCI IRB. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
53 
 
8 
PHARMACEUTICAL INFORMATION 
8.1 
DOCETAXEL (TAXOTERE-AVENTIS PHARMACEUTICAL, INC.; BRIDGEWATER, NJ) 
8.1.1 Chemical formula:  
[2aR-[2aa,4b,4ab,6b,9a(aR*,bS*),11a,12a,12aa,12ba]]-12b-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-
7,11-methano-1H-cyclodeca 
[3,4]benz[1,2-b]-oxet-9-yl 
b-[[(1,1-dimethylethoxy)carbonyl]-
amino]-a-hydroxybenzenepropanoate, trihydrate. 
C43H53NO14· 3H2O 
Molecular weight of 861.9 Daltons 
Synonyms: RP56976 
8.1.2 Availability  
The drug will be purchased from commercial sources by the Clinical Center pharmacy. 
8.1.3 Formulation 
 
Docetaxel is supplied in single-dose vials as a sterile, non-pyrogenic, non-aqueous, clear 
yellow to brownish-yellow viscous solution and is packaged with a sterile, non-pyrogenic, diluent 
in single-use vials.  Both the Docetaxel® for Injection Concentrate and the diluent vials contain 
excess volume to compensate for fluid lost during product preparation. 
The commercial drug product is available in packages containing either: 
[1] 
Docetaxel (anhydrous) 80 mg in 2 mL polysorbate 80 (2080 mg).  The diluent vial 
contains 6 mL 13% (w/w) in Water for Injection. 
OVERFILL: 
Docetaxel® for Injection Concentrate vial overfilled to 94.4 mg 
docetaxel/2.36 mL.  Diluent vial overfilled to 6.96–7.70 mL.  Approximate 
extractable volume = 7.1 mL. 
[2] 
Docetaxel (anhydrous) 20 mg in 0.5 mL polysorbate 80 (520 mg). The diluent vial 
contains 1.5 mL 13% (w/w) in Water for Injection. 
OVERFILL: Docetaxel® for Injection Concentrate vial is overfilled to 23.6 mg 
docetaxel/0.59 mL. Diluent vial overfilled to 1.88–2.08 mL.  Approximate 
extractable volume = 1.8 mL. 
8.1.4 Preparation 
Docetaxel® for Injection Concentrate requires TWO dilutions prior to administration. 
 Preparing the “INITIAL DILUTED SOLUTION” (10 mg docetaxel/mL)41 
[1] 
Before proceeding, inspect the vial containing Docetaxel® for Injection 
Concentrate solution for clarity. 
[2] 
After removing vials from refrigeration, allow them to stand at room temperature 
for approximately five minutes. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
54 
 
[3] 
Partially invert a vial containing diluent, aseptically withdraw the ENTIRE 
CONTENTS (including overfill) of the vial into a syringe, and transfer the solution to 
a vial containing docetaxel. 
[4] 
The INITIAL DILUTED SOLUTION should be clear; however, there may be some foam 
on top of the solution due to the polysorbate 80.  Allow the solution to stand for a 
few minutes to allow any foam to dissipate.  It is not required that all foam 
dissipates prior to continuing the preparation process.  The INITIAL DILUTED 
SOLUTION may be used immediately or stored either in the refrigerator or at room 
temperature for a maximum of 8 hours. 
 Preparing “DOCETAXEL INFUSION SOLUTION”41 
[1] 
With a syringe, aseptically withdraw the required amount of docetaxel INITIAL 
DILUTED SOLUTION (10 mg/mL) and inject it into a non-polyvinylchloride bag 
containing an appropriate amount of 5% Dextrose, or 0.9% Sodium Chloride 
Injection, USP, to produce a final concentration between 0.3–0.74 mg 
docetaxel/mL. 
 
 
Do not exceed a concentration > 0.74 mg docetaxel/mL. 
[2] 
Thoroughly mix the INFUSION SOLUTION by repeatedly inverting the drug container. 
[3] 
Visually inspect the INFUSION SOLUTION for particulate matter or discoloration.  If 
the solution is not clear or appears to have precipitation, it should be discarded. 
Docetaxel must not come into contact with polyvinylchloride (PVC) equipment or devices during 
solution preparation or administration.  Docetaxel should be prepared in polypropylene- or 
polyolefin-lined drug product containers and administered using polyethylene-lined administration 
sets41; e.g., ALARIS™ LOW SORBING SET #2264-0500 (non-PVC, polyethylene-lined fluid 
pathway, with integral 0.2 µm polysulfone filter [Alaris Medical Systems; San Diego, CA]). 
8.1.5 Stability 
DOCETAXEL INFUSION SOLUTION (in either 0.9% NS or D5%W), if stored between 2°–25°C (36°–
77°F) is stable for four hours and should be used within four hours after preparation.41 
8.1.6 Storage 
Store between 2°–25°C (36°–77°F).  Retain in the original package to protect from bright light.  
Freezing does not adversely affect the product.  
8.1.7 Dosage and Administration 
Premedication 
All patients will receive dexamethasone 8 mg po 12 hours, 3 hours and 1 hour prior to docetaxel 
administration to reduce the incidence and severity of fluid retention and the severity of 
hypersensitivity reactions.  Patients who were on prior regimen which included a lower dose of 
decadron and did not have a reaction do not have to increase their decadron to the 8 mg dose.   
8.1.8 Administration 
Docetaxel 75 mg/m2 will be administered as an intravenous infusion over one hour on scheduled 
days per section 5.2.1. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
55 
 
8.1.9 Drug Interaction 
Docetaxel and dexamethasone are metabolized by the cytochrome P450 (CYP) enzyme, CYP3A4.  
Many other drugs and herbal and nutritional supplements are similarly metabolized, and may in 
addition, perturb docetaxel and dexamethasone metabolism by inhibiting or inducing the enzyme. 
Whenever possible we will take efforts to limit patients from being on such medications while 
receiving treatment on protocol Enzyme induction may hasten docetaxel and dexamethasone 
clearance; CYP3A4 inhibition may delay clearance.  Both enzyme induction and inhibition alter 
the pharmacokinetic behavior of drugs that are substrates for CYP enzymes, and consequently, 
their pharmacodynamic effects, potentially compromising the benefit of treatment and 
exacerbating toxicity. 
Docetaxel and dexamethasone likewise may alter the pharmacokinetics and pharmacodynamic 
effects of other drugs metabolized by CYP3A4.  Caregivers may circumspectly permit 
continuation of treatment with CYP3A4 substrate drugs for patients on this study after gaining the 
approval of a medically responsible investigator. 
Contact a medically-responsible study investigator about patient volunteers who are receiving 
treatment before study enrollment and to discuss using any of the drugs listed in Appendix A for 
patients on study. 
8.1.10 Toxicities 
COMMON: Leukopenia, Neutropenia, Anemia, Alopecia, Asthenia, Neurosensory deficits, Fluid 
retention, Nausea, Vomiting 
SERIOUS: Myelosuppression, Thrombocytopenia, Neutropenia, Hypersensitivity reaction, Skin 
toxicity 
Please see package insert for additional toxicities. 
8.2 
LENALIDOMIDE  
(Celgene Corporation, Warren, NJ) CC-5013 (NSC 703813) 
 
 
8.2.1 Chemical Name   
3-(4’aminoisoindoline-1’-one)-1-piperidine-2,6-dione;  α-(3-aminothalamido) glucaride. 
Other Names:       Lenalidomide, Revlimid™ (formerly known as Revlimid™), CDC-501 
Classification:      Immunomodulatory Agent  
NOTE: 
Before lenalidomide is dispensed, patients must have 1) a negative pregnancy test (if 
applicable) and 2) be counseled by a trained counselor. Pharmacists may be trained 
counselors (see Lenalidomide Counselor Program Site Counselor Identification Form in 
the protocol). The counseling requirements for investigational-use lenalidomide are 
separate from the RevAssist program. Only a 28-day supply may be dispensed to a 
patient at one time. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
56 
 
CAS Registry Number:       191732-72-6 
Molecular Formula:   C13H13N303 
 
 
M.W.:   259.26 
Mode of Action:  CC-5013, a thalidomide analog, is an immunomodulatory agent with a spectrum of 
activity that is not fully characterized.  In vitro, it inhibits secretion of the pro-inflammatory cytokines 
TNF-α, IL-1β, and IL-6 and increases secretion of the anti-inflammatory cytokine IL-10.  It also 
induces T-cell proliferation, IL-2 and IFN-γ production in vitro.  
8.2.2 How Supplied    
Celgene supplies and CTEP, NCI, DCTD distributes lenalidomide 5 mg (size 2) and 25 mg (size 0) 
hard gelatin capsules in tamper-evident, child-resistant, opaque, high density polyethylene (HDPE) 
bottles with HDPE caps. Bottles contain 100 capsules per container.  
The capsules also contain anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and 
magnesium stearate. 
8.2.3 Storage  
The capsules should be stored at room temperature (15-30°C) away from moisture and direct sunlight.   
8.2.4 Stability   
Refer to the package labeling for expiration date. Lenalidomide stability is adequate for at least 28 
days after transferring to a pharmacy vial. 
8.2.5 Route of Administration  
Take lenalidomide by mouth with or without food. Do not crush, chew or open capsules. 
8.2.6  Potential Drug Interactions   
Periodic monitoring of digoxin levels is recommended during co administration with CC-5013.  
Digoxin levels were slightly higher when digoxin was administered with CC-5013 in a clinical study.  
There was no effect on CC-5013 pharmacokinetics. Warfarin and CC-5013 may be co-administered 
without additional monitoring.  No pharmacokinetic or pharmacodynamic interactions were observed 
between CC-5013 and warfarin.  
Nonclinical in vitro metabolism studies suggest that CC-5013 is not likely to result in metabolic drug 
interactions in humans.  In vitro, CC-5013 did not significantly inhibit marker enzyme activities for 
CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4.  In rats, no induction of any 
CYP450 enzymes was observed. Administration of CC-5013 in monkeys showed no effects on the 
activities of CYP1A, CYP2B, CYP2C, CYP2E, CYP3A, or CYP4A.  
8.2.7 Agent Ordering 
Lenalidomide (CC-5013, NSC 703813) may be requested by the Principal Investigator (or their 
authorized designee) at each participating institution.  Pharmaceutical Management Branch (PMB) 
policy requires that agent be shipped directly to the institution where the patient is to be treated.  
PMB does not permit the transfer of agents between institutions (unless prior approval from PMB 
is obtained.)  The CTEP assigned protocol number must be used for ordering all CTEP supplied 
investigational agents.  The responsible investigator at each participating institution must be 
registered with CTEP, DCTD through an annual submission of FDA form 1572 (Statement of 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
57 
 
Investigator), Curriculum Vitae, Supplemental Investigator Data Form (IDF), and Financial 
Disclosure Form (FDF).  If there are several participating investigators at one institution, CTEP 
supplied investigational agents for the study should be ordered under the name of one lead 
investigator at that institution. 
Active CTEP-registered investigators and investigator-designated shipping designees and ordering 
designees can submit agent requests through the PMB Online Agent Order Processing (OAOP) 
application https://eapps-ctep.nci.nih.gov/OAOP/pages/login.jspx. Access to OAOP requires the 
establishment of a CTEP Identity and Access Management (IAM) account https://eapps-
ctep.nci.nih.gov/iam/ and the maintenance of “active” account status and a “current” password. 
For questions about drug orders, transfers, returns or accountability, call 240 276 6575 Monday 
through Friday between 8:30 am and 4:30 pm (ET) or email PMBAfterHours@mail.nih.gov 
anytime. 
8.2.8 Agent Accountability 
Agent Inventory Records – The investigator, or a responsible party designated by the investigator, 
must maintain a careful record of the inventory and disposition of all agents received from DCTD 
using the NCI Drug Accountability Record Form (DARF).  (See the CTEP home page at 
http://ctep.cancer.gov for the Procedures for Drug Accountability and Storage and to obtain a copy 
of the DARF and Clinical Drug Request form.)  
8.2.9 Dispensing 
Only a 28-day supply may be dispensed at one time. Sites may not mail lenalidomide to patients. 
8.2.10 Patient Care Implications and Counseling 
Risks Associated with Pregnancy 
Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic 
active substance that causes severe life-threatening birth defects.  An embryofetal development 
study in animals indicates that lenalidomide produced malformations in the offspring of female 
monkeys who received the drug during pregnancy.  The teratogenic effect of lenalidomide in 
humans cannot be ruled out.  Therefore, a risk minimization plan to prevent pregnancy must be 
observed. 
Before starting study drug: 
Male Subjects:   
 Must agree to use a latex condom during sexual contact with females of childbearing 
potential while participating in the study and for at least 28 days following discontinuation 
from the study even if he has undergone a successful vasectomy.  
All Subjects: 
 Only enough lenalidomide for one cycle of therapy may be dispensed with each cycle of 
therapy.  
 
 If pregnancy or a positive pregnancy test does occur in a study subject or the partner of a 
male study subject during study participation, lenalidomide must be immediately 
discontinued. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
58 
 
 
Counseling 
 In investigational studies where lenalidomide is supplied by the NCI, patients will be 
counseled by a qualified healthcare professional (including but not limited to, nurses, 
pharmacists and physicians).  Two healthcare professionals at each site will be trained by 
Celgene in requirements specific to counseling of subjects (investigators cannot counsel 
patients as part of this requirement). Refer to specific protocol sections for more information 
about training requirements. 
 
Once trained, these healthcare staff will counsel subjects prior to medication being dispensed to 
ensure that the subject has complied with all requirements including use of birth control and 
pregnancy testing (FCBP) and that the subject understands the risks associated with 
lenalidomide.  This step will be documented with a completed Lenalidomide Education and 
Counseling Guidance Document (Appendix F) and no drug will be dispensed until this step 
occurs. Counseling includes verification with the female patient that required pregnancy testing 
was performed and results were negative. A Lenalidomide Information Sheet (Appendix G) will 
be supplied with each medication dispense. 
8.3 
PREDNISONE 
8.3.1 Chemical formula  
17a, 32-Dihydroxy-1,4-pregnadiene- 3,11,20-trione 
  
C21H26O5,  Molecular weight of 358.4 
Classification: Glucocoticorticoids 
8.3.2 Mechanism of Action   
Multiple mechanisms leading to anti-inflammatory and immune suppression outcomes 
8.3.3 How supplied  
Prednisone is supplied as a tablet or suspension.  We will use commercially available 5 mg tablets 
for this study. 
8.3.4 Storage   
Prednisone should be stored in original containers at room temperature, out of direct sunlight. 
8.3.5 Stability   
Prednisone tablets are stable for three years from date of manufacture 
8.3.6 Route of administration 
 Oral 
8.3.7 Toxicities 
Anemia, eosinopenia, leukocytosis, lymphopenia, thrombocytopenia, leukocytosis, hypertensive 
crisis, hypertension, psychosis, schizophrenic psychosis, extrapyramidal effects, pseudotumor 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
59 
 
cerebri, hyperglycemia, hyperuricemia, hypercalcemia, adrenal suppression, Cushing’s syndrome, 
porphyria, lipid abnormalities, hypokalemia, peptic ulcers, pancreatitis, abdominal pain, 
nephrotoxicity, proteinuria, cataracts, papilledema, acne, osteonecrosis, osteoporosis, myopathy, 
and superinfections. 
8.3.8 Availability 
Prednisone will be obtained from commercial stock purchased by the NIH CC Pharmacy 
Department.  See package insert for further information. 
8.4 
BEVACIZUMAB    
(Avastin – Genentech BioOncology, South San Francisco, CA) 
8.4.1 Chemical name and identification  
Recombinant humanized monoclonal anti-VEGF antibody (rhuMAB VEGF) 
Classification: Recombinant humanized monoclonal antibody 
8.4.2 Mechanism of Action  
Inhibition of vascular endothelial growth factor (VEGF) resulting in inhibition of angiogenesis. 
8.4.3 Approximate Solubility 
0.19 mg/100 mL in 0.1 N HCl, 453 mg/100 mL in Ethanol, and 2971 mg/100 mL in PEG 400. 
8.4.4 How Supplied  
Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid for parenteral 
administration.    Each 400 mg (25mg/ml – 16 mL fill) glass vial contains bevacizumab with 
phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP. 
8.4.5 Agent Ordering 
Bevacizumab (NSC 704865) may be requested by the Principal Investigator (or their authorized 
designee) at each participating institution.  Pharmaceutical Management Branch (PMB) policy 
requires that agent be shipped directly to the institution where the patient is to be treated.  PMB 
does not permit the transfer of agents between institutions (unless prior approval from PMB is 
obtained.)  The CTEP assigned protocol number must be used for ordering all CTEP supplied 
investigational agents.  The responsible investigator at each participating institution must be 
registered with CTEP, DCTD through an annual submission of FDA form 1572 (Statement of 
Investigator), Curriculum Vitae, Supplemental Investigator Data Form (IDF), and Financial 
Disclosure Form (FDF).  If there are several participating investigators at one institution, CTEP 
supplied investigational agents for the study should be ordered under the name of one lead 
investigator at that institution. 
Active CTEP-registered investigators and investigator-designated shipping designees and ordering 
designees can submit agent requests through the PMB Online Agent Order Processing (OAOP) 
application https://eapps-ctep.nci.nih.gov/OAOP/pages/login.jspx. Access to OAOP requires the 
establishment of a CTEP Identity and Access Management (IAM) account https://eapps-
ctep.nci.nih.gov/iam/ and the maintenance of “active” account status and a “current” password. 
For questions about drug orders, transfers, returns or accountability, call 240 276 6575 Monday 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
60 
 
through Friday between 8:30 am and 4:30 pm (ET) or email PMBAfterHours@mail.nih.gov 
anytime. 
8.4.6 Agent Accountability 
Agent Inventory Records – The investigator, or a responsible party designated by the investigator, 
must maintain a careful record of the inventory and disposition of all agents received from DCTD 
using the NCI Drug Accountability Record Form (DARF).  (See the CTEP home page at 
http://ctep.cancer.gov for the Procedures for Drug Accountability and Storage and to obtain a copy 
of the DARF and Clinical Drug Request form.) 
8.4.7 Preparation 
 
Bevacizumab must be stored under refrigeration at 2°–8°C (36°–46°F) and protected from light.  
Store in the original overwrap carton until the product is used.  Do not freeze the product. Do not 
shake bevacizumab during handling or preparation for clinical use. 
An amount of bevacizumab needed to prepare a dose of 15 mg/kg (patient’s body weight) should 
be withdrawn from one or more vials and diluted in a total volume of 0.9% Sodium Chloride 
Injection, USP, (qs.) 100 mL. 
8.4.8 Storage  
Bevacizumab must be stored under refrigeration at 2°–8°C (36°–46°F) upon receipt and should 
remain refrigerated until just prior to use.  DO NOT FREEZE.  DO NOT SHAKE.   Vials should 
be protected from light. 
Opened vials must be used within 8 hours.  VIALS ARE FOR SINGLE USE ONLY.  Vials used 
for 1 subject may not be used for any other subject.  Once study drug has been added to a bag of 
sterile saline, the solution must be administered within 8 hours. 
8.4.9 Stability   
Intact vials bear the manufacturer’s expiration dating and are stable until that date if stored at 2°–
8°C.  Partially used vials should be discarded because the product does not contain an antimicrobial 
preservative.  
Bevacizumab should be diluted only with 0.9% Sodium Chloride Injection, USP (0.9%NS).  
Diluted bevacizumab solutions are stable in both polyvinylchloride (PVC) and polyolefin 
containers. 
 No significant changes were observed in protein concentration, pH, turbidity, or potency after 
bevacizumab dilution with 0.9%NS to concentrations of 0.9, 2.25, 3, 6.6, 7.5, and 16.5 mg/mL and 
storage for 24 hours in commercial PVC and polyolefin containers at 30°C.  No changes were 
observed with respect to protein concentration, turbidity, or potency for the undiluted drug product 
(25 mg/mL) and after bevacizumab dilution with 0.9%NS to 1 mg/mL and 12.5 mg/mL and 
storage for 24 hours in non-PVC, polyolefin bags at 5°C (41°F) and 30°C (86°F). [DRKohler 
personal communication with Genentech Medical Communications; 04/13/04] 
8.4.10 Route of Administration   
Intravenous 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
61 
 
8.4.11 Reported Adverse Events and Potential Risks 
See Section 7.2 
8.4.12 Method of Administration   
Bevacizumab will be administered intravenously through a secondary IV set piggybacked above 
the infusion control device (pump) into a primary IV set containing 0.9% NS.  When the 
bevacizumab drug product container is empty, 0.9% NS from the primary line should be used to 
flush the secondary set to complete bevacizumab delivery.  0.9% NS infusion should be continued 
to flush the primary IV set with a volume of fluid at least equal to the tubing priming volume, thus 
insuring complete drug delivery.  Note that this flush is not included in the infusion times below. 
The initial dose should be administered over a minimum of 90 minutes.  If no adverse reactions 
occur, the second dose should be administered over a minimum of 60 minutes.  Again, if no 
adverse reactions occur, the third and subsequent doses should be administered over a minimum 
of 30 minutes.  If infusion-related adverse reactions occur, subsequent infusions should be 
administered over the shortest period that was well tolerated. 
8.5 
PEGFILGRASTIM  
 (Neulasta™, Amgen Inc., Thousand Oaks, CA) 
8.5.1 Chemical Name and Identification 
A covalent conjugate of recombinant methionyl human granulocyte colony stimulating factor 
(Filgrastim) and monomethoxypolyethylene glycol 
Average molecular weight: ~ 39 kiloDaltons 
8.5.2 Classification 
Colony stimulating factors acting on hematopoietic cells 
8.5.3 Mechanism of Action 
Binding to a specific cell surface receptor thereby stimulating myeloid proliferation, 
differentiation, commitment, and end cell functional activation 
8.5.4 How Supplied 
In 0.6 mL prefilled syringes for subcutaneous (SC) injection containing 6 mg pegfilgrastim in a 
sterile, clear, colorless, preservative-free solution (pH 4.0).  The manufacturer’s product 
(Neulasta®; Amgen) is intended for a single use and comes with a fixed 27 Gauge 1/2-inch needle 
and an UltraSafe® Needle Guard 
8.5.5 Storage 
Stored refrigerated at 2° to 8°C (36° to 46°F) and kept in carton to protect from light until time of 
use. Shaking should be avoided. 
8.5.6 Stability 
Intact syringes bear the manufacturer’s expiration dating and are stable until that date if stored at 
2°–8°C.  The syringes may be allowed to reach room temperature for a maximum of 48 hours but 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
62 
 
should be protected from light. If left at room temperature for more than 48 hours or discoloration 
or particulates are observed in the product, it should be discarded. 
8.5.7 Route of Administration 
Subcutaneous (SC) injection of 6 mg/0.6 mL administered once per chemotherapy cycle 
approximately 24 hours after docetaxel administration. 
8.5.8 Reported Adverse Events and Potential Risks 
COMMON: Bone pain, Reversible elevations in LDH, alkaline phosphatase, and uric acid 
SERIOUS, but very rare: (with filgrastim, the parent compound of pegfilgrastim), Adult 
respiratory distress syndrome (ARDS), Allergic-type reactions (anaphylaxis, skin rash, and 
urticaria), Splenic rupture 
9 
CORRELATIVE STUDIES (MANDATORY FOR STUDY PARTICIPANTS) 
Proposed correlative studies follow. Other studies may be performed as further data is developed 
both within the study and from other investigators.   
As stipulated in the informed protocol consent, the following correlative studies are mandatory 
and include:  
9.1 
GENOTYPING OF PATIENTS 
Single nucleotide polymorphisms (SNPs) in genes that play an important role in elimination 
pathways for docetaxel and lenalidomide will be evaluated.  For this purpose, one 10ml EDTA 
lavender top tube (BD366643) will be obtained when the patient enters onto the study. In addition, 
urine samples will be collected. DNA will be isolated only for the purpose of genotype analysis of 
enzymes with putative relevance for docetaxel or lenalidomide disposition. The genotyping will 
be performed on a research basis in the Molecular Pharmacology Program (Bldg. 10 Room 5A01; 
William Figg, Pharm D.).  (See Sample Processing and Storage under Section 9.3 Angiogenesis 
Markers for labeling and storage of samples in Dr. Figg’s lab.) 
Based on the findings of this analysis of docetaxel/lenalidomide metabolism it may be possible to 
identify certain patients as likely responder or unlikely responders.  This may have ramifications 
in the treatment of future patients. 
9.2 
CELLULAR ANALYSIS 
9.2.1 Analysis of circulating endothelial cells (CEC) and circulating endothelial progenitor 
cells (CEP) 
For this analysis, peripheral blood is drawn into 3 CPT citrate (blue/black tiger top) tubes. 
Mononuclear cells are isolated by centrifugation.  Approximately 2 cc of plasma is removed and 
stored (see Immune Correlates below).  Mononuclear cells are washed with PBS, and FcR solution 
(Miltenyi) is added to block non-specific binding. following centrifugation and stored at For 
identification of CECs and CEPs, cells are stained with FITC- conjugated anti-CD31 (BD), PerCP-
conjugated anti-CD45 (BD), APC-conjugated anti-CD133 (Miltenyi) and PE-conjugated CD146 
(Chemicon) for 30 min on ice.  For isotype controls, cells are incubated with FITC-conjugated 
IgG1, PerCP-conjugated IgG1, APC-conjugated IgG1 and PE-conjugated IgG1.  After washing 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
63 
 
with 0.1% BSA in PBS, the cells are incubated with Hoechst 33258 dye as an indicator of cell 
viability and analyzed by multiparametric flow cytometry on an LSR II flow cytometer (BD 
Biosciences), using LSR II-equipped digital data acquisition and FlowJo cytometric data analysis 
software. The CEC and CEP cell concentrations are calculated as a percentage of the total number 
of mononuclear cells or as the number of cells/microliter of whole blood after an evaluation of a 
minimum of 105 cellular events, and preferable 106 cellular events.  CEC cells are defined by the 
co-expression, or absence of expression on a single cell of the following parameters: CD45-, 
CD31+, CD133- and CD146+, Hoechst 33258- (viable CEC) or CD45-, CD31+, CD133- and 
CD146+, Hoechst 33258+ (nonviable CEC).  CEP cells are defined by the co-expression, or 
absence of expression on a single cell of the following parameters: CD45- or dim, CD31+, CD133+ 
and CD146-, Hoechst 33258- (viable CEP) or CD45- or dim, CD31+, CD133+ and CD146-, 
Hoechst 33258+ (nonviable CEP).  CEC and CEP markers may be modified or expanded in 
response to new studies in this rapidly developing field.  
The assays will be performed by Dr. Min-Jung Lee and Dr. Yeong Sang Kim in Jane Trepel’s 
laboratory in the Medical Oncology Branch, Building 10, Room 12N218.  
 Samples will be obtained prior to the initiation of treatment (C1D1 pre), prior to administration 
of the cycle two dose (C2D1 pre-dose), prior to administration of the cycle three dose (C3D1 pre-
dose) and prior to administration of the cycle six dose (C6D1 pre-dose).  If a pre-treatment (C1D1 
pre) sample was unable to be collected, cycle 2, 3 and 6 samples will not be drawn. The outcome 
measures will be the number of CEC and CEP per 106 mononuclear cells or per microliter of 
peripheral blood, analyzed in samples taken before and after treatment.  These numbers will then 
be examined for correlations with various parameters to assess their potential utility as surrogate 
biomarkers for drug activity, for establishing the optimal biologic dose, for patient stratification, 
and monitoring of therapy-related side effects.  
 Modulation of immune parameters will be explored using the samples above.  Immune cell subsets 
including NK and NKTlevel will be determined by multiparameter flow cytometry. 
Approximately 1 cc of plasma is removed and stored.  Depending on cell-based assay results 
cytokine and angiogenic factor modulation, including the Th1 cytokine interferon-gamma and IL-
2 may be examined by technology appropriate to the sample such as Luminex or Molecular 
Diagnostics chips... 
Sample Collection and Processing 
Biospecimens will be collected and processed using validated SOPs that will ensure both specimen 
quality and patient confidentiality pursuant to informed consent provisions.   Using a computerized 
inventory system and a backup hardcopy process, all specimen collection and processing steps will 
be documented and the specific location of each specimen will be tracked.  Each new specimen 
collected will be assigned a unique barcode identifier that can be linked to the original specimen 
collected and other relevant information within the inventory system.  To ensure patient 
confidentiality, only containers used for the initial specimen collections will be labeled with patient 
identifiers.  Only the barcode identifier will be applied to all subsequent specimen containers.  
When specimens are processed and aliquoted, no patient information will be included on the new 
containers.  Original specimen containers will be discarded.  Only barcode-labeled specimens 
without patient identifiers will be shipped for analysis and/or storage.  Specimen labels will 
indicate protocol number, order in which the patient enrolled on the trial, type of sample, collection 
time, and total cell number/volume, as appropriate.   

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
64 
 
The inventory process contains other security provisions sufficient to safeguard patient privacy 
and confidentiality.  Access to the inventory system and associated documents will be restricted to 
appropriate individuals.  Requests to use specimens stored in the repository must be approved.  
The only patient information available in the inventory system will be the patient sex, date of birth, 
diagnosis, and level of informed consent given.  SOPs ensure that any changes in informed consent 
made by a patient and relayed to the PI will be reflected in the inventory system to ensure that 
specimens are destroyed as appropriate.  All laboratory personnel will be trained to adhere to SOPs 
and will be monitored for high-quality performance. 
Following completion of this study, samples will remain in storage as detailed above.  Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the 
rights to use the material.  Any samples lost (in transit or by a researcher) or destroyed due to 
unknown sample integrity (i.e., broken freezer allows for extensive sample thawing, etc.) will be 
reported as such to the IRB.  If, at any time, a patient withdraws from the study and does not wish 
for their existing samples to be utilized, the individual must provide a written request.  Following 
receipt of this request, the samples will be destroyed (or returned to the patient, if so requested), 
and reported as such to the IRB. 
9.3 
ANGIOGENESIS MARKERS 
We will collect both serum and urine samples at baseline and monthly to measure vascular 
endothelial growth factor (VEGF) levels.  These studies will be done by the Molecular 
Pharmacology Program, under the direction of Dr. Figg. 
A Serum research sample (one 7ml red top (BD 366431) is to be drawn and kept at room 
temperature (RT) for 30 minutes and then placed in a 4 degree C refrigerator.   
Please e-mail Julie Barnes at Julie.barnes@nih.gov and Paula Carter pcartera@mail.nih.gov at 
least 24 hours before transporting samples (the Friday before is preferred). 
For sample pickup, page 102-11964. 
For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). 
For questions regarding sample processing, contact Julie Barnes by e-mail or at 240-760-6044.  
Blood collected in the course of this research project may be banked and used in the future to 
investigate new scientific questions related to this study.  However, this research may only be done 
if the risks of the new questions were covered in the consent document.  If new risks are associated 
with the research (e.g. analysis of germ line genetic mutations), the principal investigator must 
amend the protocol and obtain informed consent from all research subjects. 
Urine Profile  
Research spot urine samples should be collected in a clean catch container (approx. 30 ml) at 
baseline and at monthly clinic visit.   
Please e-mail Julie Barnes at Julie.barnes@nih.gov and Paula Carter pcartera@mail.nih.gov at least 
24 hours before transporting samples (the Friday before is preferred). 
For sample pickup, page 102-11964. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
65 
 
For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). 
For questions regarding sample processing, contact Julie Barnes by e-mail or at 240-760-6044. 
 
The inclusion of bevacizumab in this treatment regimen allows for the measurement of changes in 
VEGF levels.  Such changes can then be evaluated in the context of the clinical response that is 
seen.   
Sample Processing and Storage 
Upon arrival in the Clinical Pharmacology Program (CPP), blood samples will be centrifuged for 
5 minutes at 1200 x g, at 4C. The serum will be transferred into two cryovials and immediately 
frozen. Serum samples will be stored at -80C until the time of analysis. Urine samples will be 
transferred to 50ml conical tubes and stored at -20C. 
All samples will be bar-coded, with data entered and stored in the Patient Sample Data 
Management System (PSDMS) (a.k.a. Labrador) utilized by the CPP. This is a secure program, 
with access to the PSDM System limited to defined CPP personnel, who are issued individual user 
accounts. The program creates a unique barcode ID for every sample and sample box, which 
cannot be traced back to patients without PSDMS access. The data recorded for each sample 
includes the patient ID, name, trial name/protocol number; time drawn, cycle time point, dose, 
material type, as well as box and freezer location. Patient demographics associated with the clinical 
center patient number are provided in the system. For each sample, there are notes associated with 
the processing method (delay in sample processing, storage conditions on the ward, etc.). 
Bar-coded samples are stored in bar-coded boxes in a locked freezer at either -20 or -80C 
according to stability requirements.  These freezers are located onsite in the CPP and offsite at NCI 
Frederick Central Repository Services in Frederick, MD. Samples will be stored until requested 
by a researcher named on the protocol. All requests are monitored and tracked in the PSDM 
System. All researchers are required to sign a form stating that the samples are only to be used for 
research purposes associated with this trial (as per the IRB approved protocol) and that any unused 
samples must be returned to the CPP. 
Following completion of this study, samples will remain in storage as detailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the 
rights to use the material.  
If, at any time, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request. Following receipt of this request, the 
samples will be destroyed (or returned to the patient, if so requested), and reported as such to the 
IRB. Any samples lost (in transit or by a researcher) or destroyed due to unknown sample integrity 
(i.e. broken freezer allows for extensive sample thawing, etc.) will be reported as such to the IRB. 
Sample barcodes are linked to patient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol, via registered use of the 
PSDMS. It is critical that the sample remains linked to patient information such as race, age, dates 
of diagnosis and death, and histological information about the tumor, in order to correlate genotype 
with these variables. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
66 
 
9.4 
TIME EFFICIENT AUTOMATIC LESION IDENTIFICATION AND MEASUREMENT ON CT 
Metastatic tumor burden and treatment response is commonly evaluated on serial CT scans with 
subjective target lesion selection and measurement on baseline and post-treatment exams 
(RECIST).  Subjective measurement error has been studied showing false categorization of partial 
response based on two measurements of the same lesion42. Semi-automated RECIST 
measurements of malignant lymph nodes produce reliable results when compared to manual 
measurements43. It is generally believed that assessment on thin section data on the most tumors 
possible44 would be the optimal approach to assessing response to therapy. However, with manual 
protocols, the detection and measurement of additional lesions compounds the total time 
investment in the evaluation that has been rarely feasible.  Various software programs have 
recently been developed to address this deficiency. 
We aim to assess time savings of semi-automated lesion localization and measurement on serial 
images of metastatic cancer patients as compared to the current manual process. The automated 
software that will be used is available in the PACS (Picture Archiving and Communications 
System) at NIH provided by Carestream Health (Rochester, NY) and called the Lesion 
Management Application (LMA). The application has advanced serial image co-registration as 
well as refined registration for lesion identification (based on original exam). The program semi-
automatically segments and measures the lesion targeted by the radiologist on baseline CT, then 
automatically localizes and measures the lesion on the subsequent exam.  Preliminary results 
demonstrate that target lesions can be identified, segmented, and measured (including RECIST 
and volume) in most cases. Routine inclusion of tumor measurements should greatly assist 
providers in quickly evaluating the efficacy of cancer therapies. Tumor evaluation by volume 
determination on serial CT studies can be enhanced and made more effective by semi-automated 
detection of previously identified and measured target lesions. 
We will retrospectively assess CT scans acquired for tumor response evaluations via automated 
volumetric measurements obtained using LMA.  We will also assess the accuracy and consistency 
of target lesion localization, segmentation, and resultant measurements, to include volumes, on 
serial CT studies.  
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
67 
 
10 STUDY CALENDAR  
Baseline evaluations are to be conducted within 15 days prior to administration of protocol therapy.  Scans and x-rays must be performed <4 weeks prior to the 
first treatment.  On study evaluations may be performed within ± 3 days of day indicated on calendar. In the event that the patient’s condition is deteriorating, 
laboratory evaluations should be repeated within 48 hours prior to initiation of the next cycle of therapy. For detailed dosing information including dose 
modifications and use of supportive treatments, please refer to Section 5. All follow-up evaluations can be done on the last week of the prior cycle.  Long term 
monitoring and evaluating of secondary primary malignancies will be done at least an annual basis until the study is complete.   
 
PreStudy 
Cycle 1 
Cycle 2 
Cycles >3 
Study Drug Discontinuation 
Day 
-15 to 0 
1 
2 
3-21 
1 
2 
3-21 
1j 
2-21 
3-4 weeks from the last day of last 
cycle 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
 
 
 
Concurrent meds 
X 
X 
 
 
X 
 
 
X 
 
 
Physical exam 
X 
X 
 
 
X 
 
 
X 
 
 
Vital signs 
X 
X 
 
 
X 
 
 
X 
 
 
Height 
X 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
 
 
X 
 
 
X 
 
 
Perform. Status 
X 
X 
 
 
X 
 
 
X 
 
 
CBC w/diff, pltsa 
X 
X 
 
Xa 
X 
 
Xa 
X 
Xa 
 
Serum chemistries b 
X 
X 
 
 
X 
 
 
X 
 
 
TSH 
X 
 
 
 
 
 
 
 
 
 
Testosterone 
X 
 
 
 
 
 
 
 
 
 
PSA 
X 
X 
 
 
X 
 
 
X 
 
 
Coagulation (PT/PTT) 
X 
X 
 
 
X 
 
 
X 
 
 
Urinalysisc 
X 
X 
 
 
X 
 
 
X 
 
 
EKG (as indicated) 
X 
 
 
 
 
 
 
 
 
 
BP monitoringd 
X 
X 
 
 
X 
 
 
X 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
68 
 
 
PreStudy 
Cycle 1 
Cycle 2 
Cycles >3 
Study Drug Discontinuation 
Day 
-15 to 0 
1 
2 
3-21 
1 
2 
3-21 
1j 
2-21 
3-4 weeks from the last day of last 
cycle 
Adverse event evaluation 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Education and counselingi 
 
X 
 
 
X 
 
 
X 
 
X 
Correlative Studies e 
X 
X 
X 
 
X 
X 
 
X 
 
 
Radiologic Studiesf 
X 
 
 
 
 
 
Xe 
 
Xf, 
 
Dental Examsg 
X 
 
 
 
 
 
 
 
 
 
NIH Advanced Directives Formk 
X 
 
 
 
 
 
 
 
 
 
Docetaxel (75 mg/m2) 
 
X 
 
 
X 
 
 
X 
 
 
Bevacizumab(15 mg/Kg) 
 
X 
 
 
X 
 
 
X 
 
 
Lenalidomide(25 mg QD)  h) 
 
X 
X 
Days 
3-14 
X 
X 
days 
3-14 
X 
days 
2-14 
 
Prednisone (5 mg BID) 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Enoxaparin (1 mg/kg QD) 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Pegfilgrastim (6mg SQ once) 
 
 
X 
 
 
X 
 
 
X 
(day 2) 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
69 
 
 
PreStudy 
Cycle 1 
Cycle 2 
Cycles >3 
Study Drug Discontinuation 
Day 
-15 to 0 
1 
2 
3-21 
1 
2 
3-21 
1j 
2-21 
3-4 weeks from the last day of last 
cycle 
a. 
Weekly except if lenalidomide and docetaxel have been held during a cycle or for continuous cycles for reasons unrelated to 
treatment toxicity. For weeks 2-3, results from other medical laboratories are accepted for monitoring. 
b. 
Electrolytes including sodium, potassium, bicarbonate, chloride, magnesium, calcium, phosphate,  BUN, creatinine, glucose, uric 
acid, LDH, total protein/albumin, hepatic transaminases, bilirubin, alkaline phosphatase. 
c. 
If UA/dipstick protein ≥2, then obtain a 24 hour urine for total protein to assess (see Section 5.3). 
d. 
BP monitoring will be done weekly during cycle one and recorded onto study diary. 
e. 
Refer to Section 9 for specific timings for different assays. 
f. 
Staging scans will be performed after the first 2 cycles of treatment and then every three cycles. Patients that have been on study 
for at least 2 years may have scans performed only at the time of clinical progression at the physician’s discretion. 
g. 
Dental evaluations will be obtained for selected patients as time allows.  Follow-up dental evaluations will occur post cycle 5, post 
cycle 11 and post cycle 17.  Additional dental examinations will be performed once per year as long as the patient remains on 
study.  
h. 
Lenalidomide will administered on days 1-14 during each cycle to the 3-6 patients at dose level of 15 to 20mg for run in phase then 
max dose of 25mg.  Only enough lenalidomide for 28 days or one cycle of study treatment (whichever is shorter) may be provided 
to the patient each cycle. For the expansion cohort, lenalidomide will be administered 15 mg po for 14 days. 
i. 
The Lenalidomide Education and Counseling Guidance Document (Appendix F) must be completed and signed by a trained 
counselor at the participating site prior to each dispensing of lenalidomide treatment.   A copy of this document must be maintained 
in the patient records. The Lenalidomide Information Sheet (Appendix G) will be given to each patient receiving lenalidomide 
treatment. The patient must read this document prior to starting lenalidomide study treatment and each time they receive a new 
supply of study drug. 
j. 
Patients who have been on study for at least 2 years and who are being treated with prednisone only, may have clinical 
evaluations performed every 6 weeks at the physician’s discretion.   
k. 
As indicated in section 16.3, all subjects will be offered the opportunity to complete an NIH advanced directives form.  This 
should be done preferably at baseline but can be done at any time during the study as long as the capacity to do so is retained.  
The completion of the form is strongly recommended, but is not required. 
 
 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
70 
 
11 MEASUREMENT OF EFFECT 
Patients will be evaluated as described in Section 5.  For exploratory purpose, changes in PSA and 
measurable lesions will be analyzed for efficacy according to the PCWG2 recommendations [JCO 
26: 1148-1159, 2008]. The recommended PSA progressions criteria will not be applied to the study 
as the criteria are arbitrarily proposed and do not necessarily reflect overall disease status.  PSA 
values will be captured at each visit and PSA declines and progression will be follow.  As 
documented in the previous ATTP trial, PSA is not sufficient in the evaluation of disease 
progression in this patient population.  This is consistent with the recent recommendations by the 
Prostate Cancer Clinical Trials Working Group 2.  (ref:  Scher, HI et al. J Clin Onc. 26(7), 2008.)  
Progression will be determined by radiographic evidence as discussed below or by clinical 
symptoms (symptomatic clinical progression).       
11.1 RESPONSE CRITERIA FOR RADIOGRAPHIC STUDIES 
11.1.1 Measuring of Soft Tissue Disease 
Response and progression will be evaluated in this study using the new international criteria 
proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline 
(version 1.1) [Eur J Ca 45:228-247, 2009].  Changes in the largest diameter (unidimensional 
measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes 
are used in the RECIST criteria. 
11.1.1.1 Evaluation of Target Lesions  
Complete Response (CR)  
Disappearance of all target lesions.  Any pathological lymph nodes (whether target 
or non-target) must have reduction in short axis to <10 mm 
Partial Response (PR)  
At least a 30% decrease in the sum of the diameters of target lesions, taking as 
reference the baseline sum diameters 
Progressive Disease (PD)  
At least a 20% increase in the sum of the diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one 
or more new lesions is also considered progressions) 
Stable Disease (SD)  
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD, taking as reference the smallest sum diameters while on study 
11.1.1.2 Evaluation of Non-Target Lesions  
Complete Response (CR)  
Disappearance of all non-target lesions and normalization of tumor marker level.  
All lymph nodes must be non-pathological in size (<10 mm short axis) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
71 
 
Note:  If tumor markers are initially above the upper normal limit, they must 
normalize for a patient to be considered in complete clinical response 
Non-CR/Non-PD (Stable Disease, SD) 
Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker 
level above the normal limits 
Progressive Disease (PD)  
Appearance of one or more new lesions and/or unequivocal progression of existing 
non-target lesions.  Unequivocal progression should not normally trump target 
lesion status.  It must be representative of overall disease status change, not a single 
lesion increase.     
Although a clear progression of “non-target” lesions only is exceptional, the 
opinion of the treating physician should prevail in such circumstances, and the 
progression status should be confirmed at a later time by the review panel (or 
Principal Investigator). 
11.1.1.3 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started).  The 
patient's best response assignment will depend on the achievement of both 
measurement and confirmation criteria. 
Target Lesions 
Non-
Target 
Lesions 
New 
Lesions 
Overall 
Response 
Best Overall 
Response when 
Confirmation is 
Required* 
CR 
CR 
No 
CR 
>4 wks. 
Confirmation** 
CR 
Non-
CR/Non-
PD 
No 
PR 
 
>4 wks. 
Confirmation** 
CR 
Not 
evaluated 
No 
PR 
PR 
Non-
CR/Non-
PD/not 
evaluated 
No 
PR 
SD 
Non-
CR/Non-
PD/not 
evaluated 
No 
SD 
documented at least 
once >4 wks. from 
baseline** 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
72 
 
Target Lesions 
Non-
Target 
Lesions 
New 
Lesions 
Overall 
Response 
Best Overall 
Response when 
Confirmation is 
Required* 
PD 
Any 
Yes or 
No 
PD 
 
no prior SD, PR or CR 
Any 
PD*** 
Yes or 
No 
PD 
Any 
Any 
Yes 
PD 
*      See RECIST 1.1 manuscript for further details on what is evidence of a 
new lesion. 
**    Only for non-randomized trials with response as primary endpoint. 
***  In exceptional circumstances, unequivocal progression in non-target 
lesions may be accepted as disease progression. 
 
 
a. Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
reported as “symptomatic deterioration.”  Every effort should be made to document 
the objective progression even after discontinuation of treatment. 
b. In some circumstances, it may be difficult to distinguish residual disease from 
normal tissue.  When the evaluation of complete response depends on this 
determination, it is recommended that the residual lesions be investigated 
(fine needle aspirate/biopsy) before confirming the complete response status. 
11.1.2 Confirmatory Measurement/Duration of Response 
11.1.2.1 Confirmation 
To be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat 
assessments that should be performed at least 4 weeks after the criteria for response are first met. 
11.1.2.2 Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented. 
11.1.3 Measurable Disease 
Measurable lesions are defined as those that can be accurately measured in at least one dimension 
(longest diameter to be recorded) as >20 mm by chest x-ray, as >10 mm with CT scan, or >10 mm 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
73 
 
with calipers by clinical exam.  All tumor measurements must be recorded in millimeters (or 
decimal fractions of centimeters). 
Note:  Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable.   
11.1.4 Malignant Lymph Nodes  
To be considered pathologically enlarged and measurable, a lymph node must be >15 mm in short 
axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 
mm).  At baseline and in follow-up, only the short axis will be measured and followed. 
11.1.5 Non-measurable Disease 
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or 
pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered non-measurable disease.  
Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis 
cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or 
MRI), are considered as non-measurable. 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
definition, simple cysts. 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if 
they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions. 
11.1.6 Target Lesions 
      All measurable lesions up to a maximum of 2 lesions per organ and 5   lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all involved organs, but in addition should be those that 
lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in which circumstance the next 
largest lesion which can be measured reproducibly should be selected.  A sum of the diameters 
(longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated 
and reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, then 
only the short axis is added into the sum.  The baseline sum diameters will be used as reference to 
further characterize any objective tumor regression in the measurable dimension of the disease. 
11.1.7 Non-Target Lesions 
All other lesions (or sites of disease) including any measurable lesions over and above the 5 target 
lesions should be identified as non-target lesions and should also be recorded at baseline.  
Measurements of these lesions are not required, but the presence, absence, or in rare cases 
unequivocal progression of each should be noted throughout follow-up.  
11.1.8 Metastatic Bone Lesions 
Disease progression is considered if a minimum of two new lesions is observed on bone scan. New 
lesions seen by the end of cycle 2 or before cycle 3 (after the first staging bone scan) may represent 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
74 
 
disease that was not detected on the pre-study scan, and a confirmatory scan will be required in 
next scheduled staging bone scan unless clinically not indicated.  If confirmed, progression should 
be dated by the initial time when the lesions are first detected.   If new lesions are seen after cycle 
2, but no additional lesions are seen on confirmatory scans, the scans from after cycle 2 would 
serve as the baseline scan to evaluate for disease progression,  (ref:  Scher, HI et al. J Clin Onc, 26 
(7), 2008) 
11.1.9 Clinical Lesions  
Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules 
and palpable lymph nodes) and 10 mm diameter as assessed using calipers (e.g., skin nodules).  
In the case of skin lesions, documentation by color photography, including a ruler to estimate the 
size of the lesion, is recommended.  
11.2 GUIDELINES FOR EVALUATION OF MEASURABLE DISEASE 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment. 
 
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam. 
11.3 METHODS OF MEASUREMENT 
11.3.1 Chest X-ray  
Lesions on chest x-ray are acceptable as measurable lesions when they are clearly defined and 
surrounded by aerated lung.  However, CT is preferable.  
11.3.2 CT and MRI  
CT and MRI are the best currently available and reproducible methods to measure target lesions 
selected for response assessment. For this study helical Multi-detector CT will be performed with 
cuts of 5 mm in slice thickness for chest, abdomen and pelvis lesions and 2-3 mm thickness for 
head and neck lesions. 
12 DATA REPORTING AND REGULATORY CONSIDERATIONS 
12.1 RECORD KEEPING 
Quality assurance complete records must be maintained on each patient treated on the protocol.  
These records should include primary documentation (e.g.: laboratory report slips, X-ray reports, 
scan reports, pathology reports, physician notes, etc.) which confirm that: 
 The patient met all eligibility criteria 
 Signed informed consent was obtained prior to treatment 
 Treatment was given according to protocol (dated notes about doses given, complications, 
and clinical outcomes) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
75 
 
 Toxicity was assessed according to protocol (laboratory report slips, etc) 
 Response was assessed according to protocol (X-ray, scan, lab reports, date noted on 
clinical assessment, as appropriate) 
Symptoms will be reviewed with the patient by the nurse or physician during each clinic visit for 
patient education and verification of medication administration, but the principal investigator 
toxicity documentation supersedes all other source documentation regarding adverse event 
reporting. 
 
The PI will be responsible for overseeing entry of data into an in-house password protected 
electronic system and ensuring data accuracy, consistency and timeliness. The principal 
investigator, associate investigators/research nurses and/or a contracted data manager will assist 
with the data management efforts. All data obtained during the conduct of the protocol will be 
kept in secure network drives or in approved alternative sites that comply with NIH security 
standards. Primary and final analyzed data will have identifiers so that research data can be 
attributed to an individual human subject participant. 
 
End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH 
Intramural Records Retention Schedule as applicable.  
 
Loss or destruction of data: Should we become aware that a major breech in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified. 
 
12.2 DRUG ACCOUNTABILITY  
The unused lenalidomide (partial bottles, empty bottles, and full bottles) will be returned for drug 
accountability at each clinic visit.  Unused drug supplies that are not returned to the patient for the 
next dose cycle will be disposed of according to the Procedure of Disposal of Returned Oral 
Agents. (http://home.ccr.cancer.gov/intra/clin_ops/policies/) 
12.3 DATA REPORTING 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7. 
Reporting guidelines as delineated by CTEP 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf) will 
be used for reporting adverse reactions and events.  The C3D data management system will be 
used to capture data and report to the clinical data update system (CDUS).  Cumulative CDUS 
data will be submitted electronically to CTEP, quarterly by  January 31, April 30, July 31 and 
October 31. The instructions for such submission can also be found at the site 
http://ctep.info.nih.gov/reporting/cdus.html). 
12.4 DATA AND SAFETY MONITORING PLAN 
All adverse events including unexpected and/or SAE will be reviewed by the research team 
monthly.  If trends of intolerance to the combination therapy and/or risks warrant it, accrual 
will be interrupted and/or the protocol and consent will be modified accordingly for study 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
76 
 
subject’s safety.  For adverse events related to the non-IND agents that have not been reported 
previously, MedWatch reporting will be performed.    
12.5 CTEP MULTICENTER GUIDELINES 
The trial is a single center study.  
13 COOPERATIVE 
RESEARCH 
AND 
DEVELOPMENT 
AGREEMENT 
(CRADA)/CLINICAL TRIALS AGREEMENT (CTA) 
 The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following obligations/guidelines, in addition to the 
provisions in the “Intellectual Property Option to Collaborator” (http://ctep.cancer.gov/industry 
http://ctep.cancer.gov/industryCollaborations2/default.htm#guidelines_for_collaborations) 
contained within the terms of award, apply to the use of the Agent(s) in this study: 
Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be 
transferred or licensed to any party not participating in the clinical study.  Collaborator(s) data for 
Agent(s) are confidential and proprietary to Collaborator(s) and shall be maintained as such by the 
investigators.  The protocol documents for studies utilizing investigational Agents contain 
confidential information and should not be shared or distributed without the permission of the NCI.  
If a copy of this protocol is requested by a patient or patient’s family member participating on the 
study, the individual should sign a confidentiality agreement.  A suitable model agreement can be 
downloaded from: http://ctep.cancer.gov. 
For a clinical protocol where there is an investigational Agent used in combination with (an)other 
investigational Agent(s), each the subject of different collaborative agreements , the access to and 
use of data by each Collaborator shall be as follows (data pertaining to such combination use shall 
hereinafter be referred to as "Multi-Party Data.”): 
NCI will provide all Collaborators with prior written notice regarding the existence and nature of 
any agreements governing their collaboration with NIH, the design of the proposed combination 
protocol, and the existence of any obligations that would tend to restrict NCI's participation in the 
proposed combination protocol. 
Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial by any 
other Collaborator solely to the extent necessary to allow said other Collaborator to develop, obtain 
regulatory approval or commercialize its own investigational Agent. 
Any Collaborator having the right to use the Multi-Party Data from these trials must agree in 
writing prior to the commencement of the trials that it will use the Multi-Party Data solely for 
development, regulatory approval, and commercialization of its own investigational Agent. 
Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement will be 
made available exclusively to Collaborator(s), the NCI, and the FDA, as appropriate and unless 
additional disclosure is required by law or court order.  Additionally, all Clinical Data and Results 
and Raw Data will be collected, used, and disclosed consistent with all applicable federal statutes 
and regulations for the protection of human subjects including, if applicable, the Standards for 
Privacy of Individually Identifiable Health Information set forth in 45 C.F.R. Part 164. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
77 
 
When a Collaborator wishes to initiate a data request, the request should first be sent to the NCI, 
who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or 
PI for other studies) of Collaborator's wish to contact them. 
Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the guidelines 
and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for this 
clinical trial. 
Any manuscripts reporting the results of this clinical trial must be provided to CTEP by the Group 
office for Cooperative Group studies or by the principal investigator for non-Cooperative Group 
studies for immediate delivery to Collaborator(s) for advisory review and comment prior to 
submission for publication.  Collaborator(s) will have 30 days from the date of receipt for review.  
Collaborator shall have the right to request that publication be delayed for up to an additional 30 
days in order to ensure that Collaborator’s confidential and proprietary data, in addition to 
Collaborator(s)’s intellectual property rights, are protected.  Copies of abstracts must be provided 
to CTEP for forwarding to Collaborator(s) for courtesy review as soon as possible and preferably 
at least three (3) days prior to submission, but in any case, prior to presentation at the meeting or 
publication in the proceedings.  Press releases and other media presentations must also be 
forwarded to CTEP prior to release.  Copies of any manuscript, abstract and/or press release/ media 
presentation should be sent to: 
Regulatory Affairs Branch, CTEP, DCTD, NCI 
Executive Plaza North, Suite 7111 
Bethesda, Maryland  20892 
FAX 301-402-1584 
Email: anshers@mail.nih.gov 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator’s confidential/ 
proprietary information. 
14 STATISTICAL CONSIDERATIONS 
The primary objectives of this trial are to identify a potentially safe dose of lenalidomide, to 
confirm that the drug does not have an excessively high rate of toxicity in a moderately large cohort 
of patients, and to evaluate the efficacy of the agent.  
Initially, there will be a small dose escalation portion of the trial. Based on a standard 3 to 6 patient 
per cohort dose escalation, the first 3 patients would be treated at a 15 mg dose, and then the next 
cohort of 3 patients will be treated at 20 mg provided there are 0 of 3 patients with unacceptable 
toxicity at the 15 mg dose. If 1 of 3 patients has dose limiting toxicity at 15 mg, then 3 more 
patients will be enrolled at that dose. If 1 of 6 has unacceptable toxicity, then accrual would 
escalate to the 20 mg dose. If 1 of 3 patients has dose limiting toxicity at 20 mg, then 3 more 
patients will be enrolled at that dose. If 1 of 6 has unacceptable toxicity, then accrual would 
escalate to the 25 mg dose. Three to 6 patients will be tested at the 25 mg dose. The dose selected 
for evaluation will be the maximum dose at which 6 patients are treated and no more than 1/6 has 
dose limiting toxicity. Provided that 25 mg is determined to be an acceptable dose, with no more 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
78 
 
than 1/6 with dose limiting toxicity at this level, we would carry out the main objectives of the trial 
at this dose level.  
The first primary objective is to rule out a 25% rate of grade 4 non-hematologic toxicity attributable 
to the study at the 25 mg dose level of lenalidomide. With respect to the stopping rule, grade 4 
hematologic toxicity will be only be considered if the episode lasts for greater than or equal to 5 
days.  Grade 4 lymphopenia of any duration will not be counted.  If an early stopping rule is not 
invoked, we will plan to enroll a total of 45 evaluable patients at the 25 mg dose and score each 
patient for the development of any grade 4 toxicity as described above during any cycle. This 
cohort of 45 patients will include the 6 patients treated as part of the initial dose escalation phase. 
If we enroll 45 patients and if 8 or more have grade 4 toxicity as described above, then the 
probability that the true rate of grade 4 toxicity is 10% is 7.6% while the probability that the true 
rate of grade 4 toxicity is 25% is 90.6%. Thus, the appearance of 8 or more patients with grade 4 
toxicity as defined above will provide evidence that the true rate of toxicity is consistent with 25%, 
and this will be considered excessive. 
The 90% and 95% confidence intervals will be constructed around the observed fraction of patients 
with grade 4 toxicity as defined above, and will be reported along with the observed incidence. If 
8/45 are noted to have toxicity, the exact two-sided 90% CI bound extends from 10.6% to 27%, 
thus confirming that this rate of toxicity exceeds 10% and is consistent with as high as 27%, thus 
confirming that this rate of toxicity exceeds 10% and is consistent with as high as 27%. As an early 
stopping rule for toxicity, if anytime within the first 18 patients have been enrolled, 7 patients are 
found to have grade 4 toxicity as defined above, no further patients will be enrolled as soon as this 
can be determined, since the lower 80% one-sided confidence bound around 7/18 is 27.3%, which 
being greater than 25% would be considered demonstration of excessive toxicity. In fact, the lower 
80% bounds range from 79% for observing 7 patients with early toxicity in the first 7 patients to 
27% for observing 7 patients with early toxicity in 18 patients.  
Efficacy will also be evaluated with respect to progression free survival (PFS). PFS curves will be 
compared between the ATTP study and the present one, although with low power to detect a 
meaningful difference. In addition, an early stopping rule based on efficacy will be incorporated, 
as follows:  
A recent analysis of progression free survival for the patients enrolled on the ATTP trial found that 
the 6 month PFS probability was 89%, the 9 month PFS was 81%, the 12 month PFS was 75% and 
the 18 month PFS was 54%. It would be important that the present study including lenalidomide 
would have PFS probabilities which are similar to those of the ATTP trial. After all 45 patients 
have been enrolled and 18 months have passed since the last patient was enrolled onto the trial, a 
Kaplan-Meier curve will be constructed, and the results will be compared to those of the ATTP 
trial using a two-tailed log-rank test. Significant differences between the two trials will not be 
expected (and the present trial may even yield superior results based on experience in other 
diseases) since the two trials use extremely similar treatment regimens, but the results will be 
determined and discussed in the context of the non-randomized comparison being made. Because 
in the ATTP trial at 6 months, the 89% PFS result had a corresponding lower two-sided 80% 
confidence bound (one-sided 90% bound) of 82%, it would be considered tolerable or better if the 
present trial is able to demonstrate a 6 month PFS that exceeds 82%. 
To ensure that an unexpectedly poor treatment outcome is not obtained, an interim, early 
evaluation for PFS will be made. After 18 patients have been enrolled and the 18th has been 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
79 
 
potentially followed for progression for 6 months (that is, 6 months have passed since his on-study 
date), an interim Kaplan-Meier curve will be constructed. As noted above, in the ATTP trial at 6 
months, the 89% PFS result had a corresponding lower two-sided 80% confidence bound (one-
sided 90% bound) of 82%. If the actual observed PFS probability of the present trial based on 18 
patients is below 82% at the 6 month time point, then the trial will no longer enroll further patients 
since this would suggest that the PFS distribution may be below the lower one-sided 90% 
confidence bound of the prior trial, which would indicate a potential for a substantially inferior 
outcome.  By the time this determination is made, approximately 25 to 30 total patients may have 
been accrued; however, such inferiority is not expected, and the determination will be more 
imprecise if the evaluation was made earlier or based on accrual of fewer than 18 patients. 
Secondary endpoints will be evaluated as follows. Survival will be determined using the Kaplan-
Meier method.   Changes from pre-treatment to post-treatment in levels of circulating prostate 
cancer and apoptotic endothelial cells, and of molecular markers of angiogenesis will be obtained 
and tested for whether they differ from zero, using a Wilcoxon signed rank test. The changes in 
these parameters may also be evaluated with respect to their possible association with PFS or 
overall survival using a Cox model. 
The primary objective of the expansion cohort is to determine if the use of a lower dose of 
lenalidomide will result in an acceptably high proportion of patients exhibiting a clinical response. 
At the highest dose of lenalidomide, a very high response rate was noted, but a large fraction of 
patients required a dose reduction because of toxicity. Thus, it would be desirable if reasonable 
efficacy could be noted at a lower dose of lenalidomide. 
This portion of the study will be conducted using a MinMax Two-Stage Phase II Trial Design45 in 
order to explore whether we can rule out an unacceptably low 60% of patients who experience a 
clinical response (CR+PR; p0=0.60) in favor of a higher 90% who have a clinical response 
(p1=0.90). With alpha=0.10 (probability of accepting a poor treatment=0.10) and beta = 0.10 
(probability of rejecting a good treatment=0.10), this portion of the study will initially enroll 10 
evaluable patients (including 3 previously enrolled during the initial dose escalation phase) and if 
no more than 7 of the 10 have a clinical response, then no further patients will be accrued. If 8 or 
more of the first 10 have a response, then accrual would continue until a total of 14 patients have 
enrolled at the lower dose. As it may take up to 3-6 months to determine if a patient has experienced 
a clinical response, a temporary pause in the accrual to this portion of the trial may be necessary 
to ensure that enrollment to the second stage is warranted. If there are 8-10 patients with a clinical 
response in 14 patients, this would be an uninterestingly low response rate, while if there were 11 
or more patients with a response in 14 patients, then this would be sufficiently interesting to 
warrant further study in later trials. Under the null hypothesis (60% response rate), the probability 
of early termination is 83%. 
It is expected that up to 45 patients receiving lenalidomide at 25mg daily will enroll onto this trial 
plus 6 to 12 patients required for the run-in phase with lenalidomide at 15mg and 20mg once daily 
and up to eleven patients in the expansion cohort.  In order to allow for a small number of 
inevaluable patients, the accrual ceiling will be set at 70 patients.  Approximately 2 patients can 
enroll on this trial per month, the trial is expected to be able to complete accrual within 2 to 3 years 
at the most.  Aggressive accrual will be pursued with a goal of 36 patients enrolled per year.  We 
are currently enrolled in discussion with Georgetown University’s Lombardi Cancer Center about 
potentially enrolling patients there if accrual at the NIH does not meet goals. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
80 
 
15 ACCRUAL TARGET TABLES 
 
 
Ethnic Category 
Sex/Gender 
 
 
Females  
Males 
 
Total 
Hispanic or Latino 
n/a 
+ 
 
3 = 
 
3 
Not Hispanic or Latino 
 
+ 
 
67 = 
 
67 
Ethnic Category: Total of all subjects 
 
 
(A
1) 
+ 
 
70
 
(B1) 
= 
 
70
 
(C1) 
Racial Category 
 
American Indian or Alaskan Native 
n/a 
+ 
 
0 = 
 
0 
Asian 
 
+ 
 
1 = 
 
1 
Black or African American 
 
+ 
 
14 = 
 
14 
Native Hawaiian or other Pacific Islander 
 
+ 
 
1 = 
 
1 
White 
 
+ 
 
54 = 
 
54 
Racial Category: Total of all subjects 
 
 
(A
2) 
+ 
 
70
 
(B2) 
= 
 
70
 
(C2) 
 
(A1 = A2) 
 
(B1 = 
B2) 
 
(C1 = C2) 
Accrual Rate:  
2 
pts/month  Total Expected 68 Min 
70 Max 
 
16 HUMAN SUBJECTS PROTECTIONS 
16.1 RATIONALE FOR SUBJECT SELECTION 
Subjects treated on this study, will be individuals with metastatic prostate cancer, which has 
recurred (or persisted) after appropriate standard treatment.  Individuals of any race or ethnic group 
will be eligible for this study.  Eligibility assessment will be based solely on the patient’s medical 
status.  Recruitment of patients onto this study will be through standard CCR mechanisms.  No 
special recruitment efforts will be conducted. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
81 
 
16.2 PARTICIPATION OF CHILDREN 
Children will not be eligible for this protocol. 
16.3 PARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT 
Adults unable to give consent are excluded from enrolling in the protocol.  However re-consent 
may be necessary and there is a possibility, though unlikely, that subjects could become 
decisionally impaired. For this reason and because there is a prospect of direct benefit from 
research participation (section 16.5), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the “NIH Advance 
Directive for Health Care and Medical Research Participation” form so that another person can 
make decisions about their medical care in the event that they become incapacitated or cognitively 
impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent 
Assessment Team for evaluation.  For those subjects that become incapacitated and do not have 
pre-determined substitute decision maker, the procedures described in MEC Policy 87-4 for 
appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) 
who do not have a legal guardian or durable power of attorney, will be followed. 
 
16.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS 
The potential benefit to a patient that goes onto study is a reduction in the bulk of their tumor and 
improvement in their metastatic lesions, which may or may not have favorable impact on 
symptoms and/or survival.  Potential risks include the possible occurrence of any of a range of side 
effects, which are listed in the Consent Document.  The procedure for protecting against or 
minimizing risks will be to medically evaluate patients on a regular basis as described in Section 
5.4. 
16.5 RISKS/BENEFITS ANALYSIS 
For patients with castration resistant prostate cancer, median survival is in the range of 12-18 
months. The agents administered in this trial have shown activity against prostate cancer in vitro 
and in vivo.  Potential risks include the possible occurrence of any of a range of side effects listed 
in section 7.     
16.6 CONSENT AND ASSENT PROCESS AND DOCUMENTATION 
Patients will meet with an attending physician in the Prostate Cancer Clinic, during the initial 
evaluation for this study.  During that meeting, the attending physician will provide verbal 
informed consent regarding this study, as well as provide a copy of the informed consent document 
that is included in this protocol.  The patient will be allowed to take as much time as he wishes, in 
deciding whether or not he wishes to participate.  If a prolonged period of time expires during the 
decision making process (several weeks, as an example), it may be necessary to reassess the patient 
for protocol eligibility.  All patients must have a signed informed consent form and an on-study 
(confirmation of eligibility) form filled out and signed by a participating investigator before 
entering on the study. 
Reconsent on this study may be obtained via telephone according to the following procedure: the 
informed consent document will be sent to the subject.  An explanation of the study will be 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
82 
 
provided over the telephone after the subject has had the opportunity to read the consent form.  
The subject will sign and date the informed consent. A witness to the subject’s signature will 
sign and date the consent.  The original informed consent document will be sent back to the 
consenting investigator who will sign and date the consent form with the date the consent was 
obtained via telephone.  A fully executed copy will be returned via mail for the subject’s records.  
The informed consent process will be documented on a progress note by the consenting 
investigator and a copy of the informed consent document and note will be kept in the subject’s 
research record. 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
83 
 
17 REFERENCES 
1. 
Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, 
two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. Nov 
1992;10(11):1754-1761. 
2. 
Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral 
estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 
Sep 1997;15(9):3156-3163. 
3. 
Pienta KJ, Redman BG, Bandekar R, et al. A phase II trial of oral estramustine and oral 
etoposide in hormone refractory prostate cancer. Urology. Sep 1997;50(3):401-406; 
discussion 406-407. 
4. 
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with 
mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. Oct 
7 2004;351(15):1513-1520. 
5. 
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. N Engl J Med. Oct 7 2004;351(15):1502-1512. 
6. 
Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5 Suppl 6:S3-6. 
7. 
Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens 
induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 
Feb 15 1995;55(4):735-738. 
8. 
McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in 
the prostate and its association with emergence of androgen-independent prostate cancer. 
Cancer Res. Dec 15 1992;52(24):6940-6944. 
9. 
Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of 
prostate cancer cells. Cancer Res. Mar 15 1996;56(6):1253-1255. 
10. 
Friedland D, Cohen J, Miller R, Jr., et al. A phase II trial of docetaxel (Taxotere) in 
hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of 
Bcl-2. Semin Oncol. Oct 1999;26(5 Suppl 17):19-23. 
11. 
Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-
refractory prostate cancer: preliminary results. Semin Oncol. Oct 1999;26(5 Suppl 17):14-
18. 
12. 
Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-
specific antigen in patients with hormone-refractory prostate cancer. Urology. Aug 
1998;52(2):252-256. 
13. 
Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol. Dec 
2001;28(6):602-606. 
14. 
Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires 
metabolic activation, which is species-dependent. Biochem Pharmacol. Jun 1 
1998;55(11):1827-1834. 
15. 
D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of 
angiogenesis. Proc Natl Acad Sci U S A. Apr 26 1994;91(9):4082-4085. 
16. 
Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide 
on experimental tumors and metastases. Anticancer Drugs. May 1996;7(3):339-343. 
17. 
Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast 
growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer 
patients: a cancer and leukemia group B study. Cancer Res. Mar 15 2001;61(6):2533-2536. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
84 
 
18. 
Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. 
J Clin Invest. Oct 1999;104(7):913-923. 
19. 
Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus 
thalidomide in androgen-independent prostate cancer. J Clin Oncol. Jul 1 
2004;22(13):2532-2539. 
20. 
Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus 
thalidomide in androgen-independent prostate cancer. Semin Oncol. Aug 2001;28(4 Suppl 
15):62-66. 
21. 
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory 
multiple myeloma. N Engl J Med. Nov 18 1999;341(21):1565-1571. 
22. 
Muller GW, Chen R, Huang S-Y, et al. Amino-substituted thalidomide analogs: Potent 
inhibitors of TNF-[alpha] production. Bioorganic & Medicinal Chemistry Letters. 
1999;9(11):1625-1630. 
23. 
Miller AA, Case D, Harmon M, et al. Phase I study of lenalidomide in solid tumors. J 
Thorac Oncol. May 2007;2(5):445-449. 
24. 
Moss R. A.  MSG, Shelton G. ,Melia  J., Petrylak D. P. A phase I open-label study using 
lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Paper 
presented at: Prostate Cancer Symposium 2007  
25. 
Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, 
docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J 
Clin Oncol. Apr 20 2010;28(12):2070-2076. 
26. 
Huang X, Ning Y, Mulquin M, Madan R. Phase II trial of bevacizumab , lenalidomide, 
docetaxel, and prednisone  in patients (pts) with metastatic castration-resistant prostate 
cancer J Clin Oncol 29: 2011 (suppl; abstr 4574). 
27. 
Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically 
relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin 
Cancer Res. Nov 1;16(21):5269-5276. 
28. 
Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic 
leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J 
Haematol. Mar;148(6):948-950. 
29. 
Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 
overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. 
Blood. Nov 1 2002;100(9):3063-3067. 
30. 
Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines 
for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. Apr 19 
2006;98(8):516-521. 
31. 
Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain 
surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. Sep 1 
2007;25(25):3965-3970. 
32. 
Christian B. 26-Week intravenous toxicity study with rhuMAB VEGF in cynomolgus 
monkeys with a 12 week recovery1999: 97-194. Located at: Genetech Report, San 
Francisco. 
33. 
Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, 
an antiangiogenic humanized monoclonal antibody. Toxicol Pathol. Jan-Feb 
1999;27(1):78-86. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
85 
 
34. 
Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential 
for corpus luteum angiogenesis. Nat Med. Mar 1998;4(3):336-340. 
35. 
Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant 
humanized monoclonal antibody to vascular endothelial growth factor in combination with 
chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. 
J Clin Oncol. Feb 1 2001;19(3):851-856. 
36. 
Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing 
bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with 
metastatic colorectal cancer. J Clin Oncol. Jan 1 2003;21(1):60-65. 
37. 
Reese D, Fratesi, P, Corry, M.  . A phase II trial of humanized anti-vascular endothelial 
growth factor antibody for the treatment of androgen-independent prostate cancer. The 
Prostate J. 2001(3(2)):65-70. 
38. 
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-
vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. Jul 
31 2003;349(5):427-434. 
39. 
Levine MN. Prevention of thrombotic disorders in cancer patients undergoing 
chemotherapy. Thromb Haemost. Jul 1997;78(1):133-136. 
40. 
Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on 
hemodynamics and cardiac performance. J Cardiovasc Pharmacol. Jun 1996;27(6):838-
844. 
41. 
Product label. Taxotere® (docetaxel) Injection Concentrate. Bridgewater, NJ: Aventis 
Pharmaceuticals Inc.; 2003. 
42. 
Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of 
response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin 
Oncol. Sep 1984;2(9):1040-1046. 
43. 
Keil S, Behrendt FF, Stanzel S, et al. RECIST and WHO criteria evaluation of cervical, 
thoracic and abdominal lymph nodes in patients with malignant lymphoma: manual versus 
semi-automated measurement on standard MDCT slices. RoFo : Fortschritte auf dem 
Gebiete der Rontgenstrahlen und der Nuklearmedizin. Sep 2009;181(9):888-895. 
44. 
Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Variability in response 
assessment in solid tumors: effect of number of lesions chosen for measurement. Clin 
Cancer Res. Oct 1 2003;9(12):4318-4323. 
45. 
Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. 
1989;10(1):1-10. 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
86 
 
18 APPENDICES 
18.1 APPENDIX A: AGENTS METABOLISED THROUGH CYP450 
Substrates 
Acetaminophen 
Dapsone 
Levobupivicaine 
Risperidone 
Alfentanil 
Dehydroepiandrostendione 
Lidocaine 
Ritonavir** 
Alosetron 
Delavirdine 
Loratadine 
Salmeterol 
Alprazolam** 
Desmethyldiazepam 
Losartan 
Saquinavir 
Amiodarone 
Dexamethasone 
Lovastatin 
Sertindole 
Amitriptyline (minor) 
Dextromethorphan (minor) 
Methadone 
Sertraline 
Amlodipine 
Diazepam (minor) 
Mibefradil 
Sibutramine 
Anastrozole 
Digitoxin 
Miconazole 
Sildenafil citrate  
Androsterone 
Diltiazem 
Midazolam 
Simvastatin 
Antipyrine 
Disopyramide 
Mifepristone 
Sirolimus 
Astemizole** 
Docetaxel 
Mirtazapine  
Sufentanil 
Atorvastatin 
Dofetilide (minor) 
Montelukast 
Tacrolimus 
Benzphetamine 
Dolasteron 
Navelbine 
Tamoxifen 
Bepridil 
Donepezil 
Nefazodone 
Temazepam 
Bexarotene 
Doxorubicin 
Nelfinavir 
Teniposide 
Bromazepam 
Doxycycline 
Nevirapine 
Terfenadine** 
Bromocriptine 
Dronabinol 
Nicardipine 
Testosterone 
Budesonide 
Enalapril 
Nifedipine 
Tetrahydrocannabinol 
Bupropion (weak) 
Erythromycin 
Niludipine 
Theophylline 
Buspirone 
Estradiol 
Nimodipine 
Tiagabine 
Busulfan 
Ethenyl estradiol 
Nisoldipine 
Tolterodine 
Caffeine 
Ethosuximide 
Nitrendipine 
Toremifene 
Cannabinoids 
Etoposide 
Omeprazole (sulfonation) 
Trazodone 
Carbamazepine 
Exemestane 
Ondasetron 
Tertinoin 
Cerivastatin 
Felodipine 
Oral contraceptives 
Triazolam** 
Cevimeline  
Fentanyl 
Orphenadrine 
Troglitazone 
Chlorpromazine 
Fexofenadine 
Paclitaxel 
Troleandomycin 
Cimetidine 
Finasteride 
Pantoprazole 
Venlafaxine 
Cisapride** 
Fluoxetine 
Pimozide** 
Verapamil 
Citalopram 
Flutamide 
Pioglitazone 
Vinblastine 
Clarithromycin 
Glyburide 
Pravastatin 
Vincristine 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
87 
 
Substrates 
Clindamycin 
Granisetron 
Prednisone 
Warfarin 
Clomipramine 
Halofantrine 
Progesterone 
Yohimbine 
Clonazepam 
Hydrocortisone 
Proguanil 
Zaleplon (minor) 
Clozapine 
Hydroxyarginine 
Propafenone 
Zatoestron 
Cocaine 
Ifosfamide 
Quercetin 
Zileuton 
Codeine 
Imipramine 
Quetiapine 
Ziprasidone 
Cortisol 
Indinavir 
Quinidine 
Zolpidem** 
Cortisone 
Isradipine 
Quinine 
Zonisamide 
Cyclobenzaprine  
Itraconazole 
Repaglinide 
 
Cyclophosphamide 
Ketoconazole 
Retinoic acid 
 
Cyclosporine 
Lansoprazole (minor) 
Rifampin 
 
 
Inducers 
Carbamazepine 
Nelfinavir 
Primidone 
Sulfadimidine 
Dexamethasone 
Nevirapine 
Progesterone 
Sulfinpyrazone 
Ethosuximide 
Oxcarbazepine 
Rifabutin 
Troglitazone 
Glucocorticoids 
Phenobarbital 
Rifampin 
 
Griseofulvin 
Phenylbutazone 
Rofecoxib (minor) 
 
Nafcillin 
Phenytoin 
St. John’s Wort 
 
 
Inhibitors 
Amiodarone 
Disulfiram 
Mibefradil** 
Ranitidine 
Anastrozole 
Entacapone 
Miconazole (moderate) 
Ritonavir** 
Azithromycin 
Erythromycin 
Nefazodone** 
Saquinavir 
Cannabinoids 
Ethenyl estradiol 
Nelfinavir 
Sertindole 
Cimetidine 
Fluconazole (weak) 
Nevirapine 
Sertraline 
Clarithromycin 
Fluoxetine 
Norfloxacin 
Troglitazone 
Clotrimazole 
Fluvoxamine** 
Norfluoxetine 
Troleandomycin 
Cyclosporine 
Gestodene 
Omeprazole (weak) 
Valproic acid (weak) 
Danazole 
Grapefruit Juice 
Oxiconazole 
Verapamil 
Delavirdine 
Indinavir 
Paroxetine (weak) 
Zarfirlukast 
Dexamethasone 
Isoniazid 
Propoxyphene 
Zileuton 
Dimethyldithiocarbamate 
Itraconazole** 
Quinidine 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
88 
 
Inhibitors 
Diltiazem 
Ketoconazole** 
Quinine** 
 
Dirithromycin 
Metronidazole 
Quinupristin and dalfopristin 
 
 
The specific pathways are CYP3A4 and CYP3A5.  These pathways are only utilized by Docetaxel.  
Also, the fact that there are two potential pathways of metabolism allows for more flexibility in 
the utilization of substrates, inducers, and inhibitors.  (i.e. if one pathway is affected, the other 
pathway may still adequately metabolize docetaxel) 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
89 
Document A _Version 2.0 July 20, 2010 
18.2 APPENDIX B: MEDICATION CHECKLIST 
 
Medication 
Schedule 
 
 
 
 
 
 
 
Day 1 
Decadron  
3 hours before Docetaxel 
 
 
 
Decadron 
1 hour before Docetaxel 
 
 
 
Prednisone 
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 2 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime 
 
 
 
Neulasta injection 
24 hours after chemo. 
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 3 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 4 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 5 
Prednisone 
AM 
 
 
 
Lovenox injection 
anytime  
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
90 
Document A _Version 2.0 July 20, 2010 
 
Medication 
Schedule 
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 6 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
 
 
 
 
 
Day 7 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
 
 
 
 
 
Day 8 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 9 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
 
 
 
 
Day 10 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
91 
Document A _Version 2.0 July 20, 2010 
 
Medication 
Schedule 
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 11 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 12 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 13 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 14 
Prednisone  
AM 
 
Stop Lenalidomide after 14 days 
 
Lovenox injection 
anytime  
 
 
 
Lenalidomide 
bedtime 
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 15 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
 
 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
92 
Document A _Version 2.0 July 20, 2010 
 
Medication 
Schedule 
 
 
Day 16 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 17 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 18 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 19 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 20 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Day 21 
Prednisone  
AM 
 
 
 
Lovenox injection 
anytime  
 
 
 
Prednisone 
PM 
 
 
 
 
 
 
 
Evening 
before 
Chemotherapy 
Decadron 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
93 
Document A _Version 2.0 July 20, 2010 
18.3 APPENDIX C: MEDICATION INSTRUCTION SHEET 
Medication Instruction Sheet 
 
The following medications should be taken every cycle: 
 
Days 1-21 – Prednisone every morning and evening. 
 
Lovenox injection anytime during the day 
 
Day 2 – Neulasta 24 hours after Chemotherapy, please inject yourself  
 
 
   
 
Days 1-14 – Lenalidomide every day for 14 days. 
 
 
On the evening before and morning of your return for your clinic appointment, 
please take the following: 
 
Evening before your clinic appointment- Decadron 
 
Morning of your clinic appointment (about 3 hours before chemotherapy)-Decadron 
 
1 hour before your Chemotherapy- Decadron (the nurses in the day hospital will 
help guide you when to take this last dose, so bring it with you to your clinic 
appointment) 
 
 
Reminders: 
 
1. If you miss a dose/day of your Lenalidomide, please notify your Research Nurse 
and DO NOT take an extra day of the medication, DO NOT take 2 on the same day. 
Just leave it in the container and return to your Research Nurse. 
 
2. Please bring back the empty container of Lenalidomide and Prednisone when you 
return for your clinic appointment, DO NOT throw it away. 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
94 
Document A _Version 2.0 July 20, 2010 
18.4 APPENDIX D: CELGENE PREGNANCY PREVENTION COUNSELING PROGRAM SITE 
COUNSELOR IDENTIFICATION FORM 
NCI Protocol#: ____________________________ 
 
• 
Please provide at least two (2) counselors and fax back to 908.673.2779  
• 
Use one form per counselor.  
• 
Identified counselors must be a licensed healthcare professional (e.g. RN, PA, RPh, 
PhD, LPN, CNP or MD).  
• 
If 
you 
have 
any 
questions, 
please 
contact 
tfranco@celgene.com  
General Information  
Principal Investigator: ___________________Institution Name: _______________________ 
CTEP site ID: _________________   
Counselor Information  
 
 
First Name: __________________________  Middle Initial:______    Last Name: ______________________________  
 
 
License Type: (circle one) MD PhD PA   CNP   RN LPN   RPh   Other:_____________________  
 
 
Email Address: _____________________________________________________________________________________  
 
 
Phone: _________________________________________ Fax: _____________________________________________  
 
 
Institution Street Address: ____________________________________________________________________________  
 
 
City: __________________________________________ State/Region: _______________________________________  
 
 
Zip/Post Code: ___________________________ Country: _________________________________________________  
 
 
 
Previously approved as a ___________ Counselor? □ No □ Yes   If Yes, which Protocol: ________________  
 
  

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
95 
 
18.5 APPENDIX E:  LENALIDOMIDE RISKS OF FETAL EXPOSURE, PREGNANCY TESTING 
GUIDELINES AND ACCEPTABLE BIRTH CONTROL METHODS 
Risks Associated with Pregnancy 
Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic 
active substance that causes severe life-threatening birth defects.  An embryofetal development 
study in animals indicates that lenalidomide produced malformations in the offspring of female 
monkeys who received the drug during pregnancy.  The teratogenic effect of lenalidomide in 
humans cannot be ruled out.  Therefore, a risk minimization plan to prevent pregnancy must be 
observed. 
Traces of lenalidomide have been found in semen.  Male patients taking lenalidomide must meet 
the following conditions (i.e., all males must be counseled concerning the following risks and 
requirements prior to the start of lenalidomide): 
 Understand the potential teratogenic risk if engaged in sexual activity with a 
pregnant female or a female of childbearing potential 
 Understand the need for the use of a condom even if he has had a vasectomy, if 
engaged in sexual activity with a pregnant female or a female of childbearing 
potential.   
Because of the increased risk of venous thromboembolism in patients with multiple myeloma 
taking lenalidomide and dexamethasone, combined oral contraceptive pills are not recommended. 
If a patient is currently using combined oral contraception the patient should switch to one of the 
effective method listed above. The risk of venous thromboembolism continues for 4 to 6 weeks 
after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be 
reduced during co-treatment with dexamethasone. 
Before starting study drug 
Male Patients: 
Must practice complete abstinence or  agree to use a condom during sexual contact with a pregnant 
female or a female of childbearing potential while participating in the study, during dose 
interruptions and for at least 28 days following study drug discontinuation, even if he has 
undergone a successful vasectomy.   
During study participation and for 28 days following study drug discontinuation  
Male Patients: 
 Counseling about the requirement for complete abstinence or condom use during 
sexual contact with a pregnant female or a female of childbearing potential and the 
potential risks of fetal exposure to lenalidomide must be conducted at a minimum 
of every 28 days.   
 If pregnancy or a positive pregnancy test does occur in the partner of a male study 
patient during study participation, the investigator must be notified immediately. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
96 
 
Additional precautions 
 Patients should be instructed never to give this medicinal product to another person 
and to return any unused capsules to the study doctor at the end of treatment. 
 Male patients should not donate blood, semen or sperm during treatment or for at 
least 28 days following discontinuation of lenalidomide. 
 Only enough study drug for 28 days or one cycle of therapy (whichever is shorter) 
may be dispensed with each cycle of therapy.  
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
97 
 
18.6 APPENDIX F:  LENALIDOMIDE EDUCATION AND COUNSELING GUIDANCE DOCUMENT 
To be completed prior to each dispensing of study drug. 
Protocol Number: ____________________________________________ 
Patient Name (Print): __________________ DOB: _____/_____/_____ (mm/dd/yyyy) 
MALE: 
I counseled the Male patient regarding the following: 
Potential risks of fetal exposure to lenalidomide (Refer to item #2 in FCBP). 
To engage in complete abstinence or use a condom when engaging in sexual contact 
(including those who have had a vasectomy) with a pregnant female or a female of 
childbearing potential,  while taking study drug, during dose interruptions and for 
28 days after stopping study drug. 
Males should notify their study doctor when their female partner becomes pregnant and 
female partners of males taking study drug should be advised to call their healthcare 
provider immediately if they get pregnant. 
NEVER share study drug with anyone else. 
Do not donate blood, semen or sperm while taking study drug and for 28 days after 
stopping study drug. 
Do not break, chew, or open study drug capsules. 
Return unused study drug capsules to the study doctor. 
Provide Lenalidomide Information Sheet to the patient. 
 
Counselor Name (Print): ____________________  
 
Counselor Signature: _______________________  Date: _____/_____/_____ 
 
**Maintain a copy of the Lenalidomide Education and Counseling Guidance Document in the 
patient records.** 
 
 
 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
98 
 
18.7 APPENDIX G:  LENALIDOMIDE INFORMATION SHEET 
FOR PATIENTS ENROLLED IN CLINICAL RESEARCH STUDIES  
Please read this Lenalidomide Information Sheet before you start taking study drug and each time 
you get a new supply. This Lenalidomide Information Sheet does not take the place of an informed 
consent to participate in clinical research or talking to your study doctor or healthcare provider 
about your medical condition or your treatment.   
What is the most important information I should know about lenalidomide? 
Lenalidomide may cause birth defects (deformed babies) or death of an unborn baby.  
Lenalidomide is similar to the medicine thalidomide. It is known that thalidomide causes life-
threatening birth defects. Lenalidomide has not been tested in pregnant women but may also cause 
birth defects. Findings from a monkey study indicate that lenalidomide caused birth defects in the 
babies of female monkeys who received the drug during pregnancy. 
If you are a man: 
Lenalidomide is detected in trace quantities in human semen. The risk to the fetus in females of 
child bearing potential whose male partner is receiving lenalidomide is unknown at this time.   
Men (including those who have had a vasectomy) must either abstain from sexual intercourse or 
use a condom during sexual contact with a pregnant female or a female that can become pregnant: 
While you are taking lenalidomide 
During dose interruptions of lenalidomide 
For 28 days after you stop taking lenalidomide 
Men should not donate sperm or semen while taking study drug and for 28 days after stopping 
lenalidomide.  
If you suspect that your partner is pregnant any time during the study, you must 
immediately inform your study doctor. The study doctor will report all cases of 
pregnancy to the National Cancer Institute and the pharmaceutical collaborator, Celgene 
Corporation. Your partner should call their healthcare provider immediately if she gets 
pregnant. 
Restrictions in sharing lenalidomide and donating blood: 
Do not share lenalidomide with other people. It must be kept out of the reach of children 
and should never be given to any other person. 
Do not donate blood while you take lenalidomide and for 28 days after stopping study drug.  
Do not break, chew, or open study drug capsules. 
You will get no more than a 28-day supply of lenalidomide at one time. 
Return unused study drug capsules to your study doctor. 
Additional information is provided in the informed consent form and you can ask your study doctor 
for more information.

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
99 
 
18.8 APPENDIX H: GUIDELINES FOR PROPHYLAXIS AND TREATMENT FOR HYPERSENSITIVITY REACTIONS (HSR) ASSOCIATED 
WITH DOCETAXEL 
 
 
Initial Regimen 
HSR Interventions 
Step 1 
HSR Interventions 
Step 2 
HSR Interventions 
Step 3 
For 
ALL 
patients 
who 
have 
not 
experienced an HSR associated with 
Docetaxel 
For pts with a H/O a 
single HSR episode 
For pts who experience a HSR 
after 
implementing 
Step 1 
interventions 
For pts with severe or repeated HSR 
episodes after implementing Steps 1 & 2 
interventions 
PREMEDICATION WITH: 
Dexamethasone 8 mg PO for 3 doses at 12 h, 
3 h, & 1 h before starting docetaxel 
OR 
Dexamethasone 8 mg IV 30 – 60 min before 
docetaxel for patients who miss ≥1 oral 
dexamethasone doses 
 
Reference: study protocol, Section 5.2.1 
PREMEDICATION WITH: 
Dexamethasone 8 mg PO for 2 doses at 12 h & 3 h before 
starting docetaxel 
 + 
Dexamethasone 8 mg IV 30 – 60 min before starting 
docetaxel 
+ 
Diphenhydramine 50 mg IV push 15 – 30 min before 
starting docetaxel 
+ 
Ranitidine 50 mg IV infusion 30 min before starting 
docetaxel 
PREMEDICATION WITH: 
Dexamethasone 8 – 20 mg PO for 2 doses 
between 24 – 36 h and at 12 hours before 
starting docetaxel 
+ 
Dexamethasone 20 mg IV 30 – 60 min before 
starting docetaxel 
+ 
Diphenhydramine 50 – 150 mg IV push 15 – 
30 min before starting docetaxel 
+ 
Ranitidine 50 mg IV infusion 15 – 30 min 
before starting docetaxel 
Docetaxel 75 mg/m2* IV over 60 minutes† 
Docetaxel 75 mg/m2* 
IV over 1 – 2 hours† 
Docetaxel 75 mg/m2* IV over 
4 hours 
 
Given in two portions‡, as: 
Docetaxel 37.5 mg/m2 IV over 
2 hours, q.2 h for 2 doses 
Docetaxel 75 mg/m2* IV 
 
Given in three portions‡, as follows: 
1. Docetaxel 5 mg in 10 mL IV via syringe 
pump over 60 min, followed 
immediately afterward by: 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
100 
 
Initial Regimen 
HSR Interventions 
Step 1 
HSR Interventions 
Step 2 
HSR Interventions 
Step 3 
For 
ALL 
patients 
who 
have 
not 
experienced an HSR associated with 
Docetaxel 
For pts with a H/O a 
single HSR episode 
For pts who experience a HSR 
after 
implementing 
Step 1 
interventions 
For pts with severe or repeated HSR 
episodes after implementing Steps 1 & 2 
interventions 
2. Docetaxel 25 mg in 50 mL IV over 
60 min, followed immediately afterward 
by: 
3. Docetaxel 75 mg/m2 (minus 30 mg) IV 
over 120 min 
PRN Orders: 
Hydrocortisone 100 mg IV push q.15 min for 2 doses, PRN docetaxel reaction 
+ 
Diphenhydramine 50 mg IV push q.15 min for 2 doses, PRN docetaxel reaction 
+ 
Ranitidine 50 mg IV, PRN docetaxel reaction 
+ 
Hydromorphone 1 mg IV push q.15 min for 4 doses, PRN pain with docetaxel reaction 
+ 
Aluminum Hydroxide 200 mg + Magnesium Hydroxide 200 mg + Simethicone 20 mg chewable tablet 
1 – 2 tablets q.3 hours, PRN epigastric discomfort (drug name in CRIS is cross-referenced with “Mylanta”) 
* 
Initial (unmodified) docetaxel dosage is identified.  Consult the study protocol or a medically responsible investigator to determine whether docetaxel 
dose/dosage modification is indicated. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
101 
 
† 
For each docetaxel product, drug delivery will be attempted over the administration period indicated, but rate titration is permitted.  If rate titration is needed 
to accommodate patient tolerance, the following escalation scheme is recommended: 
Initial Rate: 
25 mL/h for 5 minutes 
Rate Escalation Steps: 
1st 
50 mL/h for 5 minutes 
2nd 
100 mL/h for 5 minutes 
3rd 
200 mL/h for 5 minutes 
4th 
250 mL/h until completed 
‡ 
Docetaxel stability is concentration dependent.  All docetaxel products diluted within the range 0.3 – 0.74 mg/mL are labeled to expire 4 hours after preparation 
was completed. 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
102 
 
CRIS Chemotherapy/Biotherapy Treatment Note 
For patients WITHOUT a 
prior H/O HSR 
For Step 1 HSR Interventions 
For Step 2 HSR Interventions 
For Step 3 HSR Interventions 
Docetaxel 
_______ mg/m2 
(calculated 
dose 
= 
_______ mg) IV over 60 min 
Docetaxel 
_______ mg/m2 
(calculated dose = _______ mg) 
IV over 1 – 2 hours 
Docetaxel 
_______ mg/m2 
(calculated 
TOTAL dose = _______ mg) continuous IV 
infusion over 2 hours, every 2 hours for 
2 doses 
Docetaxel 
_______ mg/m2 
(calculated 
TOTAL dose = _______ mg) given in 
3 portions, as follows: 
#1 of 3: Docetaxel 5 mg IV over 
60 minutes 
#2 of 3: Docetaxel 25 mg IV over 
60 minutes 
#3 
of 
3: 
Docetaxel 
_______ mg 
(calculated TOTAL dose minus 30 mg 
from products #1 & #2, above) IV over 
2 hours 
Because patient, ____________________, has a history of hypersensitivity reaction with docetaxel administration, they will 
receive pre-medication and docetaxel according to Step #_______ of the guidelines for Prophylaxis and Treatment for 
Hypersensitivity Reactions (HSR) Associated with Docetaxel. 
In the event of a hypersensitivity reaction associated with docetaxel administration: 
1. Immediately STOP docetaxel administration. 
2. Rapidly administer PRN doses of hydrocortisone & diphenhydramine. 
3. Assess patient to determine whether additional PRN meds are indicated. 
4. Reinitiate docetaxel after hypersensitivity signs and symptoms have completely resolved. 
5. In the event of a hypersensitivity reaction, contact: 
Dr. ______________________________at 102-____________. 
Anna Couvillon at 102-10744. 
 

Abbreviated Title: ART-P for mCRPC 
 
CTEP # 8217 
Version date: 11/15/2016 
103 
 
TAKE HOME Dexamethasone Orders for the Next Treatment Cycle 
For patients WITHOUT a prior H/O HSR 
For Step 1 HSR 
Interventions 
For Step 2 HSR 
Interventions 
For Step 3 HSR Interventions 
Dexamethasone 8 mg PO for 3 doses at 12 h, 
3 h, & 1 h before starting docetaxel 
Dexamethasone 8 mg PO for 2 doses at 12 h & 3 h 
before starting docetaxel 
Dexamethasone 8 – 20 mg PO for 2 doses between 24 
– 36 h and at 12 hours before starting docetaxel 
 
 

 
MEDICAL RECORD 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
INSTITUTE: 
National Cancer Institute 
STUDY NUMBER: 
09-C-0195 
PRINCIPAL INVESTIGATOR: 
Ravi Madan, M.D. 
STUDY TITLE:  
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for 
Treatment of Metastatic Castrate-Resistant Prostate Cancer 
Continuing Review Approved by the IRB on 08/08/16 
Amendment Approved by the IRB on 01/12/17 (X) 
           Date posted to web: 01/25/17  
Standard 
 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
NIH-2514-1 (07-09) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent (1) 
 
INTRODUCTION 
You are invited to take part in a research study at the National Institutes of Health (NIH). 
First, we want you to know that: 
Taking part in NIH research is entirely voluntary. 
 
You may choose not to take part, or you may withdraw from the study at any time.  In 
either case, you will not lose any benefits to which you are otherwise entitled.  
However, to receive care at the NIH, you must be taking part in a study or be under 
evaluation for study participation. 
 
You may receive no benefit from taking part.  The research may give us knowledge that 
may help people in the future. 
Second, some people have personal, religious or ethical beliefs that may limit the kinds of 
medical or research treatments they would want to receive (such as blood transfusions).  If you 
have such beliefs, please discuss them with your NIH doctors and research team before you 
agree to the study. 
Your doctors have told you that you have advanced prostate cancer that is not responding to 
hormonal therapy.  Although "standard" treatment can be administered to you, there is no known 
curative option for your cancer. For this reason, we are offering you experimental treatment on 
this research study. Although we hope that this experimental therapy may be of benefit to you, 
there is no guarantee that your cancer will respond. Benefit cannot be promised, nor can the 
chance of benefit be accurately predicted.  
Now we will describe this research study.  Before you decide to take part, please take as much 
time as you need to ask any questions and discuss this study with anyone at NIH, or with 
family, friends or your personal physician or other health professional. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 2 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Why is this study being done? 
The purpose of this research is to determine if a specific treatment regimen is effective for 
prostate cancer patients.  Each treatment will be given in a 21-day cycle.  If you have been on the 
study more than 2 years, being treated with prednisone only and your disease is stable, your 
cycles may be 42 days long.  Your treatment regimen will consist of four anticancer agents.  We 
know that two of these agents (Prednisone and Docetaxel) have been used successfully in 
treating patients with prostate cancer, either when used alone or in combination with other 
agents.  We have reason to believe that these anticancer effects can be increased by giving them 
in this specific combination. 
There have been studies that demonstrate that the combination of docetaxel and prednisone 
increases survival for patients with prostate cancer. In a previous study at the National Cancer 
Institute, we combined docetaxel and prednisone with bevacizumab and thalidomide.  The results 
of this study were promising; 52 of 58 patients saw their PSA levels decrease by at least half. Of 
the 33 patients who had prostate cancer that could be measured on imaging studies, 21 of them 
had a significant decrease in the size of their tumors. However, most patients in the study 
required a dose reduction of thalidomide due to its side effects. Lenalidomide, a drug similar to 
thalidomide, may have less severe side effects. Based on previous studies, lenalidomide is well 
tolerated in patients with solid tumors when used alone or in combination with docetaxel.  We 
think lenalidomide may be a good substitute for thalidomide.   We are also attempting to 
understand how these drugs work together and what side effects may commonly occur. All four 
drugs are approved by the U.S. Food and Drug Administration (FDA).  
The first agent is docetaxel, a type of chemotherapy, which is used in the treatment of many types 
of cancer.  Docetaxel will be given through a vein over 60 minutes on the first day of each cycle.  
In association with receiving docetaxel, we will ask you to take 3 doses of dexamethasone (a 
steroid agent), one at 12 hours before docetaxel, and a second dose 1 hour before the infusion, and 
a third dose 12 hours after the infusion. Docetaxel may cause fluid retention (edema) in some 
patients and dexamethasone helps to prevent this.  
The second agent is prednisone, a steroid that has been used safely in the treatment of many 
diseases and is used in combination with docetaxel for the treatment of prostate cancer.  
Prednisone will be taken by mouth on each day of the cycle. 
The third agent is bevacizumab.  This drug is a man-made antibody that blocks the development 
and growth of new blood vessels.  It has been shown to be effective in the treatment of many 
types of cancer including colorectal, breast and lung.   Bevacizumab will be given through a 
vein, over 30 to 90 minutes on the first day of each 21day cycle following the infusion of 
docetaxel.  Recently, data was reported from a large clinical trial (CALGB 90401) revealing that 
the addition of bevacizumab to docetaxel and prednisone did not increase overall survival when 
compared to docetaxel and prednisone alone in men with metastatic castrate resistant prostate 
cancer. While this trial failed to demonstrate an overall survival benefit for the addition of 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 3 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
bevacizumab, this combination did prolong the time before the prostate cancer progressed and 
increased the number of patients whose PSA and tumors responded to therapy. In the study, we 
are conducting (ART-P): the addition of lenalidomide to bevacizumab, docetaxel and prednisone 
is designed to improve bevacizumab's ability to kill cancer cells by targeting the same process of 
new blood vessel growth in a different but complementary way. It is our hope that the 
combination of lenalidomide and bevacizumab in addition to docetaxel and prednisone will be 
more potent than either drug given alone with docetaxel and prednisone. 
The fourth agent is lenalidomide.  This drug has shown an ability to block the development of 
new blood vessels. Lenalidomide has been shown to be effective for the treatment of multiple 
myeloma, a type of blood cell cancer. In prior clinical trials in patients with solid tumor cancer, 
some patients had a clinical benefit after taking lenalidomide by itself or in combination with 
docetaxel.  The first 3-6 patients on the trial will receive 15 mg daily of lenalidomide.  If this is 
well tolerated, the next 3-6 patients will receive lenalidomide at a dose of 20 mg daily. If this is 
well tolerated, all subsequent patients to be enrolled on the study will receive lenalidomide at a 
dose of 25 mg daily. Lenalidomide is a capsule that will be taken by mouth the first 2 weeks of 
each cycle. All patients will continue to receive lenalidomide at their original starting dose 
throughout their time on study. Patients in the expansion arm of the study will receive 
lenalidomide at 15 mg po daily.   
The chance of developing death of some cells in a part of the bone of your jaw can be increased, 
while you are receiving bisphosphonate treatment for prostate cancer in the bones. This is called 
osteonecrosis of the jaw (ONJ). It is probable that the combination of drugs used in this clinical 
trial may increases your risk of developing this condition. You may experience exposed jaw 
bone, jaw/gum pain, swelling or infection. Therefore, you will be scheduled for dental exam and 
imaging study of your jaw bone before the start of the protocol therapy. You will also receive 
scheduled dental exams after cycle 5 and every 6 cycles thereafter. Appropriate treatment, 
including antibiotics, will be used if it is needed. 
It is possible that some of the prostate cancer cells in your body may still grow if exposed to the 
male hormone testosterone. Thus your testosterone must be suppressed either surgically (removal 
of the testicles) or medically with injections (shot) of an LHRH agonist drug (leuprolide or 
goserelin) that are repeated approximately every three months.  
 
It is possible that the combination of these drugs may increase your risk of developing a blood 
clot; therefore, we will ask you to give yourself or have a caregiver give you a daily injection of 
enoxaparin, a blood-thinning agent. 
 
How many people will take part in the study?  
Approximately 70 patients will participate in this study, which will be conducted at the NIH 
Clinical Center. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 4 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
What will happen if you take part in this research study? 
Before you begin the study:  
You will need to have the following exams and procedures to determine if this study is suitable 
for you.  These exams and procedures are part of regular cancer care and may be done even if 
you do not join the study.  If you have had some of done them recently, they may not need to be 
repeated.  This will be up to the study team. 
 
• A complete medical history will be taken from you, a history of your cancer, and prior 
cancer treatments you have taken.   
• You will be asked to give information about all drugs (including over the counter drugs, 
vitamins and herbal supplements) that you are currently taking.   
• Your study doctor will do a complete physical examination, assess your ability to do 
physical activities, measure your blood pressure, heart rate, and respiration rate.  
• You will be asked to have a 12-lead electrocardiogram (ECG) and a chest x-ray. 
• A sample of your blood (approximately 2 tablespoon) and urine will be taken for laboratory 
testing.  
• An evaluation of your cancer will be done.  This will include a CT scan and bone scan. 
• Mandatory research urine samples will be obtained prior to starting the study drug and at 
monthly clinic visits. 
During the study:  
If you choose to join this study you will return to NIH to begin the first treatment cycle.  On this 
regimen, treatment cycles are generally 3 weeks (21 days) in duration.  If you have been on the 
study for more than 2 years, being treated with prednisone only and your disease is stable, your 
treatment cycles may be 42 days in duration. 
 
Cycle 1 and Cycle 2 
Day 1 
 
• On day 1 of the first and second treatment cycle, you will be asked to report to the NIH 
Clinical Center Outpatient Cancer Center.  
• Samples of your blood (approximately 8 teaspoons) will be taken for laboratory testing 
before you take your first dose of study drug.   
• Samples of your blood (approximately 6 teaspoons) will be taken for research prior to the 
first treatment dose, and prior to the treatment for cycles 2, 3 and 6, if possible.  These 
samples will be used for various immune function testing, specifically looking at T-cell 
function.  

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 5 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
• You will receive an intravenous infusion of docetaxel at a dose of 75 mg/m2.    
• You will also receive an intravenous infusion of bevacizumab at a dose of 15 mg/kg. 
• You will begin taking prednisone by mouth at a dose of 10 mg on the first day of each 
cycle and continue to take it daily throughout the cycle.  
• You will also begin taking lenalidomide by mouth at a dose of either 15 mg or higher on 
the first evening of each cycle and continue to take it for the first two weeks of the three 
week cycle.  
• You will be taught how to inject enoxaparin for the prevention of blood clots and take it 
every day of the cycle, including 7 days after stopping lenalidomide.  
• You will be observed for any side effects that you may experience during and after the 
infusions of docetaxel and bevacizumab. 
 
Cycle 1 and Cycle 2 
 
Day 2 
  
• You will be given a medicine called Pegfilgrastim to help keep your white blood cell count 
from dropping on the second day of each cycle, at least 24 hours after you receive the 
docetaxel. 
• You will be asked to have a weekly blood count drawn at home during the cycle and the 
results faxed to the Outpatient cancer center. 
During each Cycle 
• We will ask you to return to NIH on or about day 21 or day 1 of the next cycle (if you are 
taking prednisone only you may return after 42 days and have blood drawn prior to coming 
to clinic.  Labs are required for both clinical and research purposes. 
• You will have scans (bone scan and possibly CT scan) prior to Cycle 3, and then every 3 
cycles.  After you have been on study for at least 2 years, scans may be done only if there is 
other evidence that your disease has worsened. Scan visits may take 2 days for all of the 
required testing to be completed and for the IV infusions to be administered.  You will be 
given a medication check list and a medication instruction sheet to help you keep track of 
the medications you will take while away from the clinic. 
• You will be asked to have a weekly blood count drawn at home and results faxed to the 
outpatient cancer center. 
• We ask that you avoid ingestion of grapefruit juice while enrolled on study as this may 
adversely interact with one or more of the study drugs.  

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 6 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
After Cycle 5 
 
• Follow up dental evaluations will occur at every other restaging visit until cycle 17.  
Thereafter, they will be performed once annually. 
 
 
Throughout your treatment PD (pharmacodynamic) studies (blood samples) will be drawn which 
allow for the evaluation of the following: 
 
1. optimal dosing of medications 
 
2. interactions between medications in your body 
3. potential relationship between the way your body handles medications and clinical 
outcome 
 
4. candidate blood tests that may reflect drug activity 
 
5. immune function testing 
Throughout your treatment it will be very important to keep us informed about any new 
symptoms you experience.  We will repeat the scans after the second cycle, and then 
approximately every 3 cycles to determine if your cancer has responded.  If you have been on the 
study for at least two years, you may have the scans only if there is other evidence that your 
disease has worsened. As long as you are tolerating the treatment and your cancer has not gotten 
worse, we will continue to give you treatment.   
 
How long will you be in the study? 
If you choose to join this trial, your participation will continue until either you or the study team 
decides that this experimental treatment is not helping you.  The following are reasons the 
treatment may be stopped: 
 
 You may request at any time to stop treatment. 
 Bone scan or CT scan results showing clear evidence that the cancer has grown. 
 Illness which would make it unsafe for you to receive further treatment. 
 Severe side effects which last for more than 21 days. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 7 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Can you stop being in the study? 
Yes.  You can decide to stop at any time.  Please tell your study team if you are thinking about 
stopping or decide to stop, we will tell you how to stop safely.  
If you decide at any time to withdraw your consent to participate in the trial, we will not collect 
any additional medical information about you. However, according to FDA guidelines, 
information collected on you up to that point may still be provided to Genentech and Celgene or 
designated representatives. If you withdraw your consent and leave the trial, any samples of 
yours that have been obtained for the study and stored at the NCI can be destroyed upon request. 
However, any samples and data generated from the samples that have already been distributed to 
other researchers or placed in the research databases cannot be recalled and destroyed. 
It is important to tell the study team if you are thinking about stopping so any risks from this 
treatment can be evaluated.  Another reason to tell your study team that you are thinking about 
stopping is to discuss what follow-up care and testing could be most helpful for you. 
What side effects or risks can you expect from being in the study? 
“If you choose to take part in this study, there is a risk that: 
• You may lose time at work or home and spend more time in the hospital or doctor’s 
office than usual 
• You may be asked sensitive or private questions which you normally do not discuss 
The medications used in this study may affect how different parts of your body work such as 
your liver, kidneys, heart, and blood. The study doctor will be testing your blood and will let you 
know if changes occur that may affect your health.  The docetaxel which is used in this study 
also contains ethanol or alcohol which may cause you to feel drunk during or after treatment.  It 
may be necessary to avoid driving, operating any machinery or performing any activities that are 
dangerous for one to two hours after the infusion of docetaxel.  Some medications such as pain 
relievers or sleep aids may interact with the alcohol in docetaxel and may worsen these effects. 
 
There is also a risk that you could have side effects from the study drug(s)/study approach. 
 
Here are important points about side effects: 
• The study doctors do not know who will or will not have side effects. 
• Some side effects may go away soon, some may last a long time, or some may never go 
away. 
• Some side effects may interfere with your ability to have children. 
• Some side effects may be serious and may even result in death. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 8 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Here are important points about how you and the study doctor can make side effects less of a 
problem: 
• Tell the study doctor if you notice or feel anything different so they can see if you are 
having a side effect. 
• The study doctor may be able to treat some side effects. 
• The study doctor may adjust the study drugs to try to reduce side effects. 
 
The tables below show the most common and the most serious side effects that researchers know 
about. There might be other side effects that researchers do not yet know about. If important new 
side effects are found, the study doctor will discuss these with you.” 
 
Docetaxel: 
(Table Version Date: May 28, 2013) 
COMMON, SOME MAY BE SERIOUS 
In 100 people receiving Docetaxel, more than 20 and up to 100 may have: 
• Swelling of the body 
• Hair loss 
• Change in nails 
• Rash, itching 
• Vomiting, diarrhea, nausea 
• Sores in mouth which may cause difficulty swallowing 
• Infection, especially when white blood cell count is low 
• Anemia which may require blood transfusions 
• Tiredness 
• Numbness and tingling of the arms and legs 
• Fever 
• Absence of menstrual period 
• Swelling and redness of the arms, leg or face 
• Pain 
• Watering, itchy eyes 
 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 9 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
OCCASIONAL, SOME MAY BE SERIOUS 
In 100 people receiving Docetaxel, from 4 to 20 may have: 
• Severe skin rash with blisters and peeling which can involve inside of mouth and other parts 
of the body 
• Belly pain 
• Bruising, bleeding 
• Liver damage which may cause yellowing of eyes and skin 
• Kidney damage which may require dialysis 
• Scarring of the lungs 
• Blood clot which may cause swelling, pain, shortness of breath 
• Abnormal heart rate 
• Shortness of breath, wheezing 
• Chest pain 
 
RARE, AND SERIOUS 
In 100 people receiving Docetaxel, 3 or fewer may have: 
• Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath, 
swelling of the face or throat 
• Liver damage which may cause yellowing of the eyes and skin 
 
Bevacizumab: 
COMMON, SOME MAY BE SERIOUS   
In 100 people receiving bevacizumab, more than 20 and up to 100 may have: 
• High blood pressure which may cause headache or blurred vision  
 
OCCASIONAL, SOME MAY BE SERIOUS   
In 100 people receiving bevacizumab, from 4 to 20 may have: 
• Anemia which may require blood transfusion 
• Low white cell count that may increase the risk of infection 
• Infection, including collection of pus in the belly or rectum 
• Abnormal heartbeat which may cause palpitations or fainting 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 10 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
OCCASIONAL, SOME MAY BE SERIOUS   
In 100 people receiving bevacizumab, from 4 to 20 may have: 
• Pain in the belly, rectum, chest, joints, muscles, or tumor 
• Low appetite, constipation, diarrhea, heartburn, nausea, vomiting, or dehydration 
• Internal bleeding which may cause black tarry stool, blood in vomit, coughing up of 
blood, or blood in urine  
• Bleeding from other sites, including the vagina or nose 
• Blockage of internal organs which may cause vomiting or inability to pass stool 
• Sores in mouth 
• Allergic reaction during or after infusion of bevacizumab which may cause fever, 
chills, rash, itching, hives, low blood pressure, wheezing, shortness of breath, 
swelling of the face or throat 
• Delay in healing of wounds or spontaneous opening of wounds 
• Weight loss, tiredness, or dizziness 
• Muscle weakness 
• Damage to organs which may cause loss of teeth or loss of motion 
• Headache 
• Numbness, tingling, or pain in the fingers or toes 
• Hoarseness, stuffy nose, or cough 
• Dry skin 
• Swelling and redness of the skin 
• Blood clot in limbs or lungs which may cause swelling, pain, or shortness of breath 
• Leakage of protein in the urine, which can rarely lead to damage to the kidney 
 
 
 
 
 
 
 
 
 
 
 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 11 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
RARE, AND SERIOUS 
In 100 people receiving bevacizumab, 3 or fewer may have: 
• Clots in the arteries, causing stroke (which may cause paralysis or weakness) or heart 
attack (which may cause chest pain or shortness of breath). This risk is significantly 
increased in patients who are elderly or with history of diabetes 
• Heart failure which may cause shortness of breath, swelling of ankles, or tiredness 
• Bowel perforation (a tear in the bowel) that can cause pain or bleeding and require 
surgery to repair 
• A tear or hole (fistula) in internal organs such as the nose, throat, lungs, esophagus, 
rectum, or vagina.  These conditions may cause serious infections or bleeding and 
require surgery to repair 
• Sores in the throat 
• Flesh-eating bacteria syndrome, an infection in the deep layers of skin 
• Bleeding in the tumor, brain, belly, or lungs which may cause confusion, blood in 
stool or coughing up blood 
• Brain damage which may cause headache, seizure, blindness (also known as 
Reversible Posterior Leukoencephalopathy Syndrome) 
• Kidney damage which may require dialysis 
• Redness, pain or peeling of palms and soles 
Additional Notes on Possible Side Effects for Bevacizumab: 
• Risk in children or adolescents: abnormal bone changes which may interfere with growth. 
• Risk in pre-menopausal women: more likely to develop menopause when taking 
bevacizumab. 
 
Lenalidomide: 
COMMON, SOME MAY BE SERIOUS   
In 100 people receiving lenalidomide, more than 20 and up to 100 may have: 
• Anemia which may require blood transfusion 
• Constipation, diarrhea 
• Tiredness 
• Bruising, bleeding 
 
 
 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 12 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
OCCASIONAL, SOME MAY BE SERIOUS   
In 100 people receiving lenalidomide, from 4 to 20 may have: 
• Nausea, vomiting 
• Chills, fever 
• Swelling of arms, legs 
• Infection, especially when white blood cell count is low 
• Weight loss, loss of appetite 
• Pain  
• Muscle spasms 
• Dizziness, headache 
• Difficulty sleeping 
• Cough, shortness of breath 
• Increased sweating 
• Itching, rash 
• Sores on the skin 
• Blood clot which may cause swelling, pain, shortness of breath 
 
RARE, AND SERIOUS 
In 100 people receiving lenalidomide, 3 or fewer may have: 
• Heart attack 
• Liver damage which may cause yellowing of eyes and skin, swelling 
• Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of 
breath, swelling of the face or throat 
• Damage to organs in the body when donor cells attack host organs which may cause 
dry skin, or muscle weakness 
• Kidney damage which may require dialysis 
• Cancer of bone marrow caused by chemotherapy 
 
• Damage to organs which may cause infection, bleeding, may require transfusions or 
changes in thinking 
• Increased tumor size 
• A new cancer resulting from treatment of earlier cancer 
 
• Stroke which may cause paralysis, weakness 
• Severe skin rash with blisters and peeling which can involve mouth and other parts of 
the body 
 
• Difficulty stimulating enough stem cells in the bloodstream for future transplant 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 13 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Prednisone: 
(Table Version Date: June 24, 2013) 
COMMON, SOME MAY BE SERIOUS 
In 100 people receiving Prednisone, more than 20 and up to 100 may have: 
• In children and adolescents: decreased height 
• Loss of bone tissue 
• Mood swings 
• Skin changes, acne 
• Swelling of the body, tiredness, bruising 
• High blood pressure which may cause headaches, dizziness, blurred vision 
• Pain in belly 
• Increased appetite and weight gain 
• Weight gain in the belly, face, back and shoulders 
 
OCCASIONAL, SOME MAY BE SERIOUS 
In 100 people receiving Prednisone, from 4 to 20 may have: 
• Cloudiness of the eye, visual disturbances 
• Glaucoma 
• Infection 
• Non-healing wound 
• Diabetes 
• Damage to the bone which may cause joint pain and loss of motion 
• Kidney stones 
• Heartburn 
 
RARE, AND SERIOUS 
In 100 people receiving Prednisone, 3 or fewer may have: 
• Bleeding from sores in the stomach 
• Broken bones 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 14 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Pegfilgrastim: 
(Table Version Date: May 28, 2013) 
COMMON, SOME MAY BE SERIOUS 
In 100 people receiving Pegfilgrastim (Neulasta), more than 20 and up to 100 may have: 
• Pain in bone 
 
OCCASIONAL, SOME MAY BE SERIOUS 
In 100 people receiving Pegfilgrastim (Neulasta), from 4 to 20 may have: 
• Anemia which may cause tiredness, or may require transfusion 
• Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath, 
swelling of the face or throat 
• Damage to the lungs which may cause shortness of breath 
 
RARE, AND SERIOUS 
In 100 people receiving Pegfilgrastim (Neulasta), 3 or fewer may have: 
• Rupture of the spleen with bleeding in the belly 
 
Enoxaparin: 
COMMON, SOME MAY BE SERIOUS 
• Swelling and redness at the site of the medication injection 
 
OCCASIONAL, SOME MAY BE SERIOUS 
• Bleeding 
• Nausea  
• Diarrhea 
• Confusion 
 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 15 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
RARE, AND SERIOUS 
• Allergic reaction: itching or hives, swelling of the face or hands, swelling or tingling in the 
mouth or throat, chest tightness, trouble breathing. 
• Blood in the urine 
• Bloody or black, tarry stools 
• Chest pain, shortness of breath or coughing up blood 
• Irregular heartbeat 
• Numbness or weakness in arm or leg, or on one side of the body. 
• Sudden or severe headache, problems with vision, speech or walking. 
• Unusual bleeding or bruising. 
• Swelling in hands, ankles or feet. 
• Vomiting blood or material that looks like coffee grounds. 
• Heparin-induced low platelet count 
 
As previously mentioned we will ask you to take 3 doses of dexamethasone (a steroid), around 
your docetaxel infusion.  The first dose is 12 hours before docetaxel, a second dose 3 hours before 
the infusion, and a third dose 1 hour before the infusion. Dexamethasone will help prevent fluid 
retention as well as the chance of infusion reactions.  Because of the short term use in this setting, 
serious side effects have not been observed.  Some patients complain that they feel jittery or 
experience difficulty sleeping when taking dexamethasone.  If this occurs, please tell the study 
team so we can make adjustments.    
 
We have seen decreases in neutrophil counts (neutropenia) in most patients on the trial thus far.  
As such, all patients will take pegfilgrastim on day 2 of each cycle.  Pegfilgrastim is a 
medication that can increase the number of neutrophils and reduce your risk of infection.  It is 
given as an injection approximately 24 hours after the docetaxel infusion.   Because there is a 
rare risk of having an allergic reaction to pegfilgrastim, we ask that you receive the first injection 
either at NIH or your local physician’s office. It is very important that you use pegfilgrastim 
every cycle at the same time thereafter.    
 
Since this combination of drugs together may increase your risk for developing blood clots, 
enoxaparin will be injected daily as previously discussed. Though the use of enoxaparin will 
increase your risk of bleeding complications, we believe this medication is necessary for this 
study and provides overall benefit to you.  
 
Notify the study team immediately if any of the following occur, these can be symptoms of a 
blood clot:  

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 16 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
 Sudden onset of swelling to one leg that may or may not be accompanied by leg pain 
(calf or thigh)  
 Chest pain 
 Shortness of breath  
Side Effects reported by patients, but not proven to be caused by study drugs 
Patients in this study have experienced dehydration (an excessive loss of body fluids) and 
imbalances of electrolytes (chemicals in the blood stream such as sodium, potassium, calcium, 
chloride and magnesium that help to regulate body functions).  Symptoms of dehydration include 
dry mouth, loose skin, dizziness and lower urine output. Symptoms of electrolyte imbalances 
vary depending on which electrolyte levels are affected, but can include muscle spasm, 
weakness, twitching, convulsions, irregular heartbeat, confusion, blood pressure changes, 
numbness and fatigue.  In this study, patients generally did not have symptoms, except dizziness, 
as a result of fluid or electrolyte imbalances. 
Risk of Second Cancer: 
Sometimes a second primary cancer arises after patients have undergone cancer therapy, 
including therapy using chemotherapeutic agents used to treat multiple myeloma.  Recently, in 
clinical trials of patients with newly diagnosed multiple myeloma, a higher number of second 
cancers has also been reported in patients treated with high doses of chemotherapy (induction 
therapy) and/or stem cell transplant followed by prolonged (maintenance) lenalidomide therapy 
compared to those who received induction therapy and/or transplant without maintenance 
lenalidomide.   
 
We do not know at this time whether prolonged lenalidomide therapy in this clinical setting 
actually increases the risk of second primary cancers.  No increase in second primary cancers has 
been observed in patients receiving lenalidomide therapy who have relapsed multiple myeloma 
or other types of cancer.   
 
We will be carefully monitoring these events (second primary cancers) in on-going studies of 
lenalidomide therapy and will inform you if there are any changes.  We want you to be aware of 
this possibility and to continue to follow standard medical advice for prevention and early 
detection of other cancers during and after your treatment.  
Pregnancy Risk: 
Lenalidomide is related to thalidomide.  Thalidomide is known to cause severe life-threatening 
human birth defects.  Preliminary findings from a monkey study appear to indicate that 
lenalidomide caused birth defects in the offspring of female monkeys who received the drug 
during pregnancy.  If lenalidomide is taken during pregnancy, it may cause birth defects or death 
to an unborn baby. Lenalidomide is detected in trace quantities in human semen according to a 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 17 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
study. The risk to the fetus in females of child bearing potential whose male partner is receiving 
lenalidomide is unknown at this time.   
Lenalidomide is present at very low levels in human semen of healthy men for three days after 
stopping the drug according to a study.  For patients who may not be able to get rid of the drug, 
such as people with kidney problems, lenalidomide may be present for more than three days.  To 
be safe, all men should use condoms when engaging in sexual intercourse while taking 
lenalidomide, when temporarily stopping lenalidomide, and for 28 days after permanently 
stopping lenalidomide treatment if their partner is either pregnant or able to have children. 
Patients should not donate blood during study treatment or for 28 days following discontinuation 
of lenalidomide. 
You will be counseled at least every 28 days during lenalidomide treatment and again one last 
time when you stop taking lenalidomide about not sharing lenalidomide (or other study drugs), 
the potential risks of fetal exposure, abstaining from blood and other donations, the risk of 
changes in blood counts and blood clots, and you will be reminded not to break, chew or open 
lenalidomide capsules. You will be provided with the “Lenalidomide Information Sheet for 
Patients Enrolled in Clinical Research Studies” with each new supply of lenalidomide as a 
reminder of these safety issues. 
Because of these risks, all patients taking lenalidomide must read the following statements that 
apply to them according to gender and menopausal status. 
 
FOR ALL MALES 
Please read thoroughly and initial each space provided if you understand each statement:  
_____: I understand that birth defects may occur with the use of lenalidomide.  I have been 
warned by my doctor that an unborn baby may have birth defects and can even die, if a female is 
pregnant or becomes pregnant while taking lenalidomide or is exposed to lenalidomide.  
_____: I have been told by my doctor that while taking lenalidomide and for 6 months after my 
last dose, I must NEVER have unprotected sexual contact with a female who can become 
pregnant.  Because lenalidomide may be present in semen, my doctor has explained that I must 
completely abstain from sexual contact including oral exposure to semen with females who are 
pregnant or able to become pregnant, or I must use a latex condom every time I engage in any 
sexual contact with females who are pregnant or may become pregnant. My sexual partner must 
also use a highly effective form of birth control.  I must do this while I am taking lenalidomide 
and for 6 months after I stop taking lenalidomide, even if I have had a successful vasectomy. 
_____: I know I must inform my doctor if I have unprotected sexual contact with a female who is 
pregnant or can become pregnant or if I think, for ANY REASON, that my sexual partner may 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 18 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
be pregnant. Female partners of male patients taking lenalidomide should be advised to call their 
own physician immediately if they get pregnant.  
_____: I understand that lenalidomide will be prescribed only for me.  I must not share it with 
ANYONE, even someone that has similar symptoms to mine.  It must be kept out of reach of 
children and should never be given to females who are able to have children. 
_____: I agree any unused drug supply will be returned to the research site at each visit.  
_____: I know that I cannot donate blood, sperm or semen while taking lenalidomide and for 2 
months days after stopping lenalidomide. 
You will be counseled at least every 28 days during lenalidomide treatment and again one last 
time when you stop taking lenalidomide about not sharing lenalidomide (and other study drugs), 
the potential risks of fetal exposure, abstaining from blood and other donations, the risk of 
changes in blood counts and blood clots, and you will be reminded not to break, chew or open 
lenalidomide capsules. 
 
You should recognize that no method of birth control besides abstinence provides 100% 
protection from pregnancy. 
 
Are there benefits to taking part in this study?  
This is a Phase 2 study, which means we are trying to determine if the experimental drug 
combination is effective for the treatment of prostate cancer.  
Individual benefit cannot be promised, nor can the chance of benefit be accurately predicted. It is 
possible that you may experience some, all, or none of the side effects described above. It is also 
possible that the combination of drugs may produce some unanticipated side effects. For that 
reason, you will be monitored closely while you are receiving this treatment for any signs which 
might signal the earliest stages of side effects so that appropriate intervention can be done.  
 
What other choices do you have if you do not participate in this study? 
It has been explained to you that you have prostate cancer that has come back after hormonal 
treatment.  At this time, docetaxel combined with prednisone is the standard treatment for your 
cancer. Other treatment alternatives which can be considered for you now include:  
 
 Getting treatment without being in a study. 
 Taking part in another study. 
 Getting no treatment. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 19 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
 Getting comfort care, also called palliative care.  This type of care helps reduce pain, 
tiredness, appetite problems and other problems caused by the cancer.  It does not treat 
the cancer directly.  Instead, it tries to improve how you feel.  Comfort care tries to keep 
you as active and comfortable as possible.   
Please talk to your doctor about your choices before you decide if you will take part in this study. 
 
Will your medical information be kept private?  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time. 
We will do our best to make sure that the personal information in your medical record will be 
kept private. However, we cannot guarantee total privacy. Your personal information may be 
given out if required by law. If information from this study is published or presented at scientific 
meetings, your name and other personal information will not be used. Organizations that may 
look at and/or copy your medical records for research, quality assurance, and data analysis 
include:  
• The National Cancer Institute (NCI) and other government agencies, like the Food and 
Drug Administration (FDA), involved in keeping research safe for people.  
• The NCI Institutional Review Board. 
• Genentech. 
• Celgene. 
 
What are the costs of taking part in this study? 
While you are on study at the National Cancer Institute, we will pay for the medications and 
treatments associated with the study including commercially available agents.  We do not assume 
the cost of your overall medical care.  Any studies done outside of the NCI may require you or 
your insurance company to cover the cost of the service. 
It is important to stress that your participation in this study does not constitute a promise of long 
term care at the NIH   Clinical Center.   
You will not be paid for taking part in this study. 
For more information on clinical trials and insurance coverage, you can visit the National Cancer 
Institute’s Web site at http://cancer.gov/clinicaltrials/understanding/insurance-coverage.  You 
can print a copy of the “Clinical Trials and Insurance Coverage” information from this Web site. 
Another way to get the information is to call 1-800-4-CANCER (1-800-422-6237) and ask them 
to send you a free copy. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 20 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Who can answer your questions about the study? 
You can talk to your study team about any questions or concerns you have about this study.  
Contact your Study Coordinator, Guinivere Chun, RN 240-760-6065, and/or Dr. Ravi Madan, 
the Principal Investigator at 301-480-7168. 
If you have any complications when you are not in the Clinical Center (e.g., at home or in a local 
hotel), you may call the page operator at (301) 496-1211 and ask for the NCI Medical Oncology 
Branch physician on call or the NIH Patients’ Rights Representative who will be available to 
answer questions concerning your involvement in this study or your rights as a research subject.  
This person is not directly associated with this study and can be contacted at (301) 496-2626. 
 
Research Subjects’ Rights 
You will be told if no benefit occurs to you as a result of taking part in this treatment program 
and your participation in the trial will be stopped.  
 
You will receive a copy of this informed consent for your own records. In addition, a copy of the 
informed consent is on file with the Medicine Oncology Branch of the National Cancer Institute 
and a copy will be made available to you whenever you want to see it. Your records will be kept 
confidential, with the exception that the FDA, and the staff of the National Cancer Institute, who 
may inspect and study your medical records.  
 
Your participation in this study is entirely voluntary, and you may refuse to participate, or 
withdraw from this protocol at any time and receive care from a physician of your choice. Your 
participation in this study may be ended without your consent by the Principal Investigator or an 
Associate Investigator if they feel that it is medically unsafe for you to continue to receive 
experimental treatment.  
 
It is important to maintain a relationship with your referring physician while you are on this 
study.  Upon completing this study, you may be given the choice of taking part in other research 
protocols that may be appropriate for you. Otherwise, you will be returned to the care of your 
referring physician. If there is no research study that can help you, you will be returned to the 
care of your private doctor.    
 
You may decide now to not receive treatment in this protocol, or you may choose at any time to 
stop the drug and withdraw from the protocol. In either case, you would be returned to the care 
of your referring physician. It is possible that participation in this study may render you 
ineligible to participate in other research studies that limit the number or types of treatment that 
have been given. 

MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: Page 21 of 23 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
 
Conflict of Interest 
The National Institutes of Health (NIH) reviews NIH staff researchers at least yearly for conflicts 
of interest.  This process is detailed in a Protocol Review Guide.  You may ask your research 
team for a copy of the Protocol Review Guide or for more information.  Members of the research 
team who do not work for NIH are expected to follow these guidelines but they do not need to 
report their personal finances to the NIH. 
 
Members of the research team working on this study may have up to $15,000 of stock in the 
companies that make products used in this study.  This is allowed under federal rules and is not a 
conflict of interest.  
 
Use of Specimens and Data for Future Research 
To advance science, it is helpful for researchers to share information they get from studying 
human samples.  They do this by putting it into one or more scientific databases, where it is 
stored along with information from other studies. A researcher who wants to study the 
information must apply to the database and be approved.  Researchers use specimens and data 
stored in scientific databases to advance science and learn about health and disease.   
We plan to keep some of your specimens and data that we collect and use them for future 
research and share them with other researchers. We will not contact you to ask about each of 
these future uses.  These specimens and data will be stripped of identifiers such as name, address 
or account number, so that they may be used for future research on any topic and shared broadly 
for research purposes. Your specimens and data will be used for research purposes only and will 
not benefit you.  It is also possible that the stored specimens and data may never be used.  
Results of research done on your specimens and data will not be available to you or your doctor.  
It might help people who have cancer and other diseases in the future.   
If you do not want your stored specimens and data used for future research, please contact us in 
writing and let us know that you do not want us to use your specimens and/or data.  Then any 
specimens that have not already been used or shared will be destroyed and your data will not be 
used for future research. However, it may not be possible to withdraw or delete materials or data 
once they have been shared with other researchers. 
 

MEDICAL RECORD 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: page 22 of 23 pages 
 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY  
(Continuation Sheet) 
• 
Adult Patient or 
• Parent, for Minor Patient 
NIH-2514-1 (07-09) 
P.A.:  09-25-0099 
 
File in Section 4:  Protocol Consent 
 
OTHER PERTINENT INFORMATION 
1. Confidentiality. When results of an NIH research study are reported in medical journals or 
at scientific meetings, the people who take part are not named and identified.  In most cases, 
the NIH will not release any information about your research involvement without your 
written permission.  However, if you sign a release of information form, for example, for an 
insurance company, the NIH will give the insurance company information from your medical 
record.  This information might affect (either favorably or unfavorably) the willingness of the 
insurance company to sell you insurance. 
The Federal Privacy Act protects the confidentiality of your NIH medical records.  However, 
you should know that the Act allows release of some information from your medical record 
without your permission, for example, if it is required by the Food and Drug Administration 
(FDA), members of Congress, law enforcement officials, or authorized hospital accreditation 
organizations. 
2. Policy Regarding Research-Related Injuries.  The Clinical Center will provide short-term 
medical care for any injury resulting from your participation in research here.  In general, no 
long-term medical care or financial compensation for research-related injuries will be 
provided by the National Institutes of Health, the Clinical Center, or the Federal Government.  
However, you have the right to pursue legal remedy if you believe that your injury justifies 
such action. 
3. Payments.  The amount of payment to research volunteers is guided by the National 
Institutes of Health policies.  In general, patients are not paid for taking part in research 
studies at the National Institutes of Health. Reimbursement of travel and subsistence will be 
offered consistent with NIH guidelines. 
4. Problems or Questions.   If you have any problems or questions about this study, or about 
your rights as a research participant, or about any research-related injury, contact the 
Principal Investigator, Ravi A. Madan, M.D., Building 10, Room 13N240B, Telephone:  
301-480-7168.  If you have any questions about the use of your specimens or data for future 
research studies, you may also contact the Office of the Clinical Director, Telephone: 240-
760-6070. 
You may also call the Clinical Center Patient Representative at 301-496-2626. 
5. Consent Document.  Please keep a copy of this document in case you want to read it again.

MEDICAL RECORD 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
STUDY NUMBER: 
09-C-0195 
CONTINUATION: page 23 of 23 pages 
 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY  
(Continuation Sheet) 
• 
Adult Patient or 
• Parent, for Minor Patient 
NIH-2514-1 (07-09) 
P.A.:  09-25-0099 
 
File in Section 4:  Protocol Consent 
 
 
 
COMPLETE APPROPRIATE ITEM(S) BELOW: 
A. Adult Patient’s Consent 
B. Parent’s Permission for Minor Patient. 
I have read the explanation about this study 
and have been given the opportunity to discuss 
it and to ask questions.  I hereby consent to 
take part in this study. 
I have read the explanation about this study 
and have been given the opportunity to discuss 
it and to ask questions.  I hereby give 
permission for my child to take part in this 
study.   
(Attach NIH 2514-2, Minor’s Assent, if 
applicable.) 
 
  
  
 
 
 
Signature of Adult Patient/ 
Legal Representative 
Date 
Signature of Parent(s)/ Guardian Date 
 
 
Print Name 
 
 
Print Name 
C. Child’s Verbal Assent (If Applicable) 
The information in the above consent was described to my child and my child agrees to 
participate in the study. 
 
  
  
 
Signature of Parent(s)/Guardian 
Date 
Print Name 
THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE  
AUGUST 8, 2016 THROUGH AUGUST 7, 2017.  
 
 
 
 
 
 
 
 
Signature of Investigator 
Date 
Signature of Witness 
Date 
 
 
Print Name 
 
 
Print Name